{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCCCC/C=C/CCCCCCCCN\nDECTAFLUR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.98 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCCCC/C=C/CCCCCCCCN\nDECTAFLUR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.98 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC\nDrug Name: MISOPROSTOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC\nDrug Name: MISOPROSTOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1ccncc1N.O=P(O)(O)O\nAMIFAMPRIDINE PHOSPHATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 207.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1ccncc1N.O=P(O)(O)O\nAMIFAMPRIDINE PHOSPHATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 207.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C\nName: TAURODEOXYCHOLIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 499.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 123.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C\nName: TAURODEOXYCHOLIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 499.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 123.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CNS(=O)(=O)c1cc(OC)c(OC)c(C(=O)NCC2CCCN2C)c1\nDrug Name: SULVERAPRIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CNS(=O)(=O)c1cc(OC)c(OC)c(C(=O)NCC2CCCN2C)c1\nDrug Name: SULVERAPRIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F\nName: FOSRAVUCONAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 547.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F\nName: FOSRAVUCONAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 547.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNC(=O)c1cccnc1\nNIACINAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 122.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNC(=O)c1cccnc1\nNIACINAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 122.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)CCC/C=C(\\c1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1)c1cccnc1\nSAMIXOGREL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 485.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)CCC/C=C(\\c1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1)c1cccnc1\nSAMIXOGREL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 485.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC/C(=C(\\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccc(C(C)C)cc1\nMIPROXIFENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 429.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.83 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC/C(=C(\\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccc(C(C)C)cc1\nMIPROXIFENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 429.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.83 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl\nBUCINDOLOL HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl\nBUCINDOLOL HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCNC(=O)ON(C(C)=O)C(=O)NC\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CARACEMIDE\n\n### Structure\n```\nCNC(=O)ON(C(C)=O)C(=O)NC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.55 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 87.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.500\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCNC(=O)ON(C(C)=O)C(=O)NC", "output": "## Molecular Property Analysis: CARACEMIDE\n\n### Structure\n```\nCNC(=O)ON(C(C)=O)C(=O)NC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.55 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 87.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.500\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TRIAZOLAM\n\n### Structure\n```\nCc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 343.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.23 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 43.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2", "output": "## Molecular Property Analysis: TRIAZOLAM\n\n### Structure\n```\nCc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 343.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.23 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 43.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1\nDrug Name: ATACIGUAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1\nDrug Name: ATACIGUAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 576.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO\nRIVICICLIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO\nRIVICICLIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(NS(=O)(=O)c2ccc(N)cc2)no1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(NS(=O)(=O)c2ccc(N)cc2)no1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1CCC(C(C)C)C(O)C1\nCandidate Name: MENTHOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 156.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1CCC(C(C)C)C(O)C1\nCandidate Name: MENTHOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 156.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CC(Oc1ccccc1)Oc1ccccc1\nMEDIFOXAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CC(Oc1ccccc1)Oc1ccccc1\nMEDIFOXAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCc1nc(N)nc(N)c1-c1ccc(Cl)cc1\nPYRIMETHAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCc1nc(N)nc(N)c1-c1ccc(Cl)cc1\nPYRIMETHAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1nc(-c2ccccc2)c2cc(Cl)ccc2n1CC(F)(F)F\nDrug Name: FLUQUAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 338.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1nc(-c2ccccc2)c2cc(Cl)ccc2n1CC(F)(F)F\nDrug Name: FLUQUAZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 338.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)OC/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 328.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)OC/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 328.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 199.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 199.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCOC(=O)c1ccc(N)cc1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCOC(=O)c1ccc(N)cc1O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CCCC(=O)C1CCCCC1)[C@@H](C)Cc1ccc(OC)cc1\nDrug Name: DEXSECOVERINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CCCC(=O)C1CCCCC1)[C@@H](C)Cc1ccc(OC)cc1\nDrug Name: DEXSECOVERINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1\nCandidate Name: TORSEMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1\nCandidate Name: TORSEMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 348.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1c([N+](=O)[O-])cc(C(C)(C)C)c(O)c1C(=O)Nc1ccc(Br)cc1C(F)(F)F\nName: BROMOXANIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 475.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.94 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1c([N+](=O)[O-])cc(C(C)(C)C)c(O)c1C(=O)Nc1ccc(Br)cc1C(F)(F)F\nName: BROMOXANIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 475.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.94 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN1CCC[C@H]1c1cccnc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 162.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN1CCC[C@H]1c1cccnc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 162.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc2c(-c3ccc(F)cc3)nc(=O)n(C(C)C)c2c1\nCandidate Name: FLUPROQUAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc2c(-c3ccc(F)cc3)nc(=O)n(C(C)C)c2c1\nCandidate Name: FLUPROQUAZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN\nGANAPLACIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN\nGANAPLACIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl\nName: BMS-794833\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl\nName: BMS-794833", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 468.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CHLORDIAZEPOXIDE\n\n### Structure\n```\nCNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 299.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.95 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 50.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1", "output": "## Molecular Property Analysis: CHLORDIAZEPOXIDE\n\n### Structure\n```\nCNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 299.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.95 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 50.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)NCC(O)c1ccc(O)c(CS(C)(=O)=O)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)NCC(O)c1ccc(O)c(CS(C)(=O)=O)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nOCc1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: BENZYL ALCOHOL\n\n### Structure\n```\nOCc1ccccc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 108.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.18 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.570\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nOCc1ccccc1", "output": "## Molecular Property Analysis: BENZYL ALCOHOL\n\n### Structure\n```\nOCc1ccccc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 108.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.18 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.570\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCC1([C@H](O)C/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCCCCCC(=O)OC)CCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCC1([C@H](O)C/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCCCCCC(=O)OC)CCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nN[C@H](CC(=O)O)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: D-ASPARTATE\n\n### Structure\n```\nN[C@H](CC(=O)O)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 133.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -1.13 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 100.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nN[C@H](CC(=O)O)C(=O)O", "output": "## Molecular Property Analysis: D-ASPARTATE\n\n### Structure\n```\nN[C@H](CC(=O)O)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 133.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -1.13 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 100.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(C)NCC(O)c1cc(O)cc(O)c1\nTERBUTALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 225.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(C)NCC(O)c1cc(O)cc(O)c1\nTERBUTALINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 225.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNCCCN1c2ccccc2CCc2ccccc21\nDESIPRAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNCCCN1c2ccccc2CCc2ccccc21\nDESIPRAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)[nH]c(N)nc21\nDrug Name: ENTECAVIR ANHYDROUS\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 277.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)[nH]c(N)nc21\nDrug Name: ENTECAVIR ANHYDROUS", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 277.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(NO)c1cccnc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 138.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(NO)c1cccnc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 138.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc(-c2nc3ccccc3[nH]2)cc1\nCompound_EXP002\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc(-c2nc3ccccc3[nH]2)cc1\nCompound_EXP002", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC[N+](CC)(CC)CC.[Br-]\nCandidate Name: TETRYLAMMONIUM BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 210.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC[N+](CC)(CC)CC.[Br-]\nCandidate Name: TETRYLAMMONIUM BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 210.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(OCCN1CCCCC1)C1(C2CCCCC2)CCCCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(OCCN1CCCCC1)C1(C2CCCCC2)CCCCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1\nDrug Name: REDAFAMDASTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 455.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1\nDrug Name: REDAFAMDASTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 455.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1\nARHALOFENATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1\nARHALOFENATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccc(C(CCN(C)C)c2ccccc2)cc1\nTOLPROPAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccc(C(CCN(C)C)c2ccccc2)cc1\nTOLPROPAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O\nName: QUINIDINE SULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 783.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O\nName: QUINIDINE SULFATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 783.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCNC[C@@H]1OC\nTICALOPRIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCNC[C@@H]1OC\nTICALOPRIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl\nDrug Name: NEFAZODONE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 506.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl\nDrug Name: NEFAZODONE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 506.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2\nTINORIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 316.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2\nTINORIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 316.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCN1C(=O)[C@@H]2C(=O)N(CCCCN3CCN(c4ccccc4OC)CC3)C(=O)[C@H](C1=O)C2(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 512.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCN1C(=O)[C@@H]2C(=O)N(CCCCN3CCN(c4ccccc4OC)CC3)C(=O)[C@H](C1=O)C2(C)C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 512.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1.CS(=O)(=O)O\nName: SAQUINAVIR MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 767.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 166.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1.CS(=O)(=O)O\nName: SAQUINAVIR MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 767.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 166.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nNCC(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: GLYCINE\n\n### Structure\n```\nNCC(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 75.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.97 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 63.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nNCC(=O)O", "output": "## Molecular Property Analysis: GLYCINE\n\n### Structure\n```\nNCC(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 75.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.97 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 63.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nNc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CYTARABINE\n\n### Structure\n```\nNc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 243.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -2.56 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 130.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nNc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1", "output": "## Molecular Property Analysis: CYTARABINE\n\n### Structure\n```\nNc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 243.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -2.56 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 130.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=CCC1(C(C)C)C(=O)NC(=O)NC1=O\nDrug Name: APROBARBITAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 210.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=CCC1(C(C)C)C(=O)NC(=O)NC1=O\nDrug Name: APROBARBITAL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 210.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)O[C@H]1C=COC=C2C[C@@]34SS[C@]5(CC6=COC=C[C@H](O)[C@H]6N5C3=O)C(=O)N4[C@@H]21\nCandidate Name: ARANOTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 462.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)O[C@H]1C=COC=C2C[C@@]34SS[C@]5(CC6=COC=C[C@H](O)[C@H]6N5C3=O)C(=O)N4[C@@H]21\nCandidate Name: ARANOTIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 462.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ADOZELESIN\n\n### Structure\n```\nCc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 502.5 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 5.30 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 111.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.310\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O", "output": "## Molecular Property Analysis: ADOZELESIN\n\n### Structure\n```\nCc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 502.5 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 5.30 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 111.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.310\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nNc1ccc(S(=O)(=O)Nc2ccccn2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: SULFAPYRIDINE\n\n### Structure\n```\nNc1ccc(S(=O)(=O)Nc2ccccn2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 249.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.46 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 85.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.810\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nNc1ccc(S(=O)(=O)Nc2ccccn2)cc1", "output": "## Molecular Property Analysis: SULFAPYRIDINE\n\n### Structure\n```\nNc1ccc(S(=O)(=O)Nc2ccccn2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 249.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.46 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 85.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.810\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2\nDrug Name: BENZGALANTAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2\nDrug Name: BENZGALANTAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSC(F)(F)F)[C@H]2SC1\nDrug Name: CEFAZAFLUR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSC(F)(F)F)[C@H]2SC1\nDrug Name: CEFAZAFLUR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2\nDrug Name: ACETOPHENAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2\nDrug Name: ACETOPHENAZINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(c1cc(O)c(O)c(O)c1)c1ccc(O)c(O)c1O\nName: EXIFONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 278.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 138.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(c1cc(O)c(O)c(O)c1)c1ccc(O)c(O)c1O\nName: EXIFONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 278.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 138.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nOCCSCCO\nName: THIODIGLYCOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 122.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nOCCSCCO\nName: THIODIGLYCOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 122.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(CC(=O)O)Cc1nc2cc(Cl)cnc2n1Cc1ccc(Cl)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(CC(=O)O)Cc1nc2cc(Cl)cnc2n1Cc1ccc(Cl)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)c1cc(-n2c(-c3ccccc3)cc3c2CCc2ccccc2-3)ccc1O\nFENDOSAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)c1cc(-n2c(-c3ccccc3)cc3c2CCc2ccccc2-3)ccc1O\nFENDOSAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC1OC(=O)c2ccccc21\nDrug Name: RAC-3-N-BUTYLPHTHALIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 190.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC1OC(=O)c2ccccc21\nDrug Name: RAC-3-N-BUTYLPHTHALIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 190.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[Na+]\nName: CARBENICILLIN INDANYL SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 516.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 113.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[Na+]\nName: CARBENICILLIN INDANYL SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 516.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 113.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1\nDrug Name: TARAFENACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1\nDrug Name: TARAFENACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCOCCOC(=O)N1c2ccccc2Sc2ccccc21\nDIMETHOXANATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCOCCOC(=O)N1c2ccccc2Sc2ccccc21\nDIMETHOXANATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1\nName: GRAZOPREVIR ANHYDROUS\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 766.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1\nName: GRAZOPREVIR ANHYDROUS", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 766.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1\nCandidate Name: DICLOFENSINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 322.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1\nCandidate Name: DICLOFENSINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 322.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CC(F)(F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nCandidate Name: CORMETHASONE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CC(F)(F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nCandidate Name: CORMETHASONE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl\nCandidate Name: CYPROHEPTADINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl\nCandidate Name: CYPROHEPTADINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCn1nc2c3c(c(NCCN)ccc31)Sc1cc(O)ccc1-2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCn1nc2c3c(c(NCCN)ccc31)Sc1cc(O)ccc1-2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOC1(OC)CCCN2CC(c3ccccc3)N=C21\nOXAMISOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 260.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOC1(OC)CCCN2CC(c3ccccc3)N=C21\nOXAMISOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 260.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[N+]1(Cc2ccc(-c3ccccc3)cc2)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2\nXENYTROPIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[N+]1(Cc2ccc(-c3ccccc3)cc2)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2\nXENYTROPIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(C(C#N)(CCCN(C)CCc2ccccc2)C(C)C)cc(OC)c1OC\nCandidate Name: METHOXYVERAPAMIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(C(C#N)(CCCN(C)CCc2ccccc2)C(C)C)cc(OC)c1OC\nCandidate Name: METHOXYVERAPAMIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O\nFOTEMUSTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O\nFOTEMUSTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCC/C=C\\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O\nDrug Name: SORBITAN MONOOLEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCC/C=C\\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O\nDrug Name: SORBITAN MONOOLEATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]\nOXACILLIN SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]\nOXACILLIN SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(C(Nc2ccc(S(N)(=O)=O)cc2)Nc2ccc(S(N)(=O)=O)cc2)ccc1O\nDrug Name: VANYLDISULFAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 173.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(C(Nc2ccc(S(N)(=O)=O)cc2)Nc2ccc(S(N)(=O)=O)cc2)ccc1O\nDrug Name: VANYLDISULFAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 173.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)Cn1cnc2c1c(=O)n(C)c(=O)n2C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)Cn1cnc2c1c(=O)n(C)c(=O)n2C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(Nc1ccc(Cl)c(Cl)c1)NS(=O)(=O)c1ccc2c(c1)CCO2\nCandidate Name: LY-295501\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 387.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(Nc1ccc(Cl)c(Cl)c1)NS(=O)(=O)c1ccc2c(c1)CCO2\nCandidate Name: LY-295501", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 387.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC12CC3CC(C)(C1)CC(N)(C3)C2.Cl\nName: MEMANTINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 215.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC12CC3CC(C)(C1)CC(N)(C3)C2.Cl\nName: MEMANTINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 215.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNc1ccc(C(=O)OCCN(C)C)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TETRACAINE\n\n### Structure\n```\nCCCCNc1ccc(C(=O)OCCN(C)C)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.62 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.580\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNc1ccc(C(=O)OCCN(C)C)cc1", "output": "## Molecular Property Analysis: TETRACAINE\n\n### Structure\n```\nCCCCNc1ccc(C(=O)OCCN(C)C)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.62 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.580\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)S[C@H]1CC(=O)C=C2C[C@@H](SC(C)=O)[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@]21C\nCandidate Name: TIOMESTERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 450.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)S[C@H]1CC(=O)C=C2C[C@@H](SC(C)=O)[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@]21C\nCandidate Name: TIOMESTERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 450.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nCompare the safety profiles of these two drugs:\nDrug 1: NC(=O)OC[C@H](N)Cc1ccccc1 (SOLRIAMFETOL)\nDrug 2: CC(C(C(=O)C(C)(C)C)c1ccc(Cl)cc1)N(C)C (Sibutramine)\n<|im_end|>\n<|im_start|>assistant\n## Comparative Drug Analysis\n\n### Head-to-Head Comparison\n\n| Property | SOLRIAMFETOL | Sibutramine | Better |\n|----------|---------|---------|--------|\n| Status | approved | withdrawn | üèÜ SOLRIAMFETOL |\n| Mol. Weight | nan Da | nan Da | üèÜ Sibutramine |\n| LogP | nan | nan | üèÜ Sibutramine |\n| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Sibutramine |\n\n### Assessment\n\n**SOLRIAMFETOL** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.\n\n**Sibutramine** has not achieved approval, which may indicate:\n- Efficacy challenges in clinical trials\n- Safety concerns that limited development\n- Strategic decision to discontinue development\n<|im_end|>", "instruction": "Compare the safety profiles of these two drugs:\nDrug 1: NC(=O)OC[C@H](N)Cc1ccccc1 (SOLRIAMFETOL)\nDrug 2: CC(C(C(=O)C(C)(C)C)c1ccc(Cl)cc1)N(C)C (Sibutramine)", "output": "## Comparative Drug Analysis\n\n### Head-to-Head Comparison\n\n| Property | SOLRIAMFETOL | Sibutramine | Better |\n|----------|---------|---------|--------|\n| Status | approved | withdrawn | üèÜ SOLRIAMFETOL |\n| Mol. Weight | nan Da | nan Da | üèÜ Sibutramine |\n| LogP | nan | nan | üèÜ Sibutramine |\n| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Sibutramine |\n\n### Assessment\n\n**SOLRIAMFETOL** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.\n\n**Sibutramine** has not achieved approval, which may indicate:\n- Efficacy challenges in clinical trials\n- Safety concerns that limited development\n- Strategic decision to discontinue development", "task_type": "comparison"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1c(CC(=O)O)cccc1C(=O)c1ccccc1\nAMFENAC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1c(CC(=O)O)cccc1C(=O)c1ccccc1\nAMFENAC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[N+](C)(C)CCCCC[N+](C)(C)C\nCandidate Name: PENTAMETHONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 188.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[N+](C)(C)CCCCC[N+](C)(C)C\nCandidate Name: PENTAMETHONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 188.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1\nName: QUINETHAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1\nName: QUINETHAZONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O\nCandidate Name: BORTEZOMIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O\nCandidate Name: BORTEZOMIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl\nCandidate Name: BETAXOLOL HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 343.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl\nCandidate Name: BETAXOLOL HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 343.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nN=C(NCCCc1c[nH]cn1)NCCNc1ccccn1\nGAPROMIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 287.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nN=C(NCCCc1c[nH]cn1)NCCNc1ccccn1\nGAPROMIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 287.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc(=O)c2c(O)c3ccoc3c(OCC(O)CNC(C)C)c2o1\nDrug Name: IPROCROLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc(=O)c2c(O)c3ccoc3c(OCC(O)CNC(C)C)c2o1\nDrug Name: IPROCROLOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1nc(NCCCCCCc2ccccc2)nc(C)c1O\nName: ENAZADREM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1nc(NCCCCCCc2ccccc2)nc(C)c1O\nName: ENAZADREM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O\nDrug Name: ERYTHROMYCIN STEARATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1018.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O\nDrug Name: ERYTHROMYCIN STEARATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1018.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCn1nc(-c2cccnc2)nc1-c1ccccc1CO\nName: FEPITRIZOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCn1nc(-c2cccnc2)nc1-c1ccccc1CO\nName: FEPITRIZOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CS(=O)(=O)O.Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1\nCandidate Name: BITOLTEROL MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 557.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CS(=O)(=O)O.Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1\nCandidate Name: BITOLTEROL MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 557.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=S(=O)(c1cccc2cnccc12)N1CCCNCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=S(=O)(c1cccc2cnccc12)N1CCCNCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nAPREPITANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 534.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nAPREPITANT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 534.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO\nCandidate Name: DESOXIMETASONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO\nCandidate Name: DESOXIMETASONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21\nFLORBENAZINE F 18\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21\nFLORBENAZINE F 18", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC\nCandidate Name: WHI-P131\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC\nCandidate Name: WHI-P131", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=c1c(-c2ccc(O)cc2)coc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)ccc12\nName: PUERARIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 160.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=c1c(-c2ccc(O)cc2)coc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)ccc12\nName: PUERARIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 160.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1CCN(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](/C=C/S(=O)(=O)c2ccccc2)CCc2ccccc2)CC1\nName: K-777\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 574.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1CCN(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](/C=C/S(=O)(=O)c2ccccc2)CCc2ccccc2)CC1\nName: K-777", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 574.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PENICILLIN V\n\n### Structure\n```\nCC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 350.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.70 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.760\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O", "output": "## Molecular Property Analysis: PENICILLIN V\n\n### Structure\n```\nCC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 350.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.70 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.760\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1c2ccccc2C(=O)C1c1ccc(Br)cc1\nDrug Name: BROMINDIONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1c2ccccc2C(=O)C1c1ccc(Br)cc1\nDrug Name: BROMINDIONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1\nCandidate Name: ISPINESIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 517.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.59 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1\nCandidate Name: ISPINESIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 517.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.59 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC(C)(C)c1ccc(OCCCCCCN2CCN(c3ccc(C)c(Cl)c3)CC2)cc1\nCandidate Name: TEROXALENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.10 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC(C)(C)c1ccc(OCCCCCCN2CCN(c3ccc(C)c(Cl)c3)CC2)cc1\nCandidate Name: TEROXALENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.10 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)CCCN.Cl\nCandidate Name: BL-1021\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)CCCN.Cl\nCandidate Name: BL-1021", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1\nName: PHENYTOIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1\nName: PHENYTOIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C1CC[C@H]2[C@H]3Cc4cccc(O)c4[C@@]2(CCN3CC2CC2)C1\nName: KETORFANOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C1CC[C@H]2[C@H]3Cc4cccc(O)c4[C@@]2(CCN3CC2CC2)C1\nName: KETORFANOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nNc1c2c(nc3ccccc13)CCCC2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TACRINE\n\n### Structure\n```\nNc1c2c(nc3ccccc13)CCCC2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 198.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.70 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 38.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.710\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nNc1c2c(nc3ccccc13)CCCC2", "output": "## Molecular Property Analysis: TACRINE\n\n### Structure\n```\nNc1c2c(nc3ccccc13)CCCC2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 198.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.70 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 38.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.710\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)Cn1cc(I)c(=O)c(I)c1\nDIODONE ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)Cn1cc(I)c(=O)c(I)c1\nDIODONE ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)O[C@H]1[C@H]2O[C@]23[C@@H]2CC[C@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]2CC[C@]3(C)[C@H]1c1ccc(=O)oc1\nCandidate Name: CINOBUFOTALIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 458.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)O[C@H]1[C@H]2O[C@]23[C@@H]2CC[C@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]2CC[C@]3(C)[C@H]1c1ccc(=O)oc1\nCandidate Name: CINOBUFOTALIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 458.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\n[Ca+2].[N-]=C=[N-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 80.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\n[Ca+2].[N-]=C=[N-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 80.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 47.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCCC(C)(O)/C=C/C1CCC(=O)[C@@H]1CCCCCCC(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 352.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCCC(C)(O)/C=C/C1CCC(=O)[C@@H]1CCCCCCC(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 352.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCCNC(=O)Cn1ncc(-c2ccccc2)c1-c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCCNC(=O)Cn1ncc(-c2ccccc2)c1-c1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 379.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 379.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: L-NAME\n\n### Structure\n```\nCOC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 233.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.43 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 143.4 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.110\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]", "output": "## Molecular Property Analysis: L-NAME\n\n### Structure\n```\nCOC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 233.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.43 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 143.4 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.110\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCOc1ccccc1O/C(=C/c1ccccc1)C(C)=O\nName: ZOCAINONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCOc1ccccc1O/C(=C/c1ccccc1)C(C)=O\nName: ZOCAINONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C=C1C[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O\nCandidate Name: MELENGESTROL ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C=C1C[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O\nCandidate Name: MELENGESTROL ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12\nDrug Name: BUTYLSCOPOLAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12\nDrug Name: BUTYLSCOPOLAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1c(Cl)cc(CC2=NCCN2)cc1Cl\nDrug Name: NEMAZOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1c(Cl)cc(CC2=NCCN2)cc1Cl\nDrug Name: NEMAZOLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCn1c(=O)c2c(ncn2CCCN[C@H]2CO[C@H]3[C@@H]2OC[C@@H]3O[N+](=O)[O-])n(C)c1=O\nName: TEOPRANITOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 144.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCn1c(=O)c2c(ncn2CCCN[C@H]2CO[C@H]3[C@@H]2OC[C@@H]3O[N+](=O)[O-])n(C)c1=O\nName: TEOPRANITOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 144.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1cccc(C)c1NC(=O)c1ccc(N)cc1\nAMELTOLIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1cccc(C)c1NC(=O)c1ccc(N)cc1\nAMELTOLIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(C)N=C(N)N=C(N)N1OCc1ccc(Cl)c(Cl)c1\nCLOCIGUANIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 316.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(C)N=C(N)N=C(N)N1OCc1ccc(Cl)c(Cl)c1\nCLOCIGUANIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 316.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOP(=O)(NC(=S)Nc1ccccc1NC(=O)NS(=O)(=O)c1ccc(C)cc1)OCC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 500.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOP(=O)(NC(=S)Nc1ccccc1NC(=O)NS(=O)(=O)c1ccc(C)cc1)OCC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 500.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(Oc1ccc(Cl)cc1)C(=O)OCc1cccc(CO)n1\nName: PIRIFIBRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(Oc1ccc(Cl)cc1)C(=O)OCc1cccc(CO)n1\nName: PIRIFIBRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C#N)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C\nCandidate Name: CICORTONIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 566.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C#N)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C\nCandidate Name: CICORTONIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 566.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5\nNALTREXONE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5\nNALTREXONE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)[O-].[K+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)[O-].[K+]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)NCc1ccc(OC(C)(C)C(=O)O)cc1\nCandidate Name: GW590735\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)NCc1ccc(OC(C)(C)C(=O)O)cc1\nCandidate Name: GW590735", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NS(=O)(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O\nName: SUNCILLIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 429.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NS(=O)(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O\nName: SUNCILLIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 429.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C=C1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO\nCandidate Name: FLUPREDNIDENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C=C1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO\nCandidate Name: FLUPREDNIDENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1Oc2ccccc2CC1N(C)C\nTREBENZOMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1Oc2ccccc2CC1N(C)C\nTREBENZOMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1\nName: SUTEZOLID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1\nName: SUTEZOLID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1\nCandidate Name: TELOTRISTAT ETHYL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 575.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1\nCandidate Name: TELOTRISTAT ETHYL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 575.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3\nDrug Name: DEXTROMETHORPHAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3\nDrug Name: DEXTROMETHORPHAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nNNC(=O)c1ccncc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ISONIAZID\n\n### Structure\n```\nNNC(=O)c1ccncc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 137.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.31 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 68.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.320\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nNNC(=O)c1ccncc1", "output": "## Molecular Property Analysis: ISONIAZID\n\n### Structure\n```\nNNC(=O)c1ccncc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 137.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.31 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 68.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.320\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCCCCCCCC(O)c1ccc(C(=O)O)c(Cl)c1\nName: LODELABEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.33 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCCCCCCCC(O)c1ccc(C(=O)O)c(Cl)c1\nName: LODELABEN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.33 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(c1cc2ccccc2s1)N(O)C(N)=O\nCandidate Name: ZILEUTON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(c1cc2ccccc2s1)N(O)C(N)=O\nCandidate Name: ZILEUTON", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)c1ccc(S(=O)(=O)N(Cl)Cl)cc1\nCandidate Name: HALAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)c1ccc(S(=O)(=O)N(Cl)Cl)cc1\nCandidate Name: HALAZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C\nName: FOSINOPRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 563.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.12 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C\nName: FOSINOPRIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 563.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.12 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCn1c(=O)c2c(ncn2CC(O)CN2CCN(CCCSc3ccccc3)CC2)n(C)c1=O\nName: TAZIFYLLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 472.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCn1c(=O)c2c(ncn2CC(O)CN2CCN(CCCSc3ccccc3)CC2)n(C)c1=O\nName: TAZIFYLLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 472.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C\nMARIMASTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C\nMARIMASTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=P1(N(CCCl)CCCl)NC(SCCS(=O)(=O)O)CCO1\nName: MAFOSFAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=P1(N(CCCl)CCCl)NC(SCCS(=O)(=O)O)CCO1\nName: MAFOSFAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 501.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 501.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)N1C\nCandidate Name: EUCATROPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)N1C\nCandidate Name: EUCATROPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21\nName: IZORLISIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21\nName: IZORLISIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 127.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC12CC3CC(C)(C1)CC(N)(C3)C2\nMEMANTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 179.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC12CC3CC(C)(C1)CC(N)(C3)C2\nMEMANTINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 179.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2.Cl\nCONIVAPTAN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 535.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2.Cl\nCONIVAPTAN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 535.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O\nName: TERAZOSIN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O\nName: TERAZOSIN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1\nDrug Name: CAMPTOTHECIN-20-O-PROPIONATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1\nDrug Name: CAMPTOTHECIN-20-O-PROPIONATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC\nName: TYLOSIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 916.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 238.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC\nName: TYLOSIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 916.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 238.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN1C(C)(C)CCCC1(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 155.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN1C(C)(C)CCCC1(C)C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 155.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN1CCCC1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 99.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN1CCCC1=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 99.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1\nDrug Name: AT-13148\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1\nDrug Name: AT-13148", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(C2(c3ccccc3)NC(=O)N(CCCN3CCC(c4ccccc4)CC3)C2=O)cc1\nName: ROPITOIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 483.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(C2(c3ccccc3)NC(=O)N(CCCN3CCC(c4ccccc4)CC3)C2=O)cc1\nName: ROPITOIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 483.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOP(=O)(CCCCCCOc1ccc(OC)cc1Cl)OCC\nFOSARILATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOP(=O)(CCCCCCOc1ccc(OC)cc1Cl)OCC\nFOSARILATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN1C(=CC=CC=Cc2sc3ccccc3[n+]2CC)Sc2ccccc21\nDrug Name: DITHIAZANINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN1C(=CC=CC=Cc2sc3ccccc3[n+]2CC)Sc2ccccc21\nDrug Name: DITHIAZANINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: BERMOPROFEN\n\n### Structure\n```\nCc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 296.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.920\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2", "output": "## Molecular Property Analysis: BERMOPROFEN\n\n### Structure\n```\nCc1ccc2c(c1)CC(=O)c1cc(C(C)C(=O)O)ccc1O2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 296.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.920\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12\nDrug Name: SCOPOLAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12\nDrug Name: SCOPOLAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TICRYNAFEN\n\n### Structure\n```\nO=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 331.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl", "output": "## Molecular Property Analysis: TICRYNAFEN\n\n### Structure\n```\nO=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 331.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1\nSARACATINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 542.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1\nSARACATINIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 542.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CLOZAPINE\n\n### Structure\n```\nCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 326.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.72 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1", "output": "## Molecular Property Analysis: CLOZAPINE\n\n### Structure\n```\nCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 326.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.72 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN1C(=CC=Cc2ccc3ccccc3[n+]2CC)C=Cc2ccccc21\nQUINALDINE BLUE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.60 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN1C(=CC=Cc2ccc3ccccc3[n+]2CC)C=Cc2ccccc21\nQUINALDINE BLUE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.60 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1cccc(CN2C(=O)N(Cc3cccc(N)c3)[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@H]2Cc2ccccc2)c1\nName: MOZENAVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 536.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1cccc(CN2C(=O)N(Cc3cccc(N)c3)[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@H]2Cc2ccccc2)c1\nName: MOZENAVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 536.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]c2ccccc2n1C1CCN(CCCc2noc3cc(F)ccc23)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]c2ccccc2n1C1CCN(CCCc2noc3cc(F)ccc23)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nOC(c1ccccc1)C1CCN(CCc2ccccc2)CC1\nGLEMANSERIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nOC(c1ccccc1)C1CCN(CCc2ccccc2)CC1\nGLEMANSERIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc(F)nc1)C(=O)O)C(=O)O\nCandidate Name: PIFLUFOLASTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc(F)nc1)C(=O)O)C(=O)O\nCandidate Name: PIFLUFOLASTAT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)C1N=C(c2ccccc2F)c2cc(Cl)ccc2NC1=O\nName: ETHYL LOFLAZEPATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)C1N=C(c2ccccc2F)c2cc(Cl)ccc2NC1=O\nName: ETHYL LOFLAZEPATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC(O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC(O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O\nName: TOBRAMYCIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -6.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 10.0 | ‚ö† High (>5) |\n| Polar Surface Area | 268.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O\nName: TOBRAMYCIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -6.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 10.0 | ‚ö† High (>5) |\n| Polar Surface Area | 268.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O.Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O.Cl", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23\nFLUMEQUINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 261.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23\nFLUMEQUINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 261.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1[nH]c(/C=C2\\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O\nCandidate Name: ORANTINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1[nH]c(/C=C2\\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O\nCandidate Name: ORANTINIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nOCCOCCOCCN1CCC(=C(c2ccccc2)c2ccccc2)CC1\nName: PIPOXIZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nOCCOCCOCCN1CCC(=C(c2ccccc2)c2ccccc2)CC1\nName: PIPOXIZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)N1c2ccccc2CC(=O)c2ccccc21\nDrug Name: OXCARBAZEPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)N1c2ccccc2CC(=O)c2ccccc21\nDrug Name: OXCARBAZEPINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCn1nnc(C2=CCCN(C)C2)n1\nName: ALVAMELINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCn1nnc(C2=CCCN(C)C2)n1\nName: ALVAMELINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C#CC(C)(O)CC\nCandidate Name: MEPARFYNOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 98.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C#CC(C)(O)CC\nCandidate Name: MEPARFYNOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 98.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O\nISOSORBIDE MONONITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O\nISOSORBIDE MONONITRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1csc2ccc3[nH]c4c(c3c12)CN(C)CC4\nTIENOCARBINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1csc2ccc3[nH]c4c(c3c12)CN(C)CC4\nTIENOCARBINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O\nCandidate Name: CARBIDOPA\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O\nCandidate Name: CARBIDOPA", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O\nSACUBITRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O\nSACUBITRIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1\nDrug Name: TEMANOGREL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 436.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1\nDrug Name: TEMANOGREL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 436.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCC[C@H](O)c1ccc(N2C(=O)CC[C@@H]2CCCc2ccc(C(=O)O)s2)cc1\nName: AGANEPAG\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 429.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.58 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCC[C@H](O)c1ccc(N2C(=O)CC[C@@H]2CCCc2ccc(C(=O)O)s2)cc1\nName: AGANEPAG", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 429.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.58 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@H]1O\nCORDYCEPIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 251.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@H]1O\nCORDYCEPIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 251.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DISOPYRAMIDE\n\n### Structure\n```\nCC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 339.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.36 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 59.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C", "output": "## Molecular Property Analysis: DISOPYRAMIDE\n\n### Structure\n```\nCC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 339.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.36 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 59.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCC\nCandidate Name: BUTANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 58.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCC\nCandidate Name: BUTANE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 58.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCn1ccnc1CC1COc2ccccc2O1\nIMILOXAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCn1ccnc1CC1COc2ccccc2O1\nIMILOXAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NCCCC(=O)O\nDrug Name: GAMMA-AMINOBUTYRIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 103.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NCCCC(=O)O\nDrug Name: GAMMA-AMINOBUTYRIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 103.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC[C@@H](COC(=O)c1cc(OC)c(OC)c(OC)c1)N(C)CCN(C)[C@@H](CC)COC(=O)c1cc(OC)c(OC)c(OC)c1\nName: BUTOBENDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 620.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC[C@@H](COC(=O)c1cc(OC)c(OC)c(OC)c1)N(C)CCN(C)[C@@H](CC)COC(=O)c1cc(OC)c(OC)c(OC)c1\nName: BUTOBENDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 620.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccccc1C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1\nName: PHTHALYLSULFATHIAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 403.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccccc1C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1\nName: PHTHALYLSULFATHIAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 403.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCOc1ccc(S(=O)(=O)O)c2cccnc12\nDrug Name: ACTINOQUINOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCOc1ccc(S(=O)(=O)O)c2cccnc12\nDrug Name: ACTINOQUINOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(CCN(C)CCCN2Cc3cc(OC)c(OC)cc3C2=O)cc1OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(CCN(C)CCCN2Cc3cc(OC)c(OC)cc3C2=O)cc1OC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 428.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN1CCC(=C(c2ccccc2)c2ccccc2)C1\nName: PRIDEFINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN1CCC(=C(c2ccccc2)c2ccccc2)C1\nName: PRIDEFINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21\nCandidate Name: TRANDOLAPRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 430.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21\nCandidate Name: TRANDOLAPRIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 430.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C\nName: PYROTINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 583.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C\nName: PYROTINIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 583.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C([O-])CCCCCCCNC(=O)c1ccccc1O.[Na+]\nCandidate Name: SALCAPROZATE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C([O-])CCCCCCCNC(=O)c1ccccc1O.[Na+]\nCandidate Name: SALCAPROZATE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=P(O)(O)Oc1ccc(C(c2ccc(OP(=O)(O)O)cc2)c2ccccn2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 437.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=P(O)(O)Oc1ccc(C(c2ccc(OP(=O)(O)O)cc2)c2ccccn2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 437.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nDrug Name: ISOFLUPREDONE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nDrug Name: ISOFLUPREDONE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1\nName: MIRISTALKONIUM ION\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.96 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1\nName: MIRISTALKONIUM ION", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.96 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN1CCCC(OC(=O)C(c2ccccc2)c2ccccc2)C1\nCandidate Name: PIPERIDOLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN1CCCC(OC(=O)C(c2ccccc2)c2ccccc2)C1\nCandidate Name: PIPERIDOLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O\nCandidate Name: OXANDROLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O\nCandidate Name: OXANDROLONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOC(=O)C(c1ccccc1)C1CCCCN1\nName: METHYLPHENIDATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOC(=O)C(c1ccccc1)C1CCCCN1\nName: METHYLPHENIDATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1\nName: TEPIRINDOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 274.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1\nName: TEPIRINDOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 274.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F\nCandidate Name: RIMEGEPANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 534.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F\nCandidate Name: RIMEGEPANT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 534.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O\nADOZELESIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 502.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 111.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O\nADOZELESIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 502.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 111.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1\nName: PF-5190457\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 512.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1\nName: PF-5190457", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 512.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O\nDAPRODUSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 124.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O\nDAPRODUSTAT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 124.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1C(I)=CC(=C(c2cc(I)c([O-])c(I)c2)c2ccccc2C(=O)[O-])C=C1I.[Na+].[Na+]\nDrug Name: IODOPHTHALEIN SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 865.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.32 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1C(I)=CC(=C(c2cc(I)c([O-])c(I)c2)c2ccccc2C(=O)[O-])C=C1I.[Na+].[Na+]\nDrug Name: IODOPHTHALEIN SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 865.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.32 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: HYDROXYFLUTAMIDE\n\n### Structure\n```\nCC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 292.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.32 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 92.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1", "output": "## Molecular Property Analysis: HYDROXYFLUTAMIDE\n\n### Structure\n```\nCC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 292.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.32 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 92.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O)C1=Cc2cc(OC(F)(F)F)ccc2OC1C(F)(F)F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 328.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O)C1=Cc2cc(OC(F)(F)F)ccc2OC1C(F)(F)F", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 328.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1cccc(Nc2ccccc2C(=O)O)c1C\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MEFENAMIC ACID\n\n### Structure\n```\nCc1cccc(Nc2ccccc2C(=O)O)c1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 241.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.860\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1cccc(Nc2ccccc2C(=O)O)c1C", "output": "## Molecular Property Analysis: MEFENAMIC ACID\n\n### Structure\n```\nCc1cccc(Nc2ccccc2C(=O)O)c1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 241.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.860\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 444.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 444.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C\nDrug Name: TELAPRISTONE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 505.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C\nDrug Name: TELAPRISTONE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 505.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1C[C@H](CC#N)C[C@@H]2c3cccc4[nH]c(Cl)c(c34)C[C@H]21\nName: LERGOTRILE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1C[C@H](CC#N)C[C@@H]2c3cccc4[nH]c(Cl)c(c34)C[C@H]21\nName: LERGOTRILE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21\nName: CHLORPROTHIXENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.19 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21\nName: CHLORPROTHIXENE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.19 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nFc1ccc(-c2ccc(CN3CCN(c4cccc5ccoc45)CC3)[nH]2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nFc1ccc(-c2ccc(CN3CCN(c4cccc5ccoc45)CC3)[nH]2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1411.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1411.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NCCc1cc[nH]n1\nCandidate Name: BETAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 111.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NCCc1cc[nH]n1\nCandidate Name: BETAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 111.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc2ccc(=O)oc2cc1OCCCN1CCC(C(O)(c2ccc(F)cc2)c2ccc(F)cc2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 535.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc2ccc(=O)oc2cc1OCCCN1CCC(C(O)(c2ccc(F)cc2)c2ccc(F)cc2)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 535.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=O\nDrug Name: OXYGEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 32.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=O\nDrug Name: OXYGEN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 32.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1C2Cc3ccccc3C1(C)CCN2CC1CC1\nVOLAZOCINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1C2Cc3ccccc3C1(C)CCN2CC1CC1\nVOLAZOCINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C([O-])O.[K+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 100.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C([O-])O.[K+]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 100.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCC1CCC(NC(=O)N(CCCl)N=O)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: SEMUSTINE\n\n### Structure\n```\nCC1CCC(NC(=O)N(CCCl)N=O)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 247.7 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.50 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCC1CCC(NC(=O)N(CCCl)N=O)CC1", "output": "## Molecular Property Analysis: SEMUSTINE\n\n### Structure\n```\nCC1CCC(NC(=O)N(CCCl)N=O)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 247.7 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.50 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(N)CCCC(C)(C)O\nCandidate Name: HEPTAMINOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 145.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(N)CCCC(C)(C)O\nCandidate Name: HEPTAMINOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 145.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)C(C)=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 116.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)C(C)=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 116.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1CC(OC(=O)C(C)O)CC(C)(C)C1\nCICLACTATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1CC(OC(=O)C(C)O)CC(C)(C)C1\nCICLACTATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1\nCandidate Name: AZD2066\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1\nCandidate Name: AZD2066", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCC1(CCCCC)Cc2c(cc(C(C)(C)C)c(O)c2C(C)(C)C)O1\nDrug Name: BO-653\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.82 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCC1(CCCCC)Cc2c(cc(C(C)(C)C)c(O)c2C(C)(C)C)O1\nDrug Name: BO-653", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.82 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1\nCandidate Name: NIMODIPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1\nCandidate Name: NIMODIPINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)C(NC(=O)Cn1c(-c2ccccc2)ncc(N)c1=O)C(=O)c1nnc(C(C)(C)C)o1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)C(NC(=O)Cn1c(-c2ccccc2)ncc(N)c1=O)C(=O)c1nnc(C(C)(C)C)o1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nc1ccc(C(CCN2CCCCCC2)c2ccccc2)cc1\nName: PROZAPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 293.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nc1ccc(C(CCN2CCCCCC2)c2ccccc2)cc1\nName: PROZAPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 293.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC(CC)C1(CC)C(=O)NC(=O)NC1=O\nDrug Name: TETRABARBITAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC(CC)C1(CC)C(=O)NC(=O)NC1=O\nDrug Name: TETRABARBITAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC(CCC)C(N)=O\nDrug Name: VALPROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 143.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC(CCC)C(N)=O\nDrug Name: VALPROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 143.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2\nDrug Name: SETROBUVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 560.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 145.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2\nDrug Name: SETROBUVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 560.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 145.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)CC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1\nName: BUTHIAZIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)CC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1\nName: BUTHIAZIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nc1ccc2c(c1)CCCC2C1=NCCN1\nTETRAHYDROZOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nc1ccc2c(c1)CCCC2C1=NCCN1\nTETRAHYDROZOLINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]\nNITROGLYCERIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 227.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 157.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]\nNITROGLYCERIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 227.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 157.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1cc(-c2ccccc2)n(-c2ccccc2)n1CCCN1CCN(c2ccccn2)CC1\nDrug Name: REVENAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1cc(-c2ccccc2)n(-c2ccccc2)n1CCCN1CCN(c2ccccn2)CC1\nDrug Name: REVENAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)=CCN1Cc2c(Cl)ccc3[nH]c(=S)n(c23)C[C@@H]1C\nTIVIRAPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)=CCN1Cc2c(Cl)ccc3[nH]c(=S)n(c23)C[C@@H]1C\nTIVIRAPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2\nZENIDOLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 277.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2\nZENIDOLOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 277.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(NCCN1CCN(c2ncccn2)CC1)C12CC3CC(CC(C3)C1)C2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(NCCN1CCN(c2ncccn2)CC1)C12CC3CC(CC(C3)C1)C2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1\nDrug Name: CEFTOBIPROLE MEDOCARIL FREE ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 690.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 264.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1\nDrug Name: CEFTOBIPROLE MEDOCARIL FREE ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 690.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 264.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN(CC)C(COC(=O)c1ccc(N)cc1)CC(C)C\nLEUCINOCAINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 292.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN(CC)C(COC(=O)c1ccc(N)cc1)CC(C)C\nLEUCINOCAINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 292.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(NO)c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NCc2ccc3cc(F)ccc3n2)nc1\nDrug Name: NANATINOSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(NO)c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NCc2ccc3cc(F)ccc3n2)nc1\nDrug Name: NANATINOSTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O\nName: FLURITHROMYCIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 751.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O\nName: FLURITHROMYCIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 751.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=P(O)(O)C(Cc1ccccn1)P(=O)(O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=P(O)(O)C(Cc1ccccn1)P(=O)(O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCOP(=S)(OCC)Oc1cc(C)nc(N(C)C)n1\nName: PYRIMITATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCOP(=S)(OCC)Oc1cc(C)nc(N(C)C)n1\nName: PYRIMITATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1.CS(=O)(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 793.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1.CS(=O)(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 793.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1\nDrug Name: TENAPANOR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1145.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1\nDrug Name: TENAPANOR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1145.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 155.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 155.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1\nGSK-729327\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1\nGSK-729327", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1ccc(C(=O)NCCc2c[nH]c3ccccc23)cc1\nName: Compound_EXP004\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1ccc(C(=O)NCCc2c[nH]c3ccccc23)cc1\nName: Compound_EXP004", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(=O)Nc1nnc(S(N)(=O)=O)s1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ACETAZOLAMIDE\n\n### Structure\n```\nCC(=O)Nc1nnc(S(N)(=O)=O)s1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.86 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 115.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(=O)Nc1nnc(S(N)(=O)=O)s1", "output": "## Molecular Property Analysis: ACETAZOLAMIDE\n\n### Structure\n```\nCC(=O)Nc1nnc(S(N)(=O)=O)s1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.86 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 115.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1\nCandidate Name: PF-04995274\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1\nCandidate Name: PF-04995274", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1\nCRENOLANIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1\nCRENOLANIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(C)CCO[N+](=O)[O-].[O-][Cl+3]([O-])([O-])[O-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(C)CCO[N+](=O)[O-].[O-][Cl+3]([O-])([O-])[O-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1\nRIZATRIPTAN BENZOATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1\nRIZATRIPTAN BENZOATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1\nName: ST1535\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1\nName: ST1535", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1oc2ccccc2c1CC(C)(C)COc1ccc(CC2SC(=O)NC2=O)cc1\nDrug Name: Troglitazone\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1oc2ccccc2c1CC(C)(C)COc1ccc(CC2SC(=O)NC2=O)cc1\nDrug Name: Troglitazone", "output": "## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(c1ccccc1)C1CCCC1)C2\nCandidate Name: CICLOTROPIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(c1ccccc1)C1CCCC1)C2\nCandidate Name: CICLOTROPIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 384.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.30 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC[C@@]1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(Cl)c(C)cc1c2CN1CCC(C)CC1\nCandidate Name: ELOMOTECAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 522.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC[C@@]1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(Cl)c(C)cc1c2CN1CCC(C)CC1\nCandidate Name: ELOMOTECAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 522.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)COC(=O)CCC(=O)[O-])CC[C@@H]12.[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)COC(=O)CCC(=O)[O-])CC[C@@H]12.[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1ncc([N+](=O)[O-])n1CCO.Cl\nName: METRONIDAZOLE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 207.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1ncc([N+](=O)[O-])n1CCO.Cl\nName: METRONIDAZOLE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 207.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1\nName: IPSAPIRONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1\nName: IPSAPIRONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2\nCandidate Name: ETHYBENZTROPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2\nCandidate Name: ETHYBENZTROPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nOCCNCCO\nName: DIETHANOLAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 105.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nOCCNCCO\nName: DIETHANOLAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 105.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCN1CCN2c3ccccc3Cc3ccccc3C2C1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MIANSERIN\n\n### Structure\n```\nCN1CCN2c3ccccc3Cc3ccccc3C2C1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.08 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.720\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCN1CCN2c3ccccc3Cc3ccccc3C2C1", "output": "## Molecular Property Analysis: MIANSERIN\n\n### Structure\n```\nCN1CCN2c3ccccc3Cc3ccccc3C2C1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 264.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.08 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.720\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(CN1CCOCC1)C(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1\nRACEMORAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(CN1CCOCC1)C(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1\nRACEMORAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 392.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1\nName: CYCLOHEXIMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1\nName: CYCLOHEXIMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1\nName: LERSIVIRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1\nName: LERSIVIRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(C)[C@H](C(=O)[O-])N2C(=O)C[C@H]2S1(=O)=O.[Na+]\nSULBACTAM SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(C)[C@H](C(=O)[O-])N2C(=O)C[C@H]2S1(=O)=O.[Na+]\nSULBACTAM SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1\nDrug Name: RIBAVIRIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 143.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1\nDrug Name: RIBAVIRIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 143.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1c(C)c2ccc(OCCCN3CCN(Cc4ccc(Cl)cc4)CC3)cc2oc1=O\nPICUMAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1c(C)c2ccc(OCCCN3CCN(Cc4ccc(Cl)cc4)CC3)cc2oc1=O\nPICUMAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3\nCandidate Name: Valdecoxib (Bextra)\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3\nCandidate Name: Valdecoxib (Bextra)", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C1c2ccccc2C(=O)C1c1ccc(C(F)(F)F)cc1\nCandidate Name: FLUINDAROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C1c2ccccc2C(=O)C1c1ccc(C(F)(F)F)cc1\nCandidate Name: FLUINDAROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)O.O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F\nFLECAINIDE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 474.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)O.O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F\nFLECAINIDE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 474.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1)C(=O)O\nCandidate Name: CMX-2043\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1)C(=O)O\nCandidate Name: CMX-2043", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12\nName: PRASTERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12\nName: PRASTERONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 634.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 634.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNCCc1c[nH]cn1\nName: HISTAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 111.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNCCc1c[nH]cn1\nName: HISTAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 111.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)c1ccc(C(F)(F)F)cc1OP(=O)(O)O\nFLUFOSAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)c1ccc(C(F)(F)F)cc1OP(=O)(O)O\nFLUFOSAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nc1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1\nL-21649\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nc1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1\nL-21649", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1\nPROPENZOLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1\nPROPENZOLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PREDNISONE\n\n### Structure\n```\nC[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.77 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.780\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO", "output": "## Molecular Property Analysis: PREDNISONE\n\n### Structure\n```\nC[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.77 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.780\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\\CCC(=O)O)c2ccccc2)cc1\nCandidate Name: IMIGLITAZAR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.01 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\\CCC(=O)O)c2ccccc2)cc1\nCandidate Name: IMIGLITAZAR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.01 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nN#Cc1ccc([C@H]2CCc3cncn32)c(F)c1.O=P(O)(O)O\nName: OSILODROSTAT PHOSPHATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nN#Cc1ccc([C@H]2CCc3cncn32)c(F)c1.O=P(O)(O)O\nName: OSILODROSTAT PHOSPHATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)[O-].CC(=O)[O-].[Ca+2]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 158.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)[O-].CC(=O)[O-].[Ca+2]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 158.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC1(C)CN2C(=O)c3[nH]cnc3N(Cc3ccc(Cl)cc3)C2=N1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC1(C)CN2C(=O)c3[nH]cnc3N(Cc3ccc(Cl)cc3)C2=N1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)Nc1c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c(I)c(N(C)C(C)=O)c1I\nName: METRIZAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 789.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 168.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)Nc1c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c(I)c(N(C)C(C)=O)c1I\nName: METRIZAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 789.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 168.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN(C)C(C)C(O)c1ccccc1\nCandidate Name: ETAFEDRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN(C)C(C)C(O)c1ccccc1\nCandidate Name: ETAFEDRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(SC(=O)c1cccs1)C(=O)NCC(=O)O\nDrug Name: STEPRONIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 273.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(SC(=O)c1cccs1)C(=O)NCC(=O)O\nDrug Name: STEPRONIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 273.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1.Cl.Cl\nName: BUCLIZINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 506.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.54 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1.Cl.Cl\nName: BUCLIZINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 506.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.54 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nO=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CLAVULANIC ACID\n\n### Structure\n```\nO=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 199.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.10 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 87.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.550\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nO=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21", "output": "## Molecular Property Analysis: CLAVULANIC ACID\n\n### Structure\n```\nO=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 199.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.10 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 87.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.550\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)CCCC(C)N\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 129.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)CCCC(C)N", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 129.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O\nCandidate Name: TADALAFIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O\nCandidate Name: TADALAFIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TAZOBACTAM\n\n### Structure\n```\nC[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 300.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.52 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 122.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O", "output": "## Molecular Property Analysis: TAZOBACTAM\n\n### Structure\n```\nC[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 300.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.52 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 122.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNC(=O)OC1CCN(CCCC(=O)c2ccc(F)cc2)C2CCCCC12\nName: CICARPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNC(=O)OC1CCN(CCCC(=O)c2ccc(F)cc2)C2CCCCC12\nName: CICARPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1ncc(/C(=N/OC2CCNC2=O)C(=O)N[C@@H]2C(=O)N3C(C(=O)[O-])=C(C[n+]4ccccc4)CS[C@H]23)s1\nCEFEMPIDONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 543.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -2.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 183.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1ncc(/C(=N/OC2CCNC2=O)C(=O)N[C@@H]2C(=O)N3C(C(=O)[O-])=C(C[n+]4ccccc4)CS[C@H]23)s1\nCEFEMPIDONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 543.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -2.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 183.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(C(O)CCC2CCNCC2)c2ccccc2n1\nDrug Name: QUINACAINOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(C(O)CCC2CCNCC2)c2ccccc2n1\nDrug Name: QUINACAINOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(c1ccccc1Nc1ccncc1)N1CCCCC1\nName: OFORNINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(c1ccccc1Nc1ccncc1)N1CCCCC1\nName: OFORNINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: FCOC(C(F)(F)F)C(F)(F)F\nDrug Name: SEVOFLURANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: FCOC(C(F)(F)F)C(F)(F)F\nDrug Name: SEVOFLURANE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\nCORTISONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\nCORTISONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12\nGENISTEIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12\nGENISTEIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(C(=O)/C(Br)=C\\C(=O)O)cc1\nCandidate Name: BROMEBRIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(C(=O)/C(Br)=C\\C(=O)O)cc1\nCandidate Name: BROMEBRIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nCandidate Name: NETUPITANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 578.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.79 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nCandidate Name: NETUPITANT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 578.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.79 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1cccnc1\nNIOMETACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1cccnc1\nNIOMETACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=S(O)CNc1ccc(S(=O)(=O)c2ccc(NCS(=O)O)cc2)cc1\nCandidate Name: SULFOXONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=S(O)CNc1ccc(S(=O)(=O)c2ccc(NCS(=O)O)cc2)cc1\nCandidate Name: SULFOXONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 404.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn([11CH3])c2Sc2ccc(Cl)cn2)cc1\nCandidate Name: MK-3168 C-11\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn([11CH3])c2Sc2ccc(Cl)cn2)cc1\nCandidate Name: MK-3168 C-11", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 411.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)N[C@@H](CSC(C)=O)C(=O)O\nDACISTEINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 205.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)N[C@@H](CSC(C)=O)C(=O)O\nDACISTEINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 205.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(-c2ccc(OCc3cc(C(=O)NS(=O)(=O)c4ccccc4C)oc3C)cc2)nc1\nName: BGC-20-1531 FREE BASE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 492.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(-c2ccc(OCc3cc(C(=O)NS(=O)(=O)c4ccccc4C)oc3C)cc2)nc1\nName: BGC-20-1531 FREE BASE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 492.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCc1c(OCCCCCOc2cc3c(cc2C(C)=O)CCC(C(=O)O)O3)ccc(C(C)=O)c1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCc1c(OCCCCCOc2cc3c(cc2C(C)=O)CCC(C(=O)O)O3)ccc(C(C)=O)c1O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCC1(C)C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@H](N)C(=O)O)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CILASTATIN\n\n### Structure\n```\nCC1(C)C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@H](N)C(=O)O)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.43 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 129.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.320\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCC1(C)C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@H](N)C(=O)O)C(=O)O", "output": "## Molecular Property Analysis: CILASTATIN\n\n### Structure\n```\nCC1(C)C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@H](N)C(=O)O)C(=O)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 358.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.43 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 129.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.320\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O\nName: FENOFIBRIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O\nName: FENOFIBRIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCl.NCCCC(N)(C(=O)O)C(F)F.O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCl.NCCCC(N)(C(=O)O)C(F)F.O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 236.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\n[F-].[Na+]\nSODIUM FLUORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 42.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\n[F-].[Na+]\nSODIUM FLUORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 42.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)NC(CCC(=O)O)C(=O)O\nACEGLUMATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 189.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)NC(CCC(=O)O)C(=O)O\nACEGLUMATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 189.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC12CCN(CC3(O)CC3)C(Cc3ccc(O)cc31)C2(C)C\nName: BREMAZOCINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC12CCN(CC3(O)CC3)C(Cc3ccc(O)cc31)C2(C)C\nName: BREMAZOCINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nN=C1C=CC(=C(c2ccc(N)cc2)c2ccc(N)cc2)C=C1\nPARAROSANILINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 287.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nN=C1C=CC(=C(c2ccc(N)cc2)c2ccc(N)cc2)C=C1\nPARAROSANILINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 287.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)c1cccnc1Nc1cccc(Cl)c1Cl\nDrug Name: DICLONIXIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 283.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)c1cccnc1Nc1cccc(Cl)c1Cl\nDrug Name: DICLONIXIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 283.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOC(=O)CCC/C=C\\C[C@@H]1[C@@H](C#C[C@@H](O)CCC2CCCCC2)[C@H](O)C[C@@H]1O\nName: ALFAPROSTOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOC(=O)CCC/C=C\\C[C@@H]1[C@@H](C#C[C@@H](O)CCC2CCCCC2)[C@H](O)C[C@@H]1O\nName: ALFAPROSTOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1\nName: CEFPIROME\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1\nName: CEFPIROME", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[S+](C)CCOC(=O)C(c1ccccc1)C1CCCCC1\nDrug Name: HEXASONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[S+](C)CCOC(=O)C(c1ccccc1)C1CCCCC1\nDrug Name: HEXASONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 427.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 148.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 427.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 148.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DIFLOXACIN\n\n### Structure\n```\nCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 399.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.72 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 65.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.730\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1", "output": "## Molecular Property Analysis: DIFLOXACIN\n\n### Structure\n```\nCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 399.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.72 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 65.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.730\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]\nDrug Name: TOLMETIN SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]\nDrug Name: TOLMETIN SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(C)CCOC(Cc1ccccc1)c1ccccc1.[Br-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(C)CCOC(Cc1ccccc1)c1ccccc1.[Br-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccccc1CN1CCN(CCOC(c2ccccc2)c2ccccc2Cl)CC1\nCHLORBENZOXAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 435.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccccc1CN1CCN(CCOC(c2ccccc2)c2ccccc2Cl)CC1\nCHLORBENZOXAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 435.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12\nName: DALFOPRISTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 690.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 176.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12\nName: DALFOPRISTIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 690.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 176.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC(=O)O[C@@]1(c2ccccc2)CCN(C)C[C@@H]1C\nCandidate Name: BETAPRODINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 261.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC(=O)O[C@@]1(c2ccccc2)CCN(C)C[C@@H]1C\nCandidate Name: BETAPRODINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 261.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nNS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MAVACOXIB\n\n### Structure\n```\nNS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 385.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.34 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 78.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.700\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nNS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1", "output": "## Molecular Property Analysis: MAVACOXIB\n\n### Structure\n```\nNS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 385.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.34 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 78.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.700\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)c1nc2c3cc(C)ccc3n(CC)c(=O)n2n1\nCandidate Name: MELQUINAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 300.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)c1nc2c3cc(C)ccc3n(CC)c(=O)n2n1\nCandidate Name: MELQUINAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 300.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nFc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1\nTEGOBUVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 517.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.73 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nFc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1\nTEGOBUVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 517.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.73 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOCCOC(=O)NS(=O)(=O)c1ccc(C)cc1\nTOSULUR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 273.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOCCOC(=O)NS(=O)(=O)c1ccc(C)cc1\nTOSULUR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 273.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12\nUMIFENOVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12\nUMIFENOVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DIAZEPAM\n\n### Structure\n```\nCN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.15 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 32.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21", "output": "## Molecular Property Analysis: DIAZEPAM\n\n### Structure\n```\nCN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.15 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 32.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.790\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(NCCCCc1ccccc1)C(O)c1ccc2c(c1)CCS2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(NCCCCc1ccccc1)C(O)c1ccc2c(c1)CCS2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCC(C)(COC(N)=O)COC(=O)NC1CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 258.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCC(C)(COC(N)=O)COC(=O)NC1CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 258.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ZD-4190 FREE BASE\n\n### Structure\n```\nCOc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 459.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.95 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 87.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1", "output": "## Molecular Property Analysis: ZD-4190 FREE BASE\n\n### Structure\n```\nCOc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 459.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.95 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 87.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nc1ccc(-c2nn(-c3ccccc3)[n+](-c3ccc(-c4ccc(-[n+]5nc(-c6ccccc6)nn5-c5ccccc5)cc4)cc3)n2)cc1\nNEOTETRAZOLIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 596.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.40 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nc1ccc(-c2nn(-c3ccccc3)[n+](-c3ccc(-c4ccc(-[n+]5nc(-c6ccccc6)nn5-c5ccccc5)cc4)cc3)n2)cc1\nNEOTETRAZOLIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 596.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.40 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TERFENADINE\n\n### Structure\n```\nCC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 471.7 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 43.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.400\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1", "output": "## Molecular Property Analysis: TERFENADINE\n\n### Structure\n```\nCC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 471.7 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 43.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.400\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cccc(C)c1C(OCCOCCN(C)C)c1c(C)cccc1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cccc(C)c1C(OCCOCCN(C)C)c1c(C)cccc1C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(C)CCCN(C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(C)CCCN(C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C(O)/C=C/c1ccc(O)c(O)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CAFFEIC ACID\n\n### Structure\n```\nO=C(O)/C=C/c1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 180.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.20 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C(O)/C=C/c1ccc(O)c(O)c1", "output": "## Molecular Property Analysis: CAFFEIC ACID\n\n### Structure\n```\nO=C(O)/C=C/c1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 180.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.20 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C(=O)OCCCNCCC(c2ccccc2)c2ccccc2)cc(OC)c1OC\nName: MEPRAMIDIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 463.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C(=O)OCCCNCCC(c2ccccc2)c2ccccc2)cc(OC)c1OC\nName: MEPRAMIDIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 463.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)CCOc1ccc(/C(=C(\\Cl)c2ccccc2)c2ccccc2)cc1\nDrug Name: ZUCLOMIPHENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)CCOc1ccc(/C(=C(\\Cl)c2ccccc2)c2ccccc2)cc1\nDrug Name: ZUCLOMIPHENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)NCC(O)COc1ccccc1NC(=O)c1ccco1\nName: ANCAROLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)NCC(O)COc1ccccc1NC(=O)c1ccco1\nName: ANCAROLOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O)[C@H]1CN(C/C=C/P(=O)(O)O)CCN1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 250.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O)[C@H]1CN(C/C=C/P(=O)(O)O)CCN1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 250.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.Cl.Cl\nName: CHLOROQUINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.Cl.Cl\nName: CHLOROQUINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOC(=O)c1nc2cc(Cl)c3cccnc3c2o1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: QUAZOLAST\n\n### Structure\n```\nCOC(=O)c1nc2cc(Cl)c3cccnc3c2o1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 262.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.82 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOC(=O)c1nc2cc(Cl)c3cccnc3c2o1", "output": "## Molecular Property Analysis: QUAZOLAST\n\n### Structure\n```\nCOC(=O)c1nc2cc(Cl)c3cccnc3c2o1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 262.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.82 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1\nName: NITRAZEPAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1\nName: NITRAZEPAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 281.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O\nName: SELODENOSON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O\nName: SELODENOSON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)=CCOc1cc(NC(=S)c2ccoc2C)ccc1Cl\nDrug Name: UC 781\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.37 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)=CCOc1cc(NC(=S)c2ccoc2C)ccc1Cl\nDrug Name: UC 781", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.37 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TRIMETREXATE\n\n### Structure\n```\nCOc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 369.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.74 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 117.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.610\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC", "output": "## Molecular Property Analysis: TRIMETREXATE\n\n### Structure\n```\nCOc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 369.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.74 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 117.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.610\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CC(C(=O)O)C(P(=O)(O)O)P(=O)(O)O\nDrug Name: BUTEDRONIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 292.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 189.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CC(C(=O)O)C(P(=O)(O)O)P(=O)(O)O\nDrug Name: BUTEDRONIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 292.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 189.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOC(=O)C(c1ccccc1)C1CCCCN1.Cl\nMETHYLPHENIDATE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 269.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOC(=O)C(c1ccccc1)C1CCCCN1.Cl\nMETHYLPHENIDATE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 269.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O\nDrug Name: Levothyroxine\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O\nDrug Name: Levothyroxine", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C\nESTRADIOL VALERATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.35 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C\nESTRADIOL VALERATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.35 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCc1c(SCCCOc2ccc(C(C)=O)c(OCCCC(=O)O)c2CCC)ccc(C(C)=O)c1O\nCandidate Name: TIPELUKAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 530.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCc1c(SCCCOc2ccc(C(C)=O)c(OCCCC(=O)O)c2CCC)ccc(C(C)=O)c1O\nCandidate Name: TIPELUKAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 530.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(OOC(=O)c1ccccc1)c1ccccc1\nBENZOYL PEROXIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(OOC(=O)c1ccccc1)c1ccccc1\nBENZOYL PEROXIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCl.O=c1[nH]ccc2cc(OC3CCNCC3)ccc12\nSAR-407899\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCl.O=c1[nH]ccc2cc(OC3CCNCC3)ccc12\nSAR-407899", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)NCC(O)COc1ccc(CCNC(=O)NC(C)C)cc1\nPAFENOLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)NCC(O)COc1ccc(CCNC(=O)NC(C)C)cc1\nPAFENOLOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O\nCILAZAPRILAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O\nCILAZAPRILAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)CCC/C=C\\C[C@@H]1[C@@H](/C=C/C2(COc3cccc(Cl)c3)OCCO2)[C@H](O)C[C@@H]1O\nName: LANPROSTON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)CCC/C=C\\C[C@@H]1[C@@H](/C=C/C2(COc3cccc(Cl)c3)OCCO2)[C@H](O)C[C@@H]1O\nName: LANPROSTON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 467.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 494.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 494.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4CC(=O)CC[C@]4(C)[C@H]3CC(=O)[C@]12C\nName: DEHYDROCHOLIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4CC(=O)CC[C@]4(C)[C@H]3CC(=O)[C@]12C\nName: DEHYDROCHOLIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCNC(=O)c1coc([C@H]2[C@@H](Cc3ccccc3CCC(=O)[O-])[C@@H]3CC[C@H]2O3)n1.[Na+]\nCandidate Name: IFETROBAN SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 462.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCNC(=O)c1coc([C@H]2[C@@H](Cc3ccccc3CCC(=O)[O-])[C@@H]3CC[C@H]2O3)n1.[Na+]\nCandidate Name: IFETROBAN SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 462.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nFc1ccccc1C1=NCCN(CC(F)(F)F)c2ccc(Cl)cc21\nFLETAZEPAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nFc1ccccc1C1=NCCN(CC(F)(F)F)c2ccc(Cl)cc21\nFLETAZEPAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nDrug Name: HYDROCORTISONE VALERATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nDrug Name: HYDROCORTISONE VALERATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ARTEMISININ\n\n### Structure\n```\nC[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 282.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.39 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 54.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.500\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4", "output": "## Molecular Property Analysis: ARTEMISININ\n\n### Structure\n```\nC[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 282.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.39 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 54.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.500\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O\nNALOXONE HYDROCHLORIDE DIHYDRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O\nNALOXONE HYDROCHLORIDE DIHYDRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12\nABEXINOSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12\nABEXINOSTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl\nName: CHLORTETRACYCLINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 515.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl\nName: CHLORTETRACYCLINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 515.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)Oc1ccccc1C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)Oc1ccccc1C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c(c1)OC(C)(C)[C@@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1\nDrug Name: LEVORMELOXIFENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c(c1)OC(C)(C)[C@@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1\nDrug Name: LEVORMELOXIFENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 457.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1.O=C(O)CCC(=O)O\nCandidate Name: IFENPRODIL TARTRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1.O=C(O)CCC(=O)O\nCandidate Name: IFENPRODIL TARTRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C)nc(-n2nc(C)cc2OC)n1\nName: EPIRIZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 234.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C)nc(-n2nc(C)cc2OC)n1\nName: EPIRIZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 234.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cnc(C(=O)O)c[n+]1[O-]\nCandidate Name: ACIPIMOX\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 154.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cnc(C(=O)O)c[n+]1[O-]\nCandidate Name: ACIPIMOX", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 154.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 327.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 327.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(C)CCC1CN(C)C(=S)c2cccnc2O1\nName: ROCASTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(C)CCC1CN(C)C(=S)c2cccnc2O1\nName: ROCASTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(-c2nnc(C)nc2-c2ccc(OC)cc2)cc1\nName: ANITRAZAFEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(-c2nnc(C)nc2-c2ccc(OC)cc2)cc1\nName: ANITRAZAFEN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3\nAPOMORPHINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3\nAPOMORPHINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCOC(=O)C(=O)Nc1nc(-c2ccc(OC)cc2)cs1\nDrug Name: TIOXAMAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCOC(=O)C(=O)Nc1nc(-c2ccc(OC)cc2)cs1\nDrug Name: TIOXAMAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc(N)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O\nCandidate Name: AZAMULIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc(N)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O\nCandidate Name: AZAMULIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 131.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC=CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C\nName: BOLDENONE UNDECYLENATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC=CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C\nName: BOLDENONE UNDECYLENATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.51 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc(=O)oc2cc(OCCN3CCOCC3)cc(OCCN3CCOCC3)c12\nDrug Name: MOXICOUMONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc(=O)oc2cc(OCCN3CCOCC3)cc(OCCN3CCOCC3)c12\nDrug Name: MOXICOUMONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.63 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.63 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1\nCandidate Name: FURAZOLIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 238.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1\nCandidate Name: FURAZOLIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 238.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)CCOC(=O)C(NCCN1CCCC1)c1ccccc1\nDrug Name: CAMIVERINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)CCOC(=O)C(NCCN1CCCC1)c1ccccc1\nDrug Name: CAMIVERINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1\nDrug Name: TRIFAROTENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 459.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1\nDrug Name: TRIFAROTENE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 459.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPropose a safer analog of this failed drug:\nVercirnon: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl\nFailure reason: Failed to show efficacy in Crohn's disease patients\n<|im_end|>\n<|im_start|>assistant\n## Structural Improvement Suggestions for Vercirnon\n\n### Original Issue\nFailed to show efficacy in Crohn's disease patients\n\n### Recommended Modifications\n\n1. **Reduce Metabolic Liability**\n   - Replace metabolically labile groups (e.g., ester ‚Üí amide)\n   - Block sites of CYP450 oxidation with fluorine substitution\n   - Reduce lipophilicity to minimize reactive metabolite formation\n\n2. **Improve Selectivity**\n   - Add stereochemical constraints to reduce off-target binding\n   - Modify substituents to exploit differences in target binding sites\n   - Use structure-guided design based on target crystal structures\n\n3. **Address Specific Toxicity**\n   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk\n   - If hepatotoxicity: remove metabolically activated groups\n   - If CNS effects: increase polarity to reduce brain penetration\n\n### General Principles\n- Maintain target engagement (measure IC50/EC50)\n- Improve therapeutic index (efficacy dose vs toxicity dose)\n- Consider prodrug strategies for problematic functional groups\n\n<|im_end|>", "instruction": "Propose a safer analog of this failed drug:\nVercirnon: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl\nFailure reason: Failed to show efficacy in Crohn's disease patients", "output": "## Structural Improvement Suggestions for Vercirnon\n\n### Original Issue\nFailed to show efficacy in Crohn's disease patients\n\n### Recommended Modifications\n\n1. **Reduce Metabolic Liability**\n   - Replace metabolically labile groups (e.g., ester ‚Üí amide)\n   - Block sites of CYP450 oxidation with fluorine substitution\n   - Reduce lipophilicity to minimize reactive metabolite formation\n\n2. **Improve Selectivity**\n   - Add stereochemical constraints to reduce off-target binding\n   - Modify substituents to exploit differences in target binding sites\n   - Use structure-guided design based on target crystal structures\n\n3. **Address Specific Toxicity**\n   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk\n   - If hepatotoxicity: remove metabolically activated groups\n   - If CNS effects: increase polarity to reduce brain penetration\n\n### General Principles\n- Maintain target engagement (measure IC50/EC50)\n- Improve therapeutic index (efficacy dose vs toxicity dose)\n- Consider prodrug strategies for problematic functional groups\n", "task_type": "improvement_suggestion"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1\nCandidate Name: TAFAMIDIS MEGLUMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 503.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1\nCandidate Name: TAFAMIDIS MEGLUMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 503.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: N#Cc1ccc(/C=N/NC(N)=S)s1\nCandidate Name: CITENAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 210.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: N#Cc1ccc(/C=N/NC(N)=S)s1\nCandidate Name: CITENAZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 210.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\nDEMANNOSE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\nDEMANNOSE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 180.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)CCOc1ccc(NC(=S)Nc2ccc(OCCC(C)C)cc2)cc1\nTIOCARLIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)CCOc1ccc(NC(=S)Nc2ccc(OCCC(C)C)cc2)cc1\nTIOCARLIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1\nCandidate Name: MOPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1\nCandidate Name: MOPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1\nHYDROXYZINE PAMOATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 763.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1\nHYDROXYZINE PAMOATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 763.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\\O)c3csc(N)n3)[C@H]2SC1\nDrug Name: CEFDINIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 395.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 158.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\\O)c3csc(N)n3)[C@H]2SC1\nDrug Name: CEFDINIR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 395.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 158.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C(O)c1cn2c(cnc3ccccc32)n1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DAZOQUINAST\n\n### Structure\n```\nO=C(O)c1cn2c(cnc3ccccc32)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 213.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 67.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C(O)c1cn2c(cnc3ccccc32)n1", "output": "## Molecular Property Analysis: DAZOQUINAST\n\n### Structure\n```\nO=C(O)c1cn2c(cnc3ccccc32)n1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 213.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.58 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 67.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C\nCandidate Name: ARBACLOFEN PLACARBIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C\nCandidate Name: ARBACLOFEN PLACARBIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]\nDOXYCYCLINE CALCIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 926.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]\nDOXYCYCLINE CALCIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 926.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: AZELASTINE\n\n### Structure\n```\nCN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 381.9 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.30 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 38.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1", "output": "## Molecular Property Analysis: AZELASTINE\n\n### Structure\n```\nCN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 381.9 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.30 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 38.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC#CCN(C)Cc1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PARGYLINE\n\n### Structure\n```\nC#CCN(C)Cc1ccccc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 159.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.610\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nC#CCN(C)Cc1ccccc1", "output": "## Molecular Property Analysis: PARGYLINE\n\n### Structure\n```\nC#CCN(C)Cc1ccccc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 159.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.75 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.610\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: AMIFLOXACIN\n\n### Structure\n```\nCNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.76 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.860\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21", "output": "## Molecular Property Analysis: AMIFLOXACIN\n\n### Structure\n```\nCNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.76 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.860\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCOc1ccc2[nH]c(NC(=O)OC)nc2c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCOc1ccc2[nH]c(NC(=O)OC)nc2c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCO[C@H](C(=O)NO)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)Nc1ccccn1)C(C)(C)C\nSOLIMASTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 129.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCO[C@H](C(=O)NO)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)Nc1ccccn1)C(C)(C)C\nSOLIMASTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 129.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl\nCandidate Name: MOLINDONE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl\nCandidate Name: MOLINDONE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nN[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O\nName: FOSLEVODOPA\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nN[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O\nName: FOSLEVODOPA", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS\nDrug Name: COENZYME_A\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 767.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |\n| H-Bond Donors | 10.0 | ‚ö† High (>5) |\n| Polar Surface Area | 346.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS\nDrug Name: COENZYME_A", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 767.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |\n| H-Bond Donors | 10.0 | ‚ö† High (>5) |\n| Polar Surface Area | 346.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(-c2coc3cc(O)ccc3c2=O)cc1\nDrug Name: FORMONONETIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 268.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(-c2coc3cc(O)ccc3c2=O)cc1\nDrug Name: FORMONONETIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 268.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nFc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nFc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12\nILORASERTIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12\nILORASERTIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O\nDrug Name: THIOTHIXENE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O\nDrug Name: THIOTHIXENE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl\nDrug Name: CHLORPROMAZINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl\nDrug Name: CHLORPROMAZINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: LAPATINIB\n\n### Structure\n```\nCS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 581.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.14 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 106.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.180\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1", "output": "## Molecular Property Analysis: LAPATINIB\n\n### Structure\n```\nCS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 581.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.14 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 106.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.180\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.O\nDrug Name: CAPMATINIB HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.O\nDrug Name: CAPMATINIB HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(O)c(CC=C(C)C)c(O)c1C(=O)/C=C/c1ccc(O)cc1\nDrug Name: XANTHOHUMOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(O)c(CC=C(C)C)c(O)c1C(=O)/C=C/c1ccc(O)cc1\nDrug Name: XANTHOHUMOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O\nCandidate Name: FLAVOXATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O\nCandidate Name: FLAVOXATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1c(OC[C@H](O)CN2CCOCC2)ccc2c1N=C(NC(=O)c1cccnc1C)N1CCN=C21\nDrug Name: BAY-1082439\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 494.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1c(OC[C@H](O)CN2CCOCC2)ccc2c1N=C(NC(=O)c1cccnc1C)N1CCN=C21\nDrug Name: BAY-1082439", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 494.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1\nCandidate Name: TAPRENEPAG\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1\nCandidate Name: TAPRENEPAG", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1.O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1.O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(O/N=C(\\C(=O)NC1CN(C(=O)NS(=O)(=O)N2CCN(NC(=O)c3cc(=O)c(O)c[nH]3)C2=O)C1=O)c1csc(N)n1)C(=O)O\nName: PIRAZMONAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 684.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -2.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 316.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(O/N=C(\\C(=O)NC1CN(C(=O)NS(=O)(=O)N2CCN(NC(=O)c3cc(=O)c(O)c[nH]3)C2=O)C1=O)c1csc(N)n1)C(=O)O\nName: PIRAZMONAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 684.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -2.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 316.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: [Ca+2].[Cl-].[Cl-]\nDrug Name: CALCIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 111.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: [Ca+2].[Cl-].[Cl-]\nDrug Name: CALCIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 111.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CNCC[C@@H](Oc1ccccc1C)c1ccccc1\nCandidate Name: ATOMOXETINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CNCC[C@@H](Oc1ccccc1C)c1ccccc1\nCandidate Name: ATOMOXETINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: LORMETAZEPAM\n\n### Structure\n```\nCN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 335.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.13 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 52.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.870\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21", "output": "## Molecular Property Analysis: LORMETAZEPAM\n\n### Structure\n```\nCN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 335.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.13 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 52.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.870\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nN=C(N)NS(=O)(=O)c1ccc(N)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nN=C(N)NS(=O)(=O)c1ccc(N)cc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(OC)c(C(O)C(C)N)c1\nCandidate Name: METHOXAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(OC)c(C(O)C(C)N)c1\nCandidate Name: METHOXAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC[N+](C)(CC)CCC(C)OC(=O)c1ccc(Br)o1.[I-]\nFUBROGONIUM IODIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 460.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC[N+](C)(CC)CCC(C)OC(=O)c1ccc(Br)o1.[I-]\nFUBROGONIUM IODIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 460.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCNCCCCNCCCCNCCCCNCC\nDrug Name: DIETHYLHOMOSPERMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCNCCCCNCCCCNCCCCNCC\nDrug Name: DIETHYLHOMOSPERMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOCCc1ccccn1\nMETYRIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 137.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 22.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOCCc1ccccn1\nMETYRIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 137.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 22.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O\nOXYMESTERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O\nOXYMESTERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC#CC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12\nPLOMESTANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC#CC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12\nPLOMESTANE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCN[C@@]12C=CC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5\nDrug Name: PENTAMORPHONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 368.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCN[C@@]12C=CC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5\nDrug Name: PENTAMORPHONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 368.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nMETHYLPREDNISOLONE ACEPONATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 472.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C\nMETHYLPREDNISOLONE ACEPONATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 472.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nNCCc1ccc(O)c(O)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DOPAMINE\n\n### Structure\n```\nNCCc1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 153.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.60 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nNCCc1ccc(O)c(O)c1", "output": "## Molecular Property Analysis: DOPAMINE\n\n### Structure\n```\nNCCc1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 153.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.60 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 375.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TETROXOPRIM\n\n### Structure\n```\nCOCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.27 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 114.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.690\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC", "output": "## Molecular Property Analysis: TETROXOPRIM\n\n### Structure\n```\nCOCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 334.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.27 | 0-5 | ‚úì |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 114.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.690\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cc(=O)oc2cc(O[C@@H]3SC[C@@H](O)[C@H](O)[C@H]3O)ccc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cc(=O)oc2cc(O[C@@H]3SC[C@@H](O)[C@H](O)[C@H]3O)ccc12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNc1c(C(=O)OCC)cnc2c1cnn2CC\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CARTAZOLATE\n\n### Structure\n```\nCCCCNc1c(C(=O)OCC)cnc2c1cnn2CC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 290.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.84 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 69.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCCCCNc1c(C(=O)OCC)cnc2c1cnn2CC", "output": "## Molecular Property Analysis: CARTAZOLATE\n\n### Structure\n```\nCCCCNc1c(C(=O)OCC)cnc2c1cnn2CC\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 290.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.84 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 69.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.630\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)C(=S)SSC(=S)N(C)C\nDrug Name: THIRAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)C(=S)SSC(=S)N(C)C\nDrug Name: THIRAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(C)CCOc1ccccc1Cc1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(C)CCOc1ccccc1Cc1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)CP(=O)(O)O\nFOSFONET\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 140.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)CP(=O)(O)O\nFOSFONET", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 140.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 519.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 519.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C/C(=C/CCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1\nDrug Name: SPIRILENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C/C(=C/CCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1\nDrug Name: SPIRILENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21\nDrug Name: ENMD-981693\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21\nDrug Name: ENMD-981693", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC1(C)S[C@@H]2[C@H](NC(=O)[C@H](/N=C/c3ccco3)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC1(C)S[C@@H]2[C@H](NC(=O)[C@H](/N=C/c3ccco3)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 443.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nHow could Reactive_Met_001 be modified to reduce its toxicity risks?\nOriginal structure: CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl\n<|im_end|>\n<|im_start|>assistant\n## Structural Improvement Suggestions for Reactive_Met_001\n\n### Original Issue\nFormation of reactive quinone-imine metabolite causing hepatotoxicity\n\n### Recommended Modifications\n\n1. **Reduce Metabolic Liability**\n   - Replace metabolically labile groups (e.g., ester ‚Üí amide)\n   - Block sites of CYP450 oxidation with fluorine substitution\n   - Reduce lipophilicity to minimize reactive metabolite formation\n\n2. **Improve Selectivity**\n   - Add stereochemical constraints to reduce off-target binding\n   - Modify substituents to exploit differences in target binding sites\n   - Use structure-guided design based on target crystal structures\n\n3. **Address Specific Toxicity**\n   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk\n   - If hepatotoxicity: remove metabolically activated groups\n   - If CNS effects: increase polarity to reduce brain penetration\n\n### General Principles\n- Maintain target engagement (measure IC50/EC50)\n- Improve therapeutic index (efficacy dose vs toxicity dose)\n- Consider prodrug strategies for problematic functional groups\n\n<|im_end|>", "instruction": "How could Reactive_Met_001 be modified to reduce its toxicity risks?\nOriginal structure: CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl", "output": "## Structural Improvement Suggestions for Reactive_Met_001\n\n### Original Issue\nFormation of reactive quinone-imine metabolite causing hepatotoxicity\n\n### Recommended Modifications\n\n1. **Reduce Metabolic Liability**\n   - Replace metabolically labile groups (e.g., ester ‚Üí amide)\n   - Block sites of CYP450 oxidation with fluorine substitution\n   - Reduce lipophilicity to minimize reactive metabolite formation\n\n2. **Improve Selectivity**\n   - Add stereochemical constraints to reduce off-target binding\n   - Modify substituents to exploit differences in target binding sites\n   - Use structure-guided design based on target crystal structures\n\n3. **Address Specific Toxicity**\n   - If cardiotoxicity: reduce basicity and lipophilicity to lower hERG risk\n   - If hepatotoxicity: remove metabolically activated groups\n   - If CNS effects: increase polarity to reduce brain penetration\n\n### General Principles\n- Maintain target engagement (measure IC50/EC50)\n- Improve therapeutic index (efficacy dose vs toxicity dose)\n- Consider prodrug strategies for problematic functional groups\n", "task_type": "improvement_suggestion"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 387.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 387.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21\nCandidate Name: SEMAGACESTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21\nCandidate Name: SEMAGACESTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@@H](C(=O)N1CCOCC1)N1CC[C@H](NS(=O)(=O)/C=C/c2ccc(Cl)s2)C1=O\nName: GW813893\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 448.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@@H](C(=O)N1CCOCC1)N1CC[C@H](NS(=O)(=O)/C=C/c2ccc(Cl)s2)C1=O\nName: GW813893", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 448.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C\nCandidate Name: PHA-793887\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C\nCandidate Name: PHA-793887", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 361.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1\nName: DIFENOXIN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1\nName: DIFENOXIN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCc1cc(=O)n(-c2ccccc2)n1C\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ANTIPYRINE\n\n### Structure\n```\nCc1cc(=O)n(-c2ccccc2)n1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 188.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.48 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 26.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCc1cc(=O)n(-c2ccccc2)n1C", "output": "## Molecular Property Analysis: ANTIPYRINE\n\n### Structure\n```\nCc1cc(=O)n(-c2ccccc2)n1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 188.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.48 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 26.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1\nCandidate Name: DIPERODON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1\nCandidate Name: DIPERODON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOCCCC/C(=N\\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\\C(=O)O\nName: FLUVOXAMINE MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOCCCC/C(=N\\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\\C(=O)O\nName: FLUVOXAMINE MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=[N+]([O-])c1nccn1CC(O)CN1CCCCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=[N+]([O-])c1nccn1CC(O)CN1CCCCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)c1ccccc1\nDrug Name: CLOPIDOGREL BESILATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)c1ccccc1\nDrug Name: CLOPIDOGREL BESILATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: BETAMETHASONE\n\n### Structure\n```\nC[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 392.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.90 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 94.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO", "output": "## Molecular Property Analysis: BETAMETHASONE\n\n### Structure\n```\nC[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 392.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.90 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 94.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.670\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Clc1ccccc1C(c1ccc(-c2ccccc2)cc1)n1ccnc1\nCandidate Name: LOMBAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.84 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Clc1ccccc1C(c1ccc(-c2ccccc2)cc1)n1ccnc1\nCandidate Name: LOMBAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.84 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 484.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 484.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1\nCandidate Name: ENTINOSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1\nCandidate Name: ENTINOSTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1\nBEPRIDIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1\nBEPRIDIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 15.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC1(c2ccccc2)OC(C(=O)O)=CC1=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ACIFRAN\n\n### Structure\n```\nCC1(c2ccccc2)OC(C(=O)O)=CC1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 218.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.47 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.820\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC1(c2ccccc2)OC(C(=O)O)=CC1=O", "output": "## Molecular Property Analysis: ACIFRAN\n\n### Structure\n```\nCC1(c2ccccc2)OC(C(=O)O)=CC1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 218.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.47 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 63.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.820\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C\nName: NORETHINDRONE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C\nName: NORETHINDRONE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 340.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: VORICONAZOLE\n\n### Structure\n```\nC[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 349.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.18 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 76.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.760\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F", "output": "## Molecular Property Analysis: VORICONAZOLE\n\n### Structure\n```\nC[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 349.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.18 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 76.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.760\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O\nN-ACETYLMANNOSAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 221.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O\nN-ACETYLMANNOSAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 221.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 119.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 45.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1\nGLASDEGIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 374.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1\nGLASDEGIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 374.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCCCCCCN1CCN(CCN2CCN(C(=O)N(CC)CC)CC2)C1=O\nIMPACARZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 493.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCCCCCCCCCCN1CCN(CCN2CCN(C(=O)N(CC)CC)CC2)C1=O\nIMPACARZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 493.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.50 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O\nCandidate Name: ZOLPIDEM TARTRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O\nCandidate Name: ZOLPIDEM TARTRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1CCC(C)[N+]1(C)CCOC(=O)C(O)(c1ccccc1)c1ccccc1\nDIMETIPIRIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 368.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1CCC(C)[N+]1(C)CCOC(=O)C(O)(c1ccccc1)c1ccccc1\nDIMETIPIRIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 368.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO\nDrug Name: ERYTHROMYCIN LACTOBIONATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1092.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO\nDrug Name: ERYTHROMYCIN LACTOBIONATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1092.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 193.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C1c2cccc(O)c2C(=O)c2c(O)cccc21\nName: DANTHRON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C1c2cccc(O)c2C(=O)c2c(O)cccc21\nName: DANTHRON", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)CN1CCN(CC(=O)O)CCN(C(CO)C(O)CO)CCN(CC(=O)O)CC1\nName: CALCOBUTROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 450.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 185.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)CN1CCN(CC(=O)O)CCN(C(CO)C(O)CO)CCN(CC(=O)O)CC1\nName: CALCOBUTROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 450.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 185.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.O=S(=O)(O)O\nName: PACTIMIBE SULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 931.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21.O=S(=O)(O)O\nName: PACTIMIBE SULFATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 931.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1\nName: DEFERASIROX\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1\nName: DEFERASIROX", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1CCO1\nDrug Name: PROPIOLACTONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 72.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1CCO1\nDrug Name: PROPIOLACTONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 72.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN.CS(=O)(=O)O\nDEFEROXAMINE MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 656.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 205.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN.CS(=O)(=O)O\nDEFEROXAMINE MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 656.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 205.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(=O)O)[C@H]12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(=O)O)[C@H]12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I\nDrug Name: IOPAMIDOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 777.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 188.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I\nDrug Name: IOPAMIDOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 777.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 188.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nN[C@H](CCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)C(=O)O\nGOLOTIMOD\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 145.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nN[C@H](CCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)C(=O)O\nGOLOTIMOD", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 145.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCCCCC(=O)NCCO\nCandidate Name: PALMIDROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCCCCC(=O)NCCO\nCandidate Name: PALMIDROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1\nCandidate Name: PROCHLORPERAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1\nCandidate Name: PROCHLORPERAZINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(OC)cc(N2CCN(C(=O)Nc3nc4cc(F)ccc4nc3OC)CC2)c1\nCandidate Name: SUPINOXIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(OC)cc(N2CCN(C(=O)Nc3nc4cc(F)ccc4nc3OC)CC2)c1\nCandidate Name: SUPINOXIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC=CC1CNCCC1CCC(=O)c1ccnc2ccc(OC)cc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC=CC1CNCCC1CCC(=O)c1ccnc2ccc(OC)cc12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccnc([N-]S(=O)(=O)c2ccc(N)cc2)n1.[Na+]\nCandidate Name: SULFAMERAZINE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccnc([N-]S(=O)(=O)c2ccc(N)cc2)n1.[Na+]\nCandidate Name: SULFAMERAZINE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc(C2CNC(=O)C2)cc1OCCCN1CCC(C(=O)c2ccc(F)cc2)CC1\nLIDANSERIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc(C2CNC(=O)C2)cc1OCCCN1CCC(C(=O)c2ccc(F)cc2)CC1\nLIDANSERIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl\nName: ESMOLOL HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl\nName: ESMOLOL HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2\nLY-2090314\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 512.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2\nLY-2090314", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 512.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1.O=S(=O)([O-])O\nName: ISAVUCONAZONIUM SULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 814.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 159.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1.O=S(=O)([O-])O\nName: ISAVUCONAZONIUM SULFATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 814.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 159.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CCC(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1\nDrug Name: SUCCINYLSULFATHIAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CCC(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1\nDrug Name: SUCCINYLSULFATHIAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nc1ccc2ccccc2c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: NAPHTHALENE\n\n### Structure\n```\nc1ccc2ccccc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 128.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 2.84 | 0-5 | ‚úì |\n| H-Bond Acceptors | 0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 0.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.510\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nc1ccc2ccccc2c1", "output": "## Molecular Property Analysis: NAPHTHALENE\n\n### Structure\n```\nc1ccc2ccccc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 128.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 2.84 | 0-5 | ‚úì |\n| H-Bond Acceptors | 0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 0.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.510\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CC(O)(CC(=O)O)C(=O)O.[O-][n+]1cccc(/C(Cl)=N/OC[C@H](O)CN2CCCCC2)c1\nCandidate Name: ARIMOCLOMOL CITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CC(O)(CC(=O)O)C(=O)O.[O-][n+]1cccc(/C(Cl)=N/OC[C@H](O)CN2CCCCC2)c1\nCandidate Name: ARIMOCLOMOL CITRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1\nName: MLN-8054\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 476.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1\nName: MLN-8054", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 476.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1\nLEXIBULIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1\nLEXIBULIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@H](O)[C@H](O)C[C@@H]12\nName: EPIMESTROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@H](O)[C@H](O)C[C@@H]12\nName: EPIMESTROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C1CCCC1.[Br-]\nName: PENOCTONIUM BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C1CCCC1.[Br-]\nName: PENOCTONIUM BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 488.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC(c1ccc(O)cc1)C(CC)C(C)c1ccc(O)cc1\nCandidate Name: BENZESTROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 298.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.42 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC(c1ccc(O)cc1)C(CC)C(C)c1ccc(O)cc1\nCandidate Name: BENZESTROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 298.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.42 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)=CCNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)=CCNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12\nCEFONICID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 542.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 204.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12\nCEFONICID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 542.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 204.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1CC(=O)N2CCSC2=N1\nOLPIMEDONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 170.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1CC(=O)N2CCSC2=N1\nOLPIMEDONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 170.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCC1=C2CC[C@]3(C)[C@@H](OC(C)=O)CC[C@H]3[C@@H]2CCC1=O\nDrug Name: INOCOTERONE ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCC1=C2CC[C@]3(C)[C@@H](OC(C)=O)CC[C@H]3[C@@H]2CCC1=O\nDrug Name: INOCOTERONE ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)COC(=O)c1ccc(N)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)COC(=O)c1ccc(N)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(NCCO[N+](=O)[O-])c1cccnc1\nName: NICORANDIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(NCCO[N+](=O)[O-])c1cccnc1\nName: NICORANDIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nOc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: HEXACHLOROPHENE\n\n### Structure\n```\nOc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 406.9 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.61 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 40.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.550\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nOc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl", "output": "## Molecular Property Analysis: HEXACHLOROPHENE\n\n### Structure\n```\nOc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 406.9 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.61 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 40.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.550\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1.O=C(O)/C=C\\C(=O)O\nDrug Name: CIPRALISANT MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1.O=C(O)/C=C\\C(=O)O\nDrug Name: CIPRALISANT MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC\nName: TRIMETHOPRIM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC\nName: TRIMETHOPRIM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O\nCandidate Name: VOGLIBOSE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 153.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O\nCandidate Name: VOGLIBOSE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 153.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C(=O)O)c1ccc(Nc2ccccc2C(=O)O)cc1\nName: ARAPROFEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C(=O)O)c1ccc(Nc2ccccc2C(=O)O)cc1\nName: ARAPROFEN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.O=C(O)[C@H](O)[C@@H](O)C(=O)O\nCandidate Name: ELIGLUSTAT TARTRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.O=C(O)[C@H](O)[C@@H](O)C(=O)O\nCandidate Name: ELIGLUSTAT TARTRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(C)CCc1c[nH]c2cccc(O)c12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 204.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(C)CCc1c[nH]c2cccc(O)c12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 204.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: [N-]=[N+]=O\nDrug Name: NITROUS OXIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 44.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: [N-]=[N+]=O\nDrug Name: NITROUS OXIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 44.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CC(=O)N/C1=N\\P(=O)(O)O\nFOSFOCREATININE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 102.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CC(=O)N/C1=N\\P(=O)(O)O\nFOSFOCREATININE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 102.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1\nGOSOGLIPTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1\nGOSOGLIPTIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O\nREMOGLIFLOZIN ETABONATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 522.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O\nREMOGLIFLOZIN ETABONATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 522.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(=O)C(C)C)n3)nc3c(Br)c(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)O\nDrug Name: FALDAPREVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 869.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.30 | ‚ö† High (>5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 198.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(=O)C(C)C)n3)nc3c(Br)c(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)O\nDrug Name: FALDAPREVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 869.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.30 | ‚ö† High (>5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 198.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccc(Cl)cc1)C2\nCandidate Name: CLOBENZTROPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccc(Cl)cc1)C2\nCandidate Name: CLOBENZTROPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C\nName: RENANOLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C\nName: RENANOLONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DITERCALINIUM CHLORIDE\n\n### Structure\n```\nCOc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 789.9 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 7.98 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 64.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.150\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]", "output": "## Molecular Property Analysis: DITERCALINIUM CHLORIDE\n\n### Structure\n```\nCOc1ccc2[nH]c3ccc4cc[n+](CCN5CCC(C6CCN(CC[n+]7ccc8ccc9[nH]c%10ccc(OC)cc%10c9c8c7)CC6)CC5)cc4c3c2c1.[Cl-].[Cl-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 789.9 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 7.98 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 64.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.150\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(CCl)c1ccc(Oc2ccc(C(=O)CCl)cc2)cc1\nCLOFENOXYDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(CCl)c1ccc(Oc2ccc(C(=O)CCl)cc2)cc1\nCLOFENOXYDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC(=O)C(CC(C)N1CCOCC1)(c1ccccc1)c1ccccc1\nName: PHENADOXONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 351.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC(=O)C(CC(C)N1CCOCC1)(c1ccccc1)c1ccccc1\nName: PHENADOXONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 351.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(-c2ccccc2)n(/N=N/n2c(-c3ccccc3)c(C)[n+]3ccccc23)c2cccc[n+]12.[Br-].[Br-]\nCandidate Name: FAZADINIUM BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 604.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1c(-c2ccccc2)n(/N=N/n2c(-c3ccccc3)c(C)[n+]3ccccc23)c2cccc[n+]12.[Br-].[Br-]\nCandidate Name: FAZADINIUM BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 604.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 42.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC\nDrug Name: ALFUZOSIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 111.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC\nDrug Name: ALFUZOSIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 389.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 111.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1[C@@H](CC(=O)c2ccccc2)CCC[C@H]1C[C@H](O)c1ccccc1\nDrug Name: LOBELINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1[C@@H](CC(=O)c2ccccc2)CCC[C@H]1C[C@H](O)c1ccccc1\nDrug Name: LOBELINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nc1ccc2c(CCC3CCNCC3)c[nH]c2c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: INDALPINE\n\n### Structure\n```\nc1ccc2c(CCC3CCNCC3)c[nH]c2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 228.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.10 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 27.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nc1ccc2c(CCC3CCNCC3)c[nH]c2c1", "output": "## Molecular Property Analysis: INDALPINE\n\n### Structure\n```\nc1ccc2c(CCC3CCNCC3)c[nH]c2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 228.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.10 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 27.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nc1csc(Cc2ccccc2OCC2CNCCO2)c1\nName: TENILOXAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nc1csc(Cc2ccccc2OCC2CNCCO2)c1\nName: TENILOXAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nN=C1SCCN1c1ccc(Cl)cc1N\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 227.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nN=C1SCCN1c1ccc(Cl)cc1N", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 227.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nO=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CHLOROGENIC ACID\n\n### Structure\n```\nO=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 354.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 6.0 | ‚â§5 | ‚ö† |\n| PSA | 164.8 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.230\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nO=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O", "output": "## Molecular Property Analysis: CHLOROGENIC ACID\n\n### Structure\n```\nO=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 354.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 6.0 | ‚â§5 | ‚ö† |\n| PSA | 164.8 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.230\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2.Cl\nCandidate Name: PROPIOMAZINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2.Cl\nCandidate Name: PROPIOMAZINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nN#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nN#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1\nTANDUTINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 562.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1\nTANDUTINIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 562.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOC(c1ccccc1)(c1ccccc1)C1CC1c1ccncc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOC(c1ccccc1)(c1ccccc1)C1CC1c1ccncc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O\nSILYBIN A\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 155.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O\nSILYBIN A", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 155.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCn1c(=O)c2nc(C3(N)CCCC3)[nH]c2n(CCC)c1=O\nName: MIDAXIFYLLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCn1c(=O)c2nc(C3(N)CCCC3)[nH]c2n(CCC)c1=O\nName: MIDAXIFYLLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 319.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O\nName: ORLISTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 495.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.88 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O\nName: ORLISTAT", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 495.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.88 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1\nEDELINONTRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 395.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1\nEDELINONTRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 395.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCc1cccc(N(C)C(=N)Nc2cccc3ccccc23)c1\nCandidate Name: APTIGANEL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCc1cccc(N(C)C(=N)Nc2cccc3ccccc23)c1\nCandidate Name: APTIGANEL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 465.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 465.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)[O-].CC(=O)[O-].[Zn+2]\nName: ZINC ACETATE ANHYDROUS\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 183.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)[O-].CC(=O)[O-].[Zn+2]\nName: ZINC ACETATE ANHYDROUS", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 183.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCC(C)C1(CCSC)C(=O)NC(=S)NC1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCC(C)C1(CCSC)C(=O)NC(=S)NC1=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1nc(-c2cc(C(=O)N3CCC(c4ccc(C#N)cc4)CC3)c(C)cc2C2CCC2)n[nH]1\nDrug Name: DENIFANSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1nc(-c2cc(C(=O)N3CCC(c4ccc(C#N)cc4)CC3)c(C)cc2C2CCC2)n[nH]1\nDrug Name: DENIFANSTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O)CC(O)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 134.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O)CC(O)C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 134.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(N(CCCC(=O)O)C(=O)c2ccc(Cl)cc2)cc1\nName: CLANOBUTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(N(CCCC(=O)O)C(=O)c2ccc(Cl)cc2)cc1\nName: CLANOBUTIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C\nDrug Name: MERICITABINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C\nDrug Name: MERICITABINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O.Cl\nVANCOMYCIN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1485.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O.Cl\nVANCOMYCIN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1485.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nN=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nN=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O\nDrug Name: ESTRONE SULFURIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O\nDrug Name: ESTRONE SULFURIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1\nNEBOGLAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1\nNEBOGLAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN(C)CCCN1c2ccccc2Sc2ccccc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PROMAZINE\n\n### Structure\n```\nCN(C)CCCN1c2ccccc2Sc2ccccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.24 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN(C)CCCN1c2ccccc2Sc2ccccc21", "output": "## Molecular Property Analysis: PROMAZINE\n\n### Structure\n```\nCN(C)CCCN1c2ccccc2Sc2ccccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 284.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.24 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 6.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 282.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 282.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O)c1cc2cc(Cc3cccnc3)ccc2o1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O)c1cc2cc(Cc3cccnc3)ccc2o1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 253.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: FLUMIZOLE\n\n### Structure\n```\nCOc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 348.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.78 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 47.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.740\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1", "output": "## Molecular Property Analysis: FLUMIZOLE\n\n### Structure\n```\nCOc1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(OC)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 348.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.78 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 47.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.740\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]1COc2cccc(OC)c2C1\nCandidate Name: ALNESPIRONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 442.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]1COc2cccc(OC)c2C1\nCandidate Name: ALNESPIRONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 442.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12.Cl\nLUCANTHONE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12.Cl\nLUCANTHONE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nCandidate Name: SERLOPITANT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 555.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1\nCandidate Name: SERLOPITANT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 555.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1\nCandidate Name: FLUNOXAPROFEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1\nCandidate Name: FLUNOXAPROFEN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O\nCandidate Name: MOEXIPRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O\nCandidate Name: MOEXIPRIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 545.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 545.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O\nCandidate Name: SOBUZOXANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 152.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O\nCandidate Name: SOBUZOXANE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -0.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 152.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nNC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TRETAZICAR\n\n### Structure\n```\nNC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 252.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.42 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nNC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]", "output": "## Molecular Property Analysis: TRETAZICAR\n\n### Structure\n```\nNC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 252.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.42 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCC(/C=C/n1ccnc1)OC(=O)c1cccnc1\nNICOGRELATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCC(/C=C/n1ccnc1)OC(=O)c1cccnc1\nNICOGRELATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl\nDrug Name: FINGOLIMOD HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 343.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl\nDrug Name: FINGOLIMOD HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 343.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc(O)c(Cl)c(C)c1Cl\nName: DICHLOROXYLENOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc(O)c(Cl)c(C)c1Cl\nName: DICHLOROXYLENOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 191.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCN(Cc1cc2ccccc2o1)c1ccccn1\nETOFURADINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCN(Cc1cc2ccccc2o1)c1ccccn1\nETOFURADINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=S(=O)(c1cccc2cnccc12)N1CCCNCC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: FASUDIL\n\n### Structure\n```\nO=S(=O)(c1cccc2cnccc12)N1CCCNCC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 291.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.22 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 62.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.900\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=S(=O)(c1cccc2cnccc12)N1CCCNCC1", "output": "## Molecular Property Analysis: FASUDIL\n\n### Structure\n```\nO=S(=O)(c1cccc2cnccc12)N1CCCNCC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 291.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.22 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 62.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.900\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(O)(C(=O)O)P(=O)(O)C(C)(O)C(=O)O\nFOSCOLIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 152.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(O)(C(=O)O)P(=O)(O)C(C)(O)C(=O)O\nFOSCOLIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 152.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21C\nTOSAGESTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 308.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21C\nTOSAGESTIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 308.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(Oc1ccc(Cl)cc1)C(=O)OC(COC(=O)c1cccnc1)COC(=O)c1cccnc1\nCandidate Name: BINIFIBRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 113.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)(Oc1ccc(Cl)cc1)C(=O)OC(COC(=O)c1cccnc1)COC(=O)c1cccnc1\nCandidate Name: BINIFIBRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 113.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O\nDrug Name: DOPEXAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O\nDrug Name: DOPEXAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1nc2ccccn2c(=O)c1CCN1CCC(C(=O)c2ccc(F)cc2)CC1\nCandidate Name: PIRENPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1nc2ccccn2c(=O)c1CCN1CCC(C(=O)c2ccc(F)cc2)CC1\nCandidate Name: PIRENPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.28 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC1(C(C)C)C(=O)NC(=O)NC1=O\nName: PROBARBITAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 198.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC1(C(C)C)C(=O)NC(=O)NC1=O\nName: PROBARBITAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 198.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc(NC(C)CCCN/C(C)=C2\\CCOC2=O)c2ncccc2c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc(NC(C)CCCN/C(C)=C2\\CCOC2=O)c2ncccc2c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)[O-])c1I.[Na+]\nCandidate Name: DIATRIZOATE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 635.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)[O-])c1I.[Na+]\nCandidate Name: DIATRIZOATE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 635.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(/C=C2/C(=O)C3(C)CCC2C3(C)C)cc1\nDrug Name: ENZACAMENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(/C=C2/C(=O)C3(C)CCC2C3(C)C)cc1\nDrug Name: ENZACAMENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 254.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O\nDrug Name: TRODUSQUEMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 685.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O\nDrug Name: TRODUSQUEMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 685.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C\nDrug Name: GAMITHROMYCIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 777.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C\nDrug Name: GAMITHROMYCIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 777.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C\nName: PIVAMPICILLIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 463.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C\nName: PIVAMPICILLIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 463.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 128.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(O)C(C)(O)c1cccc(Cl)c1\nMETAGLYCODOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(O)C(C)(O)c1cccc(Cl)c1\nMETAGLYCODOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1\nCandidate Name: NGD-8243\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1\nCandidate Name: NGD-8243", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.47 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCn1c(=O)c2c(ncn2CCOC(=O)C(C)(C)Oc2ccc(Cl)cc2)n(C)c1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCn1c(=O)c2c(ncn2CCOC(=O)C(C)(C)Oc2ccc(Cl)cc2)n(C)c1=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(-c2[nH]c3ccccc3c2-c2ccc(OC)cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(-c2[nH]c3ccccc3c2-c2ccc(OC)cc2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1\nName: BITOLTEROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1\nName: BITOLTEROL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C1OC(CN2CCOCC2)CN1/N=C/c1ccc([N+](=O)[O-])o1\nFURALTADONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C1OC(CN2CCOCC2)CN1/N=C/c1ccc([N+](=O)[O-])o1\nFURALTADONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNc1ncc2ncn(CC3(OCP(=O)(O)O)CC3)c2n1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 136.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNc1ncc2ncn(CC3(OCP(=O)(O)O)CC3)c2n1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 136.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: KETOTIFEN\n\n### Structure\n```\nCN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 309.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.01 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.730\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1", "output": "## Molecular Property Analysis: KETOTIFEN\n\n### Structure\n```\nCN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 309.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.01 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.730\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc(-c2ccccc2)nnc1N1CCN(c2ncccn2)CC1\nName: MINOZAC FREE BASE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc(-c2ccccc2)nnc1N1CCN(c2ncccn2)CC1\nName: MINOZAC FREE BASE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 332.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12\nABIRATERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 349.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12\nABIRATERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 349.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.40 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(/C=C/C2=CC(=O)[C@H]3C[C@@H]2C3(C)C)cc(O)c1O\nDrug Name: SP-8356\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 300.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(/C=C/C2=CC(=O)[C@H]3C[C@@H]2C3(C)C)cc(O)c1O\nDrug Name: SP-8356", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 300.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 533.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 533.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(O)cccc1C3=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 513.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(O)cccc1C3=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 513.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.73 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\\C(=O)O\nName: CHLORPHENIRAMINE MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\\C(=O)O\nName: CHLORPHENIRAMINE MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: LEVORPHANOL\n\n### Structure\n```\nCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 257.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.08 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 23.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.770\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13", "output": "## Molecular Property Analysis: LEVORPHANOL\n\n### Structure\n```\nCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 257.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.08 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 23.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.770\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(C[S+]([O-])C(c1ccccc1)c1ccccc1)NO\nDrug Name: ADRAFINIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(C[S+]([O-])C(c1ccccc1)c1ccccc1)NO\nDrug Name: ADRAFINIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C=CCSCC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1\nCandidate Name: ALTHIAZIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C=CCSCC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1\nCandidate Name: ALTHIAZIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cccc([C@H]2C[C@@H](N[C@H](C)c3ccccc3)C(=O)N2c2ccc(C(F)(F)F)cc2)c1\nDrug Name: MEPPEP\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.91 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cccc([C@H]2C[C@@H](N[C@H](C)c3ccccc3)C(=O)N2c2ccc(C(F)(F)F)cc2)c1\nDrug Name: MEPPEP", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.91 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(CCO)CC(=O)[O-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 147.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(CCO)CC(=O)[O-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 147.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nc1ccc2[nH]c(-c3cscn3)nc2c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: THIABENDAZOLE\n\n### Structure\n```\nc1ccc2[nH]c(-c3cscn3)nc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.69 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nc1ccc2[nH]c(-c3cscn3)nc2c1", "output": "## Molecular Property Analysis: THIABENDAZOLE\n\n### Structure\n```\nc1ccc2[nH]c(-c3cscn3)nc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.69 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 41.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc2c(Br)cc(Br)c(O)c2n1\nCandidate Name: BROQUINALDOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccc2c(Br)cc(Br)c(O)c2n1\nCandidate Name: BROQUINALDOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=c1c2ccccc2[se]n1CCn1[se]c2ccccc2c1=O\nETHASELEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 422.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=c1c2ccccc2[se]n1CCn1[se]c2ccccc2c1=O\nETHASELEN", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 422.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(C)Cc1ccco1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 140.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 13.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[N+](C)(C)Cc1ccco1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 140.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 13.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCNCCCN1c2ccccc2CCc2ccccc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DESIPRAMINE\n\n### Structure\n```\nCNCCCN1c2ccccc2CCc2ccccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 266.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.53 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 15.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCNCCCN1c2ccccc2CCc2ccccc21", "output": "## Molecular Property Analysis: DESIPRAMINE\n\n### Structure\n```\nCNCCCN1c2ccccc2CCc2ccccc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 266.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.53 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 15.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12\nCandidate Name: AMSACRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12\nCandidate Name: AMSACRINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 569.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(OCCCl)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 569.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O\nCandidate Name: TRYPAN BLUE FREE ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 872.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)cc(N)c2c1O\nCandidate Name: TRYPAN BLUE FREE ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 872.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C.Cl\nName: BACAMPICILLIN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 502.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 137.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C.Cl\nName: BACAMPICILLIN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 502.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 137.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC(=O)OCC(C(=O)O[C@@H]1C[C@@H]2[C@@H]3O[C@H]3[C@H](C1)N2C)c1ccccc1\nName: POSKINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC(=O)OCC(C(=O)O[C@@H]1C[C@@H]2[C@@H]3O[C@H]3[C@H](C1)N2C)c1ccccc1\nName: POSKINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)[C@H](Br)C[C@@H]12\nName: 16.ALPHA.-BROMOEPIANDROSTERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)[C@H](Br)C[C@@H]12\nName: 16.ALPHA.-BROMOEPIANDROSTERONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 369.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(Cn1c(Cl)cnc(NCC(F)(F)c2ccccn2)c1=O)NCc1ncccc1F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(Cn1c(Cl)cnc(NCC(F)(F)c2ccccn2)c1=O)NCc1ncccc1F", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O\nDrug Name: AV-101\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O\nDrug Name: AV-101", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNCCOC(c1ccc(F)cc1)c1ccc(Cl)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNCCOC(c1ccc(F)cc1)c1ccc(Cl)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: [Cl-].[Cl-].c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1\nDrug Name: HEDAQUINIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 553.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: [Cl-].[Cl-].c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1\nDrug Name: HEDAQUINIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 553.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1OC2(CS1)CN1CCC2CC1\nDrug Name: CEVIMELINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 199.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1OC2(CS1)CN1CCC2CC1\nDrug Name: CEVIMELINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 199.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc2c(cc1OC)[C@@H]1CN(C)CC[C@@H]1N=C2c1ccc(NC(C)=O)cc1\nCandidate Name: BENAFENTRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc2c(cc1OC)[C@@H]1CN(C)CC[C@@H]1N=C2c1ccc(NC(C)=O)cc1\nCandidate Name: BENAFENTRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NCc1cc(O)no1\nDrug Name: MUSCIMOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 114.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NCc1cc(O)no1\nDrug Name: MUSCIMOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 114.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1nc2[nH]cnc2c(=S)[nH]1\nTHIOGUANINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 167.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1nc2[nH]cnc2c(=S)[nH]1\nTHIOGUANINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 167.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 990.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 201.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 990.2 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 201.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1c(Cl)c(=O)oc2cc(OP(=O)(OCCCl)OCCCl)ccc12\nDrug Name: HALOXON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1c(Cl)c(=O)oc2cc(OP(=O)(OCCCl)OCCCl)ccc12\nDrug Name: HALOXON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCOC(=O)c1ccc(N)cc1\nBUTAMBEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCOC(=O)c1ccc(N)cc1\nBUTAMBEN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 193.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1.Cl.Cl\nCandidate Name: CEFOTIAM HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1.Cl.Cl\nCandidate Name: CEFOTIAM HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1\nName: BROMPERIDOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1\nName: BROMPERIDOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CARZELESIN\n\n### Structure\n```\nCCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 729.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 9.40 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 135.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.110\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1", "output": "## Molecular Property Analysis: CARZELESIN\n\n### Structure\n```\nCCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 729.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 9.40 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 135.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.110\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(C)c1ccc(C(O)CCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1\nTRENIZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(C)c1ccc(C(O)CCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1\nTRENIZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C\nCandidate Name: CHOLIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C\nCandidate Name: CHOLIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1\nDrug Name: SULFADIAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 250.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1\nDrug Name: SULFADIAZINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 250.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1.Cl\nNARATRIPTAN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1.Cl\nNARATRIPTAN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1C(=O)CC[C@H]1c1cccnc1\nCandidate Name: COTININE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 176.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1C(=O)CC[C@H]1c1cccnc1\nCandidate Name: COTININE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 176.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(=O)c(c5oc6cc(N7CCN(CC(C)C)CC7)cc(O)c6nc-5c4c3C2=O)NC(=O)/C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 941.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.43 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 230.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(=O)c(c5oc6cc(N7CCN(CC(C)C)CC7)cc(O)c6nc-5c4c3C2=O)NC(=O)/C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 941.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.43 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 230.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21\nQUINELORANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21\nQUINELORANE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nC[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: SANGUINARIUM\n\n### Structure\n```\nC[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 332.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.43 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 40.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.370\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nC[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3", "output": "## Molecular Property Analysis: SANGUINARIUM\n\n### Structure\n```\nC[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 332.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.43 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 40.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.370\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Nc1c(I)c(NC(=O)CO)c(I)c(C(=O)O)c1I\nCandidate Name: IOXOTRIZOIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 629.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)Nc1c(I)c(NC(=O)CO)c(I)c(C(=O)O)c1I\nCandidate Name: IOXOTRIZOIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 629.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCC(c1ccc(CCCl)cc1)c1c(O)c2ccccc2oc1=O\nCLOCOUMAROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.21 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCC(c1ccc(CCCl)cc1)c1c(O)c2ccccc2oc1=O\nCLOCOUMAROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.21 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nC=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: METHOHEXITAL\n\n### Structure\n```\nC=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 262.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.31 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nC=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O", "output": "## Molecular Property Analysis: METHOHEXITAL\n\n### Structure\n```\nC=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 262.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.31 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.470\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(CCO)CC(=O)N(C)c1ccc(Cl)cc1C(=O)c1ccccc1\nDrug Name: OXAZAFONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(CCO)CC(=O)N(C)c1ccc(Cl)cc1C(=O)c1ccccc1\nDrug Name: OXAZAFONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C\nName: EPELSIBAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 518.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C\nName: EPELSIBAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 518.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CNC(=S)C1(c2cccc(C)n2)CCCS1\nCandidate Name: LUCARTAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CNC(=S)C1(c2cccc(C)n2)CCCS1\nCandidate Name: LUCARTAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 252.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1\nCandidate Name: DAPIPRAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1\nCandidate Name: DAPIPRAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCl.N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O\nSITAGLIPTIN HYDROCHLORIDE MONOHYDRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCl.N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O\nSITAGLIPTIN HYDROCHLORIDE MONOHYDRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O\nDrug Name: STREPTOMYCIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 581.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -8.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 12.0 | ‚ö† High (>5) |\n| Polar Surface Area | 336.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O\nDrug Name: STREPTOMYCIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 581.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -8.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 12.0 | ‚ö† High (>5) |\n| Polar Surface Area | 336.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1\nCandidate Name: HEXETIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 339.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1\nCandidate Name: HEXETIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 339.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=S(=O)(O)CC(S)CS\n2,3-DIMERCAPTO-1-PROPANESULFONIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 188.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=S(=O)(O)CC(S)CS\n2,3-DIMERCAPTO-1-PROPANESULFONIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 188.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccccc1OCC(O)CNC(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 239.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccccc1OCC(O)CNC(C)C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 239.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN=C(N)NC(=O)Nc1c(C)cccc1C\nName: LIDAMIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 220.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN=C(N)NC(=O)Nc1c(C)cccc1C\nName: LIDAMIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 220.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCN(Cc1ccccc1)c1ccccn1\nTRIPELENNAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCN(Cc1ccccc1)c1ccccn1\nTRIPELENNAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1\nCandidate Name: BENZNIDAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 260.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1\nCandidate Name: BENZNIDAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 260.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO/N=C/c1cc[n+](COC[n+]2ccc(/C=N/O)cc2)cc1.[Cl-].[Cl-]\nOBIDOXIME CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO/N=C/c1cc[n+](COC[n+]2ccc(/C=N/O)cc2)cc1.[Cl-].[Cl-]\nOBIDOXIME CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 359.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 82.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nN=C(N)c1ccc(-c2ccc(OC[C@@H]3C[C@@H](CC(=O)O)C(=O)N3)cc2)cc1\nName: FRADAFIBAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 367.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nN=C(N)c1ccc(-c2ccc(OC[C@@H]3C[C@@H](CC(=O)O)C(=O)N3)cc2)cc1\nName: FRADAFIBAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 367.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNCC[C@@H](O)c1cccc(OCC2CCCCC2)c1\nName: EMIXUSTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNCC[C@@H](O)c1cccc(OCC2CCCCC2)c1\nName: EMIXUSTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1.O=P(O)(O)O\nLENIOLISIB PHOSPHATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1.O=P(O)(O)O\nLENIOLISIB PHOSPHATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-]\nDrug Name: CETALKONIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-]\nDrug Name: CETALKONIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.74 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCc1ccc(C(=O)C(C)CN2CCCCC2)cc1\nName: EPERISONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 259.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCc1ccc(C(=O)C(C)CN2CCCCC2)cc1\nName: EPERISONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 259.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@]12CC[C@H](O)CC1=CC(=O)C1C2CC[C@]2(C)C(=O)CCC12\n7-KETO-DEHYDROEPIANDROSTERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@]12CC[C@H](O)CC1=CC(=O)C1C2CC[C@]2(C)C(=O)CCC12\n7-KETO-DEHYDROEPIANDROSTERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nN=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.Nc1ccc(P(=O)(O)O)cc1.Nc1ccc(P(=O)(O)O)cc1\nName: CHLORHEXIDINE PHOSPHANILATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 851.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 10.0 | ‚ö† High (>5) |\n| Polar Surface Area | 167.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nN=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.Nc1ccc(P(=O)(O)O)cc1.Nc1ccc(P(=O)(O)O)cc1\nName: CHLORHEXIDINE PHOSPHANILATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 851.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 10.0 | ‚ö† High (>5) |\n| Polar Surface Area | 167.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C)cc3)CC2)nc2ccccc21\nALINASTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 433.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.79 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C)cc3)CC2)nc2ccccc21\nALINASTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 433.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.79 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C=CC(C)NC(=S)NNC(=S)NC\nCandidate Name: METHALLIBURE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C=CC(C)NC(=S)NNC(=S)NC\nCandidate Name: METHALLIBURE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 570.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 570.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN[C@@H](C)Cc1cccc(C(F)(F)F)c1.Cl\nDEXFENFLURAMINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN[C@@H](C)Cc1cccc(C(F)(F)F)c1.Cl\nDEXFENFLURAMINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 267.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21\nName: ENZASTAURIN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 552.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21\nName: ENZASTAURIN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 552.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[Se]CC[C@H](N)C(=O)O\nDrug Name: SELENOMETHIONINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 196.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[Se]CC[C@H](N)C(=O)O\nDrug Name: SELENOMETHIONINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 196.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\n[NH-]c1c[n+](N2CCOCC2)no1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 170.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\n[NH-]c1c[n+](N2CCOCC2)no1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 170.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1\nDrug Name: REPOTRECTINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1\nDrug Name: REPOTRECTINIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.O.O.O.[Cl-]\nCandidate Name: METHYLENE BLUE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.O.O.O.[Cl-]\nCandidate Name: METHYLENE BLUE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21\nName: RAMIPRIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21\nName: RAMIPRIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)CN1C(=O)[C@@H](N[C@@H](CCc2ccccc2)C(=O)O)CCc2ccccc21\nBENAZEPRILAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)CN1C(=O)[C@@H](N[C@@H](CCc2ccccc2)C(=O)O)CCc2ccccc21\nBENAZEPRILAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 396.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(O)(CC(=O)O)C1CCCCC1\nCandidate Name: CYCLOBUTOIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 186.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(O)(CC(=O)O)C1CCCCC1\nCandidate Name: CYCLOBUTOIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 186.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1\nCandidate Name: OXYBUTYNIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 357.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1\nCandidate Name: OXYBUTYNIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 357.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 134.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 266.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 134.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 353.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)COc1ccc2c(-c3ccccc3F)noc2c1Br\nCandidate Name: BROCRINAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)COc1ccc2c(-c3ccccc3F)noc2c1Br\nCandidate Name: BROCRINAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 366.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=P(O)(O)OCC(Cl)(Cl)Cl\nName: TRICLOFOS\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 229.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=P(O)(O)OCC(Cl)(Cl)Cl\nName: TRICLOFOS", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 229.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 438.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 438.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)NCC(O)c1ccc(O)c2ncccc12\nDrug Name: QUINTERENOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)NCC(O)c1ccc(O)c2ncccc12\nDrug Name: QUINTERENOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 246.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@](C)(O)CC[C@H]3[C@H]1C5\nMETHYLDIHYDROMORPHINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@](C)(O)CC[C@H]3[C@H]1C5\nMETHYLDIHYDROMORPHINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 301.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(Cc1ccccc1)Cc1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(Cc1ccccc1)Cc1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 211.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(C)CC(C)(C)c1cc(Cc2cc(C(C)(C)CC(C)(C)C)cc(-n3nc4ccccc4n3)c2O)c(O)c(-n2nc3ccccc3n2)c1\nBISOCTRIZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 658.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.58 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(C)CC(C)(C)c1cc(Cc2cc(C(C)(C)CC(C)(C)C)cc(-n3nc4ccccc4n3)c2O)c(O)c(-n2nc3ccccc3n2)c1\nBISOCTRIZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 658.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.58 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1C\nName: REPROMICIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 565.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1C\nName: REPROMICIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 565.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Br.COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1\nCandidate Name: CLOPIDOGREL HYDROBROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Br.COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1\nCandidate Name: CLOPIDOGREL HYDROBROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12\nCandidate Name: FORMESTANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12\nCandidate Name: FORMESTANE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1\nName: DEXMETHYLPHENIDATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1\nName: DEXMETHYLPHENIDATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1\nDrug Name: LINEZOLID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1\nDrug Name: LINEZOLID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cccc(C)c1OCC(C)N.Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 215.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cccc(C)c1OCC(C)N.Cl", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 215.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(CCN2CCN(CCCCOc3ccccc3[C@@]3(C(C)C)Sc4ccccc4N(C)C3=O)CC2)cc(OC)c1OC\nCandidate Name: IPROTIAZEM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 647.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cc(CCN2CCN(CCCCOc3ccccc3[C@@]3(C(C)C)Sc4ccccc4N(C)C3=O)CC2)cc(OC)c1OC\nCandidate Name: IPROTIAZEM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 647.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.35 | ‚ö† High (>5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1c(C)c2c(c(C)c1OC(=O)COc1ccc(Cl)cc1)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2\nTOCOFENOXATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 599.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 10.77 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1c(C)c2c(c(C)c1OC(=O)COc1ccc(Cl)cc1)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2\nTOCOFENOXATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 599.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 10.77 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C\nCandidate Name: LINAGLIPTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 472.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C\nCandidate Name: LINAGLIPTIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 472.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C\nName: BMS-582949\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C\nName: BMS-582949", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)[N-]S(=O)(=O)C6CC6)C[C@H]5/C=C\\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C.[Na+]\nSIMEPREVIR SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 771.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)[N-]S(=O)(=O)C6CC6)C[C@H]5/C=C\\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C.[Na+]\nSIMEPREVIR SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 771.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MAZAPERTINE\n\n### Structure\n```\nCC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 421.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.42 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 36.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.690\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1", "output": "## Molecular Property Analysis: MAZAPERTINE\n\n### Structure\n```\nCC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 421.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.42 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 36.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.690\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1\nCandidate Name: BUTOXYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 480.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1\nCandidate Name: BUTOXYLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 480.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.26 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN\nName: ASTROMICIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 405.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 192.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN\nName: ASTROMICIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 405.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 192.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1nccnc1N1CCCCC1\nName: MODALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 177.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1nccnc1N1CCCCC1\nName: MODALINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 177.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccccc1OCCOCCOCCN1CCCCC1\nName: GUAIAPATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccccc1OCCOCCOCCN1CCCCC1\nName: GUAIAPATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1\nDrug Name: NICERITROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 556.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1\nDrug Name: NICERITROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 556.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCOc1ccc(C2SC(=O)NC2=O)cc1OCC\nCandidate Name: RISARESTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCOc1ccc(C2SC(=O)NC2=O)cc1OCC\nCandidate Name: RISARESTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1\nName: SEPROXETINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1\nName: SEPROXETINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 35.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC(C)(C)C(=O)[O-].[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 138.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC(C)(C)C(=O)[O-].[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 138.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 373.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: BRIVUDINE\n\n### Structure\n```\nO=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 333.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.46 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 104.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.690\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br", "output": "## Molecular Property Analysis: BRIVUDINE\n\n### Structure\n```\nO=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1/C=C/Br\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 333.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.46 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 104.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.690\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCC(/C=C/n1ccnc1)OCc1ccccc1\nName: MIDAZOGREL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCC(/C=C/n1ccnc1)OCc1ccccc1\nName: MIDAZOGREL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12\nCandidate Name: PSILOCYBIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12\nCandidate Name: PSILOCYBIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 284.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]\nDrug Name: MECLOFENAMATE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 336.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]\nDrug Name: MECLOFENAMATE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 336.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl\nDONEPEZIL HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl\nDONEPEZIL HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C/C(=C\\c1ccc(C(=O)O)cc1)c1ccc(C(C)C)s1\nDrug Name: NAMIROTENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C/C(=C\\c1ccc(C(=O)O)cc1)c1ccc(C(C)C)s1\nDrug Name: NAMIROTENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1\nCandidate Name: DNK333\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 624.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1\nCandidate Name: DNK333", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 624.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DELTA-8-TETRAHYDROCANNABINOL\n\n### Structure\n```\nCCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.74 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.570\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21", "output": "## Molecular Property Analysis: DELTA-8-TETRAHYDROCANNABINOL\n\n### Structure\n```\nCCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C)C[C@@H]21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.74 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.570\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 282.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 282.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)SCCN(S(=O)(=O)c2ccc(Oc3ccncc3)cc2)[C@H]1C(=O)NO\nCandidate Name: PRINOMASTAT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 423.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)SCCN(S(=O)(=O)c2ccc(Oc3ccncc3)cc2)[C@H]1C(=O)NO\nCandidate Name: PRINOMASTAT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 423.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 108.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cccc(C)c1N(CCCc1cccnc1)C(=O)[C@@H](C)N\nName: MILACAINIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cccc(C)c1N(CCCc1cccnc1)C(=O)[C@@H](C)N\nName: MILACAINIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1\nDrug Name: CLOMIPHENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1\nDrug Name: CLOMIPHENE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.56 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: FC(F)(F)COCC(F)(F)F\nCandidate Name: FLUROTHYL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 182.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: FC(F)(F)COCC(F)(F)F\nCandidate Name: FLUROTHYL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 182.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nO=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: LOSULAZINE\n\n### Structure\n```\nO=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 558.6 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 5.28 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 82.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.340\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nO=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1", "output": "## Molecular Property Analysis: LOSULAZINE\n\n### Structure\n```\nO=C(c1ccc(Nc2ccnc3cc(C(F)(F)F)ccc23)cc1)N1CCN(S(=O)(=O)c2ccc(F)cc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 558.6 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 5.28 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 82.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.340\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1\nName: ARGATROBAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 508.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 177.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1\nName: ARGATROBAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 508.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 177.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1\nDrug Name: LINCOMYCIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1\nDrug Name: LINCOMYCIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: METESIND\n\n### Structure\n```\nCN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 436.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 88.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2", "output": "## Molecular Property Analysis: METESIND\n\n### Structure\n```\nCN(Cc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1ccc2c3c(cccc13)C(N)=N2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 436.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.85 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 88.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.660\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1.CS(=O)(=O)O\nName: DELAVIRDINE MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 552.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1.CS(=O)(=O)O\nName: DELAVIRDINE MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 552.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C1NOCC1/N=C/c1ccc(/C=N/C2CONC2=O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C1NOCC1/N=C/c1ccc(/C=N/C2CONC2=O)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCNC(=O)OC1CCN(c2nncc3cc(OC)c(OC)cc23)CC1\nCandidate Name: CARBAZERAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCNC(=O)OC1CCN(c2nncc3cc(OC)c(OC)cc23)CC1\nCandidate Name: CARBAZERAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 360.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC=C1/C(=C\\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O\nName: ALFACALCIDOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.59 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC=C1/C(=C\\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O\nName: ALFACALCIDOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.59 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCc1ccccc1NC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)O[C@@H]1N2C\nGANSTIGMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCc1ccccc1NC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)O[C@@H]1N2C\nGANSTIGMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: AMFONELIC ACID\n\n### Structure\n```\nCCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 308.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 72.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21", "output": "## Molecular Property Analysis: AMFONELIC ACID\n\n### Structure\n```\nCCn1cc(C(=O)O)c(=O)c2ccc(Cc3ccccc3)nc21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 308.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 72.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC\nCandidate Name: LAPAQUISTAT ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 645.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 131.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC\nCandidate Name: LAPAQUISTAT ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 645.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 131.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2\nBIRABRESIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 492.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2\nBIRABRESIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 492.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCNc1ccc(-c2cc3cc(O)ccc3o2)c(F)n1\nName: FLUTAFURANOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 258.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCNc1ccc(-c2cc3cc(O)ccc3o2)c(F)n1\nName: FLUTAFURANOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 258.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 276.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 276.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOc1cc(NC(C)CCCN)c2ncccc2c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PRIMAQUINE\n\n### Structure\n```\nCOc1cc(NC(C)CCCN)c2ncccc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.78 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 60.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.840\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOc1cc(NC(C)CCCN)c2ncccc2c1", "output": "## Molecular Property Analysis: PRIMAQUINE\n\n### Structure\n```\nCOc1cc(NC(C)CCCN)c2ncccc2c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.78 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 60.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.840\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@@](Cc1ccc(OP(=O)(O)O)c(O)c1)(NN)C(=O)O\nName: FOSCARBIDOPA\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@@](Cc1ccc(OP(=O)(O)O)c(O)c1)(NN)C(=O)O\nName: FOSCARBIDOPA", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCSc1ccccc1OCC(O)CNC(C)C\nTIPRENOLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCSc1ccccc1OCC(O)CNC(C)C\nTIPRENOLOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc2c(cc1OCCCF)CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21\nDrug Name: FLORBENAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc2c(cc1OCCCF)CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21\nDrug Name: FLORBENAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 365.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21\nZONAMPANEL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21\nZONAMPANEL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)C[C@@H]1C[C@@H](COc2ccc(-c3ccc(C(=N)NC(=O)OC)cc3)cc2)NC1=O\nCandidate Name: LEFRADAFIBAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 126.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)C[C@@H]1C[C@@H](COc2ccc(-c3ccc(C(=N)NC(=O)OC)cc3)cc2)NC1=O\nCandidate Name: LEFRADAFIBAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 439.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 126.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNS(=O)(=O)c1cc2c(cc1Cl)N=C[N-]S2(=O)=O.[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNS(=O)(=O)c1cc2c(cc1Cl)N=C[N-]S2(=O)=O.[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCNC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)NC)CC(=O)O)CC(=O)O\nName: CALDIAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 419.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 179.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCNC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)NC)CC(=O)O)CC(=O)O\nName: CALDIAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 419.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 179.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1\nMIZOLASTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1\nMIZOLASTINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 432.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nN[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+]\nName: DEXTROTHYROXINE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 816.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nN[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+]\nName: DEXTROTHYROXINE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 816.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)[C@@H](O)[C@]1(C)O\nName: IDREMCINAL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 744.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 165.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)[C@@H](O)[C@]1(C)O\nName: IDREMCINAL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 744.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 165.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nO=S(=O)([O-])NC1CCCCC1.[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: SODIUM CYCLAMATE\n\n### Structure\n```\nO=S(=O)([O-])NC1CCCCC1.[Na+]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | nan | 0-5 | ‚ö† |\n| H-Bond Acceptors | nan | ‚â§10 | ‚ö† |\n| H-Bond Donors | nan | ‚â§5 | ‚ö† |\n| PSA | nan √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | nan | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** nan\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nO=S(=O)([O-])NC1CCCCC1.[Na+]", "output": "## Molecular Property Analysis: SODIUM CYCLAMATE\n\n### Structure\n```\nO=S(=O)([O-])NC1CCCCC1.[Na+]\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 201.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | nan | 0-5 | ‚ö† |\n| H-Bond Acceptors | nan | ‚â§10 | ‚ö† |\n| H-Bond Donors | nan | ‚â§5 | ‚ö† |\n| PSA | nan √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | nan | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** nan\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc(/C=C/C(=O)O)ccc1OCCO\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 238.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc(/C=C/C(=O)O)ccc1OCCO", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 238.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\n[Cl-].[Na+]\nName: SODIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 58.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\n[Cl-].[Na+]\nName: SODIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 58.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1\nMAZAPERTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 421.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1\nMAZAPERTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 421.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCN/C(=N\\CC)NC(=N)N\nETOFORMIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 185.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCN/C(=N\\CC)NC(=N)N\nETOFORMIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 185.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl\nDrug Name: Vercirnon\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl\nDrug Name: Vercirnon", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O\nDORAVIRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O\nDORAVIRINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nc1ccc(C2CN=C3NCCN32)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 187.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nc1ccc(C2CN=C3NCCN32)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 187.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: AZITHROMYCIN\n\n### Structure\n```\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 749.0 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.90 | 0-5 | ‚úì |\n| H-Bond Acceptors | 14.0 | ‚â§10 | ‚ö† |\n| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |\n| PSA | 180.1 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.240\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O", "output": "## Molecular Property Analysis: AZITHROMYCIN\n\n### Structure\n```\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 749.0 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.90 | 0-5 | ‚úì |\n| H-Bond Acceptors | 14.0 | ‚â§10 | ‚ö† |\n| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |\n| PSA | 180.1 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |\n| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.240\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCNC1(c2ccccc2Cl)CCCCC1=O\nName: KETAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 237.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCNC1(c2ccccc2Cl)CCCCC1=O\nName: KETAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 237.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1cc(-c2ccc(/N=N/c3ccc4c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c4c3O)c(C)c2)ccc1/N=N/c1ccc2c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c2c1O.[Na+].[Na+].[Na+].[Na+]\nEVANS BLUE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 960.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1cc(-c2ccc(/N=N/c3ccc4c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c4c3O)c(C)c2)ccc1/N=N/c1ccc2c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c2c1O.[Na+].[Na+].[Na+].[Na+]\nEVANS BLUE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 960.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC/C(=C(/CCO)SSCC1CCCO1)N(C=O)Cc1cnc(C)nc1N\nName: FURSULTIAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC/C(=C(/CCO)SSCC1CCCO1)N(C=O)Cc1cnc(C)nc1N\nName: FURSULTIAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12\nDrug Name: PRINABEREL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12\nDrug Name: PRINABEREL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC1(CC)C(=O)NC(=O)N(C)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 198.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC1(CC)C(=O)NC(=O)N(C)C1=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 198.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)C(=O)Oc1ccc[n+](Cc2ccccc2)c1\nBENZPYRINIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)C(=O)Oc1ccc[n+](Cc2ccccc2)c1\nBENZPYRINIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)CN1C=CCC(C(N)=O)=C1\nDrug Name: CARICOTAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NC(=O)CN1C=CCC(C(N)=O)=C1\nDrug Name: CARICOTAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(c1ccc(F)cc1)C1CCN(CCCn2c(=O)[nH]c3cc(Cl)ccc32)CC1\nMILENPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(c1ccc(F)cc1)C1CCN(CCCn2c(=O)[nH]c3cc(Cl)ccc32)CC1\nMILENPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)NC(=N)N\nDrug Name: RIMEPORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)NC(=N)N\nDrug Name: RIMEPORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 333.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)OC(=O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1\nDrug Name: TAPRENEPAG ISOPROPYL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 520.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)OC(=O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1\nDrug Name: TAPRENEPAG ISOPROPYL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 520.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23\nCandidate Name: ELLAGIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23\nCandidate Name: ELLAGIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1c(Nc2ncccc2C(=O)O)cccc1C(F)(F)F\nDrug Name: FLUNIXIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1c(Nc2ncccc2C(=O)O)cccc1C(F)(F)F\nDrug Name: FLUNIXIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 711.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 235.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 711.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 235.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(O/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)[O-].[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 568.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 191.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(O/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)[O-].[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 568.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.30 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 191.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2\nName: ACEPROMAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2\nName: ACEPROMAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O\nDrug Name: PALBOCICLIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 447.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O\nDrug Name: PALBOCICLIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 447.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@]12C=C(C=O)C(=O)C=C1CC[C@@H]1[C@@H]2[C@H](O)C[C@@]2(C)[C@H]1CC[C@]2(C)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@]12C=C(C=O)C(=O)C=C1CC[C@@H]1[C@@H]2[C@H](O)C[C@@]2(C)[C@H]1CC[C@]2(C)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCON(C)Cc1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl\nSARECYCLINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 524.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 173.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCON(C)Cc1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl\nSARECYCLINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 524.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 173.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1\nCandidate Name: Y-39983\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1\nCandidate Name: Y-39983", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21\nPARTHENOLIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21\nPARTHENOLIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 248.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNC1=NCCc2ccccc21\nIQUINDAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 245.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNC1=NCCc2ccccc21\nIQUINDAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 245.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nN=C(N)C(O)c1ccc2c(c1)OCO2\nOLMIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 194.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nN=C(N)C(O)c1ccc2c(c1)OCO2\nOLMIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 194.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1\nName: EBROTIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1\nName: EBROTIDINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CSc1ccc(C(=O)c2cc(CC(=O)O)cc3ccoc23)cc1\nDrug Name: TIFURAC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CSc1ccc(C(=O)c2cc(CC(=O)O)cc3ccoc23)cc1\nDrug Name: TIFURAC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1\nName: BROMFENAC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1\nName: BROMFENAC", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 334.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nClc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MICONAZOLE\n\n### Structure\n```\nClc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 416.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 27.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.460\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nClc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1", "output": "## Molecular Property Analysis: MICONAZOLE\n\n### Structure\n```\nClc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 416.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 6.45 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 27.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.460\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(/C=C/C=C(\\C)C(=O)[O-])=C\\C=C\\C=C(C)\\C=C\\C=C(/C)C(=O)[O-].[Na+].[Na+]\nTRANSCROCETINATE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(/C=C/C=C(\\C)C(=O)[O-])=C\\C=C\\C=C(C)\\C=C\\C=C(/C)C(=O)[O-].[Na+].[Na+]\nTRANSCROCETINATE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2\nName: CARMEGLIPTIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2\nName: CARMEGLIPTIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 377.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nFc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: VANOXERINE\n\n### Structure\n```\nFc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 450.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.32 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 15.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nFc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1", "output": "## Molecular Property Analysis: VANOXERINE\n\n### Structure\n```\nFc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 450.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.32 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 15.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.420\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2\nDrug Name: VANZACAFTOR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2\nDrug Name: VANZACAFTOR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)c1nc(=O)c2cc3cc(OC)c(OC)cc3nc2[nH]1\nName: PIROLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCOC(=O)c1nc(=O)c2cc3cc(OC)c(OC)cc3nc2[nH]1\nName: PIROLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccn([C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1\nDrug Name: THIARABINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 259.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccn([C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1\nDrug Name: THIARABINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 259.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1\nDrug Name: GANCICLOVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1\nDrug Name: GANCICLOVIR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 255.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O\n(+)-SECOISOLARICIRESINOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O\n(+)-SECOISOLARICIRESINOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=N/NC(=S)NCCN1CCCCC1)/C(C)=N/NC(=S)NCCN1CCCCC1\nDrug Name: BITIPAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=N/NC(=S)NCCN1CCCCC1)/C(C)=N/NC(=S)NCCN1CCCCC1\nDrug Name: BITIPAZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 79.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(Oc1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O\nISOPROPICILLIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(Oc1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O\nISOPROPICILLIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC/C=C(\\C)c1ccc(OC(C)=O)cc1\nFENABUTENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 190.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC/C=C(\\C)c1ccc(OC(C)=O)cc1\nFENABUTENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 190.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1\nCandidate Name: TOVORAFENIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 506.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1\nCandidate Name: TOVORAFENIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 506.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 135.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 195.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 113.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 195.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 113.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccccc1CN1CCN(CCSC(c2ccccc2)c2ccccc2Cl)CC1\nBENTIPIMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 451.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.29 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccccc1CN1CCN(CCSC(c2ccccc2)c2ccccc2Cl)CC1\nBENTIPIMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 451.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.29 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze why Vercirnon was withdrawn/failed and what lessons can be learned:\nStructure: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Failure Analysis: Vercirnon\n\n### Summary\n**Phase Failed:** Phase II\n**Year:** 2013.0\n**Therapeutic Area:** Immunology\n**Failure Category:** Lack of Efficacy\n\n### Detailed Failure Reason\n\nFailed to show efficacy in Crohn's disease patients\n\n### Mechanism of Toxicity\n\nnan\n\n### Efficacy Failure Analysis\n\n**Common Reasons for Efficacy Failure:**\n1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology\n2. **Patient Population Heterogeneity:** Subgroups may respond differently\n3. **Dose Selection:** May not achieve adequate target engagement\n4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes\n\n**Prevention Strategies:**\n- Extensive target validation using human genetics data\n- Biomarker-driven patient stratification\n- PK/PD modeling to optimize dosing\n- Adaptive trial designs\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy\n<|im_end|>", "instruction": "Analyze why Vercirnon was withdrawn/failed and what lessons can be learned:\nStructure: CC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)Cl", "output": "## Drug Failure Analysis: Vercirnon\n\n### Summary\n**Phase Failed:** Phase II\n**Year:** 2013.0\n**Therapeutic Area:** Immunology\n**Failure Category:** Lack of Efficacy\n\n### Detailed Failure Reason\n\nFailed to show efficacy in Crohn's disease patients\n\n### Mechanism of Toxicity\n\nnan\n\n### Efficacy Failure Analysis\n\n**Common Reasons for Efficacy Failure:**\n1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology\n2. **Patient Population Heterogeneity:** Subgroups may respond differently\n3. **Dose Selection:** May not achieve adequate target engagement\n4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes\n\n**Prevention Strategies:**\n- Extensive target validation using human genetics data\n- Biomarker-driven patient stratification\n- PK/PD modeling to optimize dosing\n- Adaptive trial designs\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy", "task_type": "failure_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCCCCCCCCCC/C=C/[C@H](O)[C@@H](CO)NC(=O)[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 551.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.22 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCCCCCCCCCC/C=C/[C@H](O)[C@@H](CO)NC(=O)[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 551.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.22 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze why BIIB023 was withdrawn/failed and what lessons can be learned:\nStructure: CC1=C(C=C(C=C1)C(=O)NC2=CC=CC=C2N3CCCC3)OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Failure Analysis: BIIB023\n\n### Summary\n**Phase Failed:** Phase I\n**Year:** 2018.0\n**Therapeutic Area:** Oncology\n**Failure Category:** Safety/Toxicity\n\n### Detailed Failure Reason\n\nDose-limiting toxicity observed in healthy volunteers\n\n### Mechanism of Toxicity\n\nnan\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy\n<|im_end|>", "instruction": "Analyze why BIIB023 was withdrawn/failed and what lessons can be learned:\nStructure: CC1=C(C=C(C=C1)C(=O)NC2=CC=CC=C2N3CCCC3)OC", "output": "## Drug Failure Analysis: BIIB023\n\n### Summary\n**Phase Failed:** Phase I\n**Year:** 2018.0\n**Therapeutic Area:** Oncology\n**Failure Category:** Safety/Toxicity\n\n### Detailed Failure Reason\n\nDose-limiting toxicity observed in healthy volunteers\n\n### Mechanism of Toxicity\n\nnan\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy", "task_type": "failure_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 276.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 276.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCOC(=O)c1ccc(N(C)C)cc1\nCandidate Name: PADIMATE A\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 235.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCOC(=O)c1ccc(N(C)C)cc1\nCandidate Name: PADIMATE A", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 235.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: OCC(CO)(CCl)CCl\nDrug Name: LOPRODIOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 173.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: OCC(CO)(CCl)CCl\nDrug Name: LOPRODIOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 173.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(/C=C\\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1\nCandidate Name: VERDINEXOR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 442.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(/C=C\\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1\nCandidate Name: VERDINEXOR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 442.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1\nDrug Name: VARLITINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 466.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1\nDrug Name: VARLITINIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 466.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.25 | ‚ö† High (>5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN1CCC(COC(=O)C(O)(c2ccccc2)c2ccccc2)C1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN1CCC(COC(=O)C(O)(c2ccccc2)c2ccccc2)C1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 325.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC[C@H](N)C(=O)c1ccccc1\nCATHINONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 149.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC[C@H](N)C(=O)c1ccccc1\nCATHINONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 149.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(C)/C=N/c1c(I)cc(I)c(CCC(=O)O)c1I\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 598.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(C)/C=N/c1c(I)cc(I)c(CCC(=O)O)c1I", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 598.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)NS(=O)(=O)c1ccc(N)cc1\nCandidate Name: SULFACETAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)NS(=O)(=O)c1ccc(N)cc1\nCandidate Name: SULFACETAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 214.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCc1oc2ccccc2c1CC1=NCCN1\nCOUMAZOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 228.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCc1oc2ccccc2c1CC1=NCCN1\nCOUMAZOLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 228.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12CC[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CCOC3=O)CC[C@]12O\nCandidate Name: ACTODIGIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 536.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[C@]12CC[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CCOC3=O)CC[C@]12O\nCandidate Name: ACTODIGIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 536.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 145.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCNCCCC1(c2ccccc2)SC(C)(C)c2ccccc21\nName: TALSUPRAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCNCCCC1(c2ccccc2)SC(C)(C)c2ccccc21\nName: TALSUPRAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 311.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(CCc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(C(N)=O)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(CCc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(C(N)=O)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 114.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: LOMEFLOXACIN\n\n### Structure\n```\nCCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 351.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.80 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.880\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21", "output": "## Molecular Property Analysis: LOMEFLOXACIN\n\n### Structure\n```\nCCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 351.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.80 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.880\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCOc1ccc(O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MEQUINOL\n\n### Structure\n```\nCOc1ccc(O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 124.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.40 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.610\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCOc1ccc(O)cc1", "output": "## Molecular Property Analysis: MEQUINOL\n\n### Structure\n```\nCOc1ccc(O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 124.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.40 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 29.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.610\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1\nREMDESIVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1\nREMDESIVIR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)c1c(C)n(C)c2ccc(O)cc12\nCandidate Name: MECARBINATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)c1c(C)n(C)c2ccc(O)cc12\nCandidate Name: MECARBINATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COS(=O)(=O)[O-].C[N+](C)(C)CCOC(c1ccccc1)c1ccccc1\nDrug Name: MEFENIDRAMIUM METILSULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COS(=O)(=O)[O-].C[N+](C)(C)CCOC(c1ccccc1)c1ccccc1\nDrug Name: MEFENIDRAMIUM METILSULFATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1\nName: NIFURIMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 238.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1\nName: NIFURIMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 238.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 101.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCOc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: GLYBURIDE\n\n### Structure\n```\nCOc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 494.0 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.64 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 113.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.520\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCOc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1", "output": "## Molecular Property Analysis: GLYBURIDE\n\n### Structure\n```\nCOc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 494.0 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.64 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 113.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.520\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(Cc2cnc(N3C(=O)c4ccccc4C3=O)nc2N)cc(OC)c1OC\nName: TALMETOPRIM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(Cc2cnc(N3C(=O)c4ccccc4C3=O)nc2N)cc(OC)c1OC\nName: TALMETOPRIM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nc1ccc2c(c1)OCC(C1=NCCN1)O2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: IDAZOXAN\n\n### Structure\n```\nc1ccc2c(c1)OCC(C1=NCCN1)O2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 204.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.83 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 42.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.740\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nc1ccc2c(c1)OCC(C1=NCCN1)O2", "output": "## Molecular Property Analysis: IDAZOXAN\n\n### Structure\n```\nc1ccc2c(c1)OCC(C1=NCCN1)O2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 204.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.83 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 42.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.740\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=CCS[C@H]12)c1csc(NC(=O)[C@H](C)N)n1\nCEFTIZOXIME ALAPIVOXIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 568.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 191.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=CCS[C@H]12)c1csc(NC(=O)[C@H](C)N)n1\nCEFTIZOXIME ALAPIVOXIL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 568.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 191.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H]1CCC[C@@H](O)CCCCCc2cc(O)cc(O)c2C(=O)O1\nDrug Name: TALERANOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 322.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H]1CCC[C@@H](O)CCCCCc2cc(O)cc(O)c2C(=O)O1\nDrug Name: TALERANOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 322.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1n[nH]c2c1N(c1ccccc1)C(=O)CC(=O)N2C\nRAZOBAZAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1n[nH]c2c1N(c1ccccc1)C(=O)CC(=O)N2C\nRAZOBAZAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: IBUTAMOREN\n\n### Structure\n```\nCC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.77 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 122.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12", "output": "## Molecular Property Analysis: IBUTAMOREN\n\n### Structure\n```\nCC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.77 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 122.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 8.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.540\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1\nCandidate Name: DAREXABAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 474.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1\nCandidate Name: DAREXABAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 474.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(C(C)=O)c1c(I)cc(I)c(OCCOC(C)C(=O)O)c1I\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 673.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(C(C)=O)c1c(I)cc(I)c(OCCOC(C)C(=O)O)c1I", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 673.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 444.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 444.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.21 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 181.6 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)cn4ccccc34)cc2)cc1OC\nName: FANTOFARONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 550.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)cn4ccccc34)cc2)cc1OC\nName: FANTOFARONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 550.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: NCCCCCC(=O)O\nDrug Name: AMINOCAPROIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 131.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: NCCCCCC(=O)O\nDrug Name: AMINOCAPROIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 131.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.59 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nClc1ccccc1-c1nc(-c2ccncc2)no1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nClc1ccccc1-c1nc(-c2ccncc2)no1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 257.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 51.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 470.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 7.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 78.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1\nDEMECARIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 556.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.76 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1\nDEMECARIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 556.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.76 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccc(F)cc1)c1ccc(F)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 413.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccc(F)cc1)c1ccc(F)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 413.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[Si](C)(C)C(C)(C)C\nName: AR-67\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[Si](C)(C)C(C)(C)C\nName: AR-67", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1c(C(O)CCc2ccc(O)cc2)c(OCCN2CCCCC2)c(OC)c2occc12\nName: PIPROFUROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 455.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1c(C(O)CCc2ccc(O)cc2)c(OCCN2CCCCC2)c(OC)c2occc12\nName: PIPROFUROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 455.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.69 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN(C)CCN(Cc1ccc(Cl)s1)c1ccccn1\nCHLOROTHEN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN(C)CCN(Cc1ccc(Cl)s1)c1ccccn1\nCHLOROTHEN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 295.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.36 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC\nVERAPAMIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC\nVERAPAMIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 454.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=P(O)(O)C(Cl)(Cl)P(=O)(O)O\nCandidate Name: CLODRONIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=P(O)(O)C(Cl)(Cl)P(=O)(O)O\nCandidate Name: CLODRONIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)NCC[C@@]341\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)NCC[C@@]341", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(O)c1cc(=O)c2ccccc2[nH]1\nTRANSTORINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 189.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(O)c1cc(=O)c2ccccc2[nH]1\nTRANSTORINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 189.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(C#Cc1ccc(-c2ccc(Cl)c3c(NS(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(C#Cc1ccc(-c2ccc(Cl)c3c(NS(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCl.N\nName: AMMONIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 53.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCl.N\nName: AMMONIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 53.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C\nCandidate Name: PATIDEGIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C\nCandidate Name: PATIDEGIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21.Cl\nVALGANCICLOVIR HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 171.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21.Cl\nVALGANCICLOVIR HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 390.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 171.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O\nName: BX 471 FREE BASE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O\nName: BX 471 FREE BASE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 434.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: OCCN(CCO)c1nc(-c2ccccc2)c(-c2ccccc2)o1\nDrug Name: DITAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: OCCN(CCO)c1nc(-c2ccccc2)c(-c2ccccc2)o1\nDrug Name: DITAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 69.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: GATIFLOXACIN\n\n### Structure\n```\nCOc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 375.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.98 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 83.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCOc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12", "output": "## Molecular Property Analysis: GATIFLOXACIN\n\n### Structure\n```\nCOc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 375.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.98 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 83.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCC(=O)/N=c1/sc(S(N)(=O)=O)nn1C\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: METHAZOLAMIDE\n\n### Structure\n```\nCC(=O)/N=c1/sc(S(N)(=O)=O)nn1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.42 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 107.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.640\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCC(=O)/N=c1/sc(S(N)(=O)=O)nn1C", "output": "## Molecular Property Analysis: METHAZOLAMIDE\n\n### Structure\n```\nCC(=O)/N=c1/sc(S(N)(=O)=O)nn1C\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -1.42 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 107.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.640\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1\nCandidate Name: MELPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1\nCandidate Name: MELPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 263.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nNCc1cc(O)no1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: MUSCIMOL\n\n### Structure\n```\nNCc1cc(O)no1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 114.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.16 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 72.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.530\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nNCc1cc(O)no1", "output": "## Molecular Property Analysis: MUSCIMOL\n\n### Structure\n```\nNCc1cc(O)no1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 114.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.16 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 72.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.530\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)NCC(O)c1ccc(O)c(O)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ISOPROTERENOL\n\n### Structure\n```\nCC(C)NCC(O)c1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 211.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.13 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.560\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)NCC(O)c1ccc(O)c(O)c1", "output": "## Molecular Property Analysis: ISOPROTERENOL\n\n### Structure\n```\nCC(C)NCC(O)c1ccc(O)c(O)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 211.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 1.13 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |\n| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.560\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOC(=O)Cn1cccc1-c1nc(-c2ccc(OC)cc2)c(-c2ccc(OC)cc2)s1\nPAMICOGREL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 448.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOC(=O)Cn1cccc1-c1nc(-c2ccc(OC)cc2)c(-c2ccc(OC)cc2)s1\nPAMICOGREL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 448.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.53 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O\nDrug Name: PENTIFYLLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O\nDrug Name: PENTIFYLLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C\nName: TAVAPADON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C\nName: TAVAPADON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O\nCandidate Name: DESVENLAFAXINE FUMARATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O\nCandidate Name: DESVENLAFAXINE FUMARATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nOCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.12 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nOCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 425.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.12 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)n1cc2c3c(cccc31)[C@H]1C[C@@H](C(=O)NC3CCCCC3)CN(C)[C@@H]1C2\nName: AMESERGIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)n1cc2c3c(cccc31)[C@H]1C[C@@H](C(=O)NC3CCCCC3)CN(C)[C@@H]1C2\nName: AMESERGIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1\nnan\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1\nnan", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(O)C(Cl)(Cl)Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 419.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.32 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(O)C(Cl)(Cl)Cl", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 419.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.32 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1ccc(CCC(O)COc2ccc(C(=O)O)cc2)cc1\nDrug Name: LIFIBROL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 342.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1ccc(CCC(O)COc2ccc(C(=O)O)cc2)cc1\nDrug Name: LIFIBROL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 342.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccc(O)cc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 405.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccc(O)cc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 405.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)=CCC[C@](C)(O)[C@@H]1CC=C(C)CC1\nName: LEVOMENOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 222.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)=CCC[C@](C)(O)[C@@H]1CC=C(C)CC1\nName: LEVOMENOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 222.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nC[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CLIDINIUM\n\n### Structure\n```\nC[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 352.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.70 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 46.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nC[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2", "output": "## Molecular Property Analysis: CLIDINIUM\n\n### Structure\n```\nC[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 352.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.70 | 0-5 | ‚úì |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 46.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1nc(-c2ccc(/N=C/NC(C)C)cc2)c[nH]1\nName: BISFENTIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1nc(-c2ccc(/N=C/NC(C)C)cc2)c[nH]1\nName: BISFENTIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCN1CCCC1=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: METHYLPYRROLIDONE\n\n### Structure\n```\nCN1CCCC1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 99.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 0.24 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.430\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCN1CCCC1=O", "output": "## Molecular Property Analysis: METHYLPYRROLIDONE\n\n### Structure\n```\nCN1CCCC1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 99.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 0.24 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 20.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.430\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1c(-c2cccc(C(F)(F)F)c2)nsc1C(=O)O\nName: AMFLUTIZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1c(-c2cccc(C(F)(F)F)c2)nsc1C(=O)O\nName: AMFLUTIZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCN(Cc1ccc(CC(C)(C)C)cc1)C(Nc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)=C1C(=O)OC(C)(C)OC1=O\nName: ELDACIMIBE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 634.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.12 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCN(Cc1ccc(CC(C)(C)C)cc1)C(Nc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)=C1C(=O)OC(C)(C)OC1=O\nName: ELDACIMIBE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 634.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.12 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C/C(=N/Oc5ccc([N+](=O)[O-])cc5)[C@H](Cl)C[C@]4(C)[C@H]3CC[C@]12C\nName: NISTERIME ACETATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 503.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C/C(=N/Oc5ccc([N+](=O)[O-])cc5)[C@H](Cl)C[C@]4(C)[C@H]3CC[C@]12C\nName: NISTERIME ACETATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 503.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1\nDrug Name: PEXIDARTINIB HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1\nDrug Name: PEXIDARTINIB HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNC12CC3CC(CC(C3)C1)C2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 151.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNC12CC3CC(CC(C3)C1)C2", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 151.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl\nDrug Name: ALFENTANIL HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 453.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl\nDrug Name: ALFENTANIL HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 453.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.38 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314\nDrug Name: OXYCODONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314\nDrug Name: OXYCODONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2\nDrug Name: PIPERACETAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2\nDrug Name: PIPERACETAZINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 410.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C\nDrug Name: PENTAZOCINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C\nDrug Name: PENTAZOCINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 285.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Nc1cc(N)c(/N=N/c2ccc(S(N)(=O)=O)cc2)c(C(=O)O)c1\nCandidate Name: SULFACHRYSOIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 174.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Nc1cc(N)c(/N=N/c2ccc(S(N)(=O)=O)cc2)c(C(=O)O)c1\nCandidate Name: SULFACHRYSOIDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 335.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 174.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 397.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 100.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5\nCandidate Name: NALMEXONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5\nCandidate Name: NALMEXONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCOC1(c2ccc(Cl)cc2)CCCCC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCOC1(c2ccc(Cl)cc2)CCCCC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)c2)cc1\nMMV-048\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCS(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc(C(F)(F)F)nc3)c2)cc1\nMMV-048", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@@H](O)CN(C)S(C)(=O)=O)cc2ccccc21\nName: VELUSETRAG\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@@H](O)CN(C)S(C)(=O)=O)cc2ccccc21\nName: VELUSETRAG", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 504.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)Nc3cnc(Nc4ccc(S(N)(=O)=O)cc4)nc3O)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O\nName: PIROXICILLIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 672.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 266.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)Nc3cnc(Nc4ccc(S(N)(=O)=O)cc4)nc3O)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O\nName: PIROXICILLIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 672.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 8.0 | ‚ö† High (>5) |\n| Polar Surface Area | 266.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(C)CN(CCN2CCN(c3cccc(Cl)c3)C2=O)C1\nZETIDOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(C)CN(CCN2CCN(c3cccc(Cl)c3)C2=O)C1\nZETIDOLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 307.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNc1c(I)cc(I)c(C(=O)N(CCC(=O)O)c2ccccc2)c1I\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 662.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNc1c(I)cc(I)c(C(=O)N(CCC(=O)O)c2ccccc2)c1I", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 662.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1\nName: INDORAMIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1\nName: INDORAMIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 347.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNC[C@@H]1CN(c2ccc(OCc3cccc(Cl)c3)cc2)C(=O)O1\nALMOXATONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 346.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNC[C@@H]1CN(c2ccc(OCc3cccc(Cl)c3)cc2)C(=O)O1\nALMOXATONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 346.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1\nDrug Name: TALOTREXIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 573.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 248.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1\nDrug Name: TALOTREXIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 573.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 248.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC=CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)NC)c(N)cc1OC\nName: ALPIROPRIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 113.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC=CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)NC)c(N)cc1OC\nName: ALPIROPRIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 113.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\n[Cl-].[K+]\nPOTASSIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 74.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\n[Cl-].[K+]\nPOTASSIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 74.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(OCCN1CCCCCCC1)(c1ccccc1)c1ccc(Cl)cc1\nDrug Name: OCTASTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.89 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(OCCN1CCCCCCC1)(c1ccccc1)c1ccc(Cl)cc1\nDrug Name: OCTASTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 371.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.89 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C/C=C/C(=O)N(CCC)C(CC)C(=O)N(C)C\nDrug Name: CROPROPAMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C/C=C/C(=O)N(CCC)C(CC)C(=O)N(C)C\nDrug Name: CROPROPAMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 240.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1\nName: SORAFENIB TOSYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 637.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1\nName: SORAFENIB TOSYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 637.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)C(=S)SC(=S)N(CC)CC\nCandidate Name: SULFIRAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)C(=S)SC(=S)N(CC)CC\nCandidate Name: SULFIRAM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O\nDrug Name: ALEGLITAZAR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 437.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O\nDrug Name: ALEGLITAZAR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 437.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNc1[nH]cnc2ncnc1-2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 135.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNc1[nH]cnc2ncnc1-2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 135.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O\nName: AVIBACTAM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O\nName: AVIBACTAM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.53 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(=O)NCCOC(=O)C(Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1\nName: HALOFENATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(=O)NCCOC(=O)C(Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1\nName: HALOFENATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 415.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1nc(C)ccc1CN1CC1C#N\nName: CIAMEXON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 203.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1nc(C)ccc1CN1CC1C#N\nName: CIAMEXON", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 203.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]\nDrug Name: L-NAME\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]\nDrug Name: L-NAME", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 143.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)CN(C)c1ccccc1C[S+]([O-])c1nc2ccccc2[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)CN(C)c1ccccc1C[S+]([O-])c1nc2ccccc2[nH]1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: [Xe]\nDrug Name: XENON\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 131.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: [Xe]\nDrug Name: XENON", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 131.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=C(CCCN1CCN2Cc3[nH]c4ccccc4c3CC2C1)c1ccc(F)cc1\nBIRIPERONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=C(CCCN1CCN2Cc3[nH]c4ccccc4c3CC2C1)c1ccc(F)cc1\nBIRIPERONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1\nCandidate Name: IVOSIDENIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1\nCandidate Name: IVOSIDENIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCC(C(=O)OCCN1CCN(CCOC(=O)C(CC)c2ccccc2)CC1)c1ccccc1\nName: FEBUVERINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 466.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCC(C(=O)OCCN1CCN(CCOC(=O)C(CC)c2ccccc2)CC1)c1ccccc1\nName: FEBUVERINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 466.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O\nName: ICOSAPENT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O\nName: ICOSAPENT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 302.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\n[2H]O[2H]\nDEUTERIUM OXIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 20.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\n[2H]O[2H]\nDEUTERIUM OXIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 20.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nOc1ccc(CCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1\nName: ARBUTAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nOc1ccc(CCCCNC[C@H](O)c2ccc(O)c(O)c2)cc1\nName: ARBUTAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.45 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCl/C(=C\\n1cncn1)c1ccc(Cl)cc1Cl\nLORECLEZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 274.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCl/C(=C\\n1cncn1)c1ccc(Cl)cc1Cl\nLORECLEZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 274.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 30.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: OCTENIDINE HYDROCHLORIDE\n\n### Structure\n```\nCCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 623.8 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 9.63 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 34.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 25.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.110\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl", "output": "## Molecular Property Analysis: OCTENIDINE HYDROCHLORIDE\n\n### Structure\n```\nCCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1.Cl.Cl\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 623.8 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 9.63 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 34.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 25.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.110\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN1C[C@H](CC(C#N)C(N)=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21\nCandidate Name: CIANERGOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 322.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN1C[C@H](CC(C#N)C(N)=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21\nCandidate Name: CIANERGOLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 322.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC=C1/C(=C\\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O\nCALCIPOTRIENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 412.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC=C1/C(=C\\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O\nCALCIPOTRIENE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 412.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.09 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 437.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 437.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 87.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1.Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1.Cl", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nClc1cnn(CCCCN2CCN(c3ncccn3)CC2)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 320.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nClc1cnn(CCCCN2CCN(c3ncccn3)CC2)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 320.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCOCC1(CO)C(=O)C2CCN1CC2\nEPRENETAPOPT\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 199.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCOCC1(CO)C(=O)C2CCN1CC2\nEPRENETAPOPT", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 199.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=C1[C@H](O)CC(=C/C=C2\\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O\nDrug Name: BECOCALCIDIOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=C1[C@H](O)CC(=C/C=C2\\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O\nDrug Name: BECOCALCIDIOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 344.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.17 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC1CNCCN1.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 562.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC1CNCCN1.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 562.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -1.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1(C)C2=CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@@]2(C)Cc2cnoc21\nAZASTENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.04 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1(C)C2=CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3CC[C@]4(C)O)[C@@]2(C)Cc2cnoc21\nAZASTENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 355.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.04 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]\nName: BROMFENAC SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 766.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]\nName: BROMFENAC SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 766.4 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nO=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TIOSPIRONE\n\n### Structure\n```\nO=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 440.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.91 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 56.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.500\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nO=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1", "output": "## Molecular Property Analysis: TIOSPIRONE\n\n### Structure\n```\nO=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 440.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.91 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 56.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.500\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OC(c1ccccc1)C1CCCCN1\nCandidate Name: LEVOFACETOPERANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(=O)OC(c1ccccc1)C1CCCCN1\nCandidate Name: LEVOFACETOPERANE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 233.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl\nFLURAZEPAM HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl\nFLURAZEPAM HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl\nDrug Name: FLUOXETINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl\nDrug Name: FLUOXETINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccc(C(=O)Cc2ccccc2)cc1C(=O)O\nDrug Name: Bromfenac (Duract)\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccc(C(=O)Cc2ccccc2)cc1C(=O)O\nDrug Name: Bromfenac (Duract)", "output": "## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1\nDrug Name: DIFENOXIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1\nDrug Name: DIFENOXIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.00 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCN(CCN2CCN(CCCN3c4ccccc4Sc4ccc(Cl)cc43)CC2)C1=O\nIMICLOPAZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 486.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCN(CCN2CCN(CCCN3c4ccccc4Sc4ccc(Cl)cc43)CC2)C1=O\nIMICLOPAZINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 486.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 33.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O\nDrug Name: ROLOFYLLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O\nDrug Name: ROLOFYLLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1\nDrug Name: MECLIZINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.56 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1\nDrug Name: MECLIZINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 391.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.56 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1nnc2ccc([C@H](c3ccc(Cl)cc3)n3cncn3)cc21\nDrug Name: VOROZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1nnc2ccc([C@H](c3ccc(Cl)cc3)n3cncn3)cc21\nDrug Name: VOROZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2\nDrug Name: SAXAGLIPTIN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 351.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2\nDrug Name: SAXAGLIPTIN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 351.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccccc1C(=O)N1CC/C(=N\\OS(=O)(=O)O)c2ccc(Cl)cc21\nDrug Name: ALILUSEM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1ccccc1C(=O)N1CC/C(=N\\OS(=O)(=O)O)c2ccc(Cl)cc21\nDrug Name: ALILUSEM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 394.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 96.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc2c(cc1N1CCNCC1)c(=O)c(C(=O)O)cn2C1CC1\nDrug Name: Grepafloxacin\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cc2c(cc1N1CCNCC1)c(=O)c(C(=O)O)cn2C1CC1\nDrug Name: Grepafloxacin", "output": "## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CC[C@H](NC(=O)N[C@@H](CSCc1ccc(F)cc1)C(=O)O)C(=O)O\nDrug Name: DCFBC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(O)CC[C@H](NC(=O)N[C@@H](CSCc1ccc(F)cc1)C(=O)O)C(=O)O\nDrug Name: DCFBC", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 153.0 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC1Oc2ccc(Cl)cc2N(CC(O)CO)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC1Oc2ccc(Cl)cc2N(CC(O)CO)C1=O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCOC(=O)/C(=C\\c1ccccc1)c1ccccc1\nName: CINNAMAVERINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)CCOC(=O)/C(=C\\c1ccccc1)c1ccccc1\nName: CINNAMAVERINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 323.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.11 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)c1nnc(NS(=O)(=O)c2ccccc2)s1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)(C)c1nnc(NS(=O)(=O)c2ccccc2)s1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1c2ccccc2nc2ccccc12\nAMINACRINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 194.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1c2ccccc2nc2ccccc12\nAMINACRINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 194.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1\nName: TRILACICLIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1\nName: TRILACICLIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C([O-])[O-].[Li+].[Li+]\nCandidate Name: LITHIUM CARBONATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 73.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C([O-])[O-].[Li+].[Li+]\nCandidate Name: LITHIUM CARBONATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 73.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCS(C)(=O)=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 94.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCS(C)(=O)=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 94.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nThis drug failed in Post-market. Explain why:\nDrug: Valdecoxib (Bextra)\nSMILES: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3\n<|im_end|>\n<|im_start|>assistant\n## Drug Failure Analysis: Valdecoxib (Bextra)\n\n### Summary\n**Phase Failed:** Post-market\n**Year:** 2005.0\n**Therapeutic Area:** Pain/Inflammation\n**Failure Category:** Cardiovascular/Dermatological\n\n### Detailed Failure Reason\n\nSerious cardiovascular events and severe skin reactions (Stevens-Johnson syndrome)\n\n### Mechanism of Toxicity\n\nnan\n\n### Cardiovascular Toxicity Analysis\n\n**Key Risk Factors:**\n1. **hERG Channel Inhibition:** Many cardiotoxic drugs block the hERG potassium channel, leading to QT prolongation and potentially fatal arrhythmias (Torsades de Pointes)\n2. **Prothrombotic Effects:** Selective COX-2 inhibitors reduce prostacyclin production, tipping the balance toward platelet aggregation\n3. **Myocardial Stress:** Some drugs cause direct cardiomyocyte damage or increase cardiac workload\n\n**Structural Alerts:**\n- Tertiary amines with lipophilic aromatic rings often show hERG liability\n- Basic nitrogen at appropriate distance from aromatic system increases hERG risk\n\n**Prevention Strategies:**\n- Early hERG screening (patch clamp assays)\n- In vivo QT studies in multiple species\n- Careful monitoring in clinical trials for PR/QT changes\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy\n<|im_end|>", "instruction": "This drug failed in Post-market. Explain why:\nDrug: Valdecoxib (Bextra)\nSMILES: CC1=C(C(=NO1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=CC=C3", "output": "## Drug Failure Analysis: Valdecoxib (Bextra)\n\n### Summary\n**Phase Failed:** Post-market\n**Year:** 2005.0\n**Therapeutic Area:** Pain/Inflammation\n**Failure Category:** Cardiovascular/Dermatological\n\n### Detailed Failure Reason\n\nSerious cardiovascular events and severe skin reactions (Stevens-Johnson syndrome)\n\n### Mechanism of Toxicity\n\nnan\n\n### Cardiovascular Toxicity Analysis\n\n**Key Risk Factors:**\n1. **hERG Channel Inhibition:** Many cardiotoxic drugs block the hERG potassium channel, leading to QT prolongation and potentially fatal arrhythmias (Torsades de Pointes)\n2. **Prothrombotic Effects:** Selective COX-2 inhibitors reduce prostacyclin production, tipping the balance toward platelet aggregation\n3. **Myocardial Stress:** Some drugs cause direct cardiomyocyte damage or increase cardiac workload\n\n**Structural Alerts:**\n- Tertiary amines with lipophilic aromatic rings often show hERG liability\n- Basic nitrogen at appropriate distance from aromatic system increases hERG risk\n\n**Prevention Strategies:**\n- Early hERG screening (patch clamp assays)\n- In vivo QT studies in multiple species\n- Careful monitoring in clinical trials for PR/QT changes\n\n### Key Takeaways for Drug Development\n\n1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development\n2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks\n3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring\n4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy", "task_type": "failure_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1\nDrug Name: HEDAQUINIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: c1ccc2c[n+](CCCCCCCCCCCCCCCC[n+]3ccc4ccccc4c3)ccc2c1\nDrug Name: HEDAQUINIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.73 | ‚ö† High (>5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 7.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: c1ccc2c(c1)cc1n2CCCNC1\nDrug Name: AZEPINDOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 186.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: c1ccc2c(c1)cc1n2CCCNC1\nDrug Name: AZEPINDOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 186.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)/C=C/C(=O)O\nName: ALISKIREN FUMARATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1219.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)/C=C/C(=O)O\nName: ALISKIREN FUMARATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1219.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1CCN(C2=Nc3ccccc3Sc3nccn32)CC1\nName: PENTIAPINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1CCN(C2=Nc3ccccc3Sc3nccn32)CC1\nName: PENTIAPINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 299.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC=C1CC[C@@H]2[C@](C)(CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CCC[C@@]2(C)[C@@H]1CCC1=CCOC1=O\nNEOANDROGRAPHOLIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 480.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC=C1CC[C@@H]2[C@](C)(CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CCC[C@@]2(C)[C@@H]1CCC1=CCOC1=O\nNEOANDROGRAPHOLIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 480.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 125.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO.O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1\nTECOVIRIMAT MONOHYDRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO.O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1\nTECOVIRIMAT MONOHYDRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN1CCC(CC1)C(=O)C2=CC=C(C=C2)F\nName: hERG_Failure_001\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN1CCC(CC1)C(=O)C2=CC=C(C=C2)F\nName: hERG_Failure_001", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[N+](C)(C)CCOP(=O)([O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O.[Na+]\nName: CITICOLINE SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 510.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 215.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[N+](C)(C)CCOP(=O)([O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O.[Na+]\nName: CITICOLINE SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 510.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -2.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 215.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1\nCandidate Name: DESONIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1\nCandidate Name: DESONIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)CC1(C(=O)O)CCCC1\nDrug Name: ABITESARTAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)CC1(C(=O)O)CCCC1\nDrug Name: ABITESARTAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 112.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C1CCC(C)C(c2ccc(O)cc2)C1\nCandidate Name: MENFEGOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 232.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)C1CCC(C)C(c2ccc(O)cc2)C1\nCandidate Name: MENFEGOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 232.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.57 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]\nCandidate Name: SODIUM LAURYL SULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]\nCandidate Name: SODIUM LAURYL SULFATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 288.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nc1csc(C2(N3CCCCC3)CCCCC2)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: TENOCYCLIDINE\n\n### Structure\n```\nc1csc(C2(N3CCCCC3)CCCCC2)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 249.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.39 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.750\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nc1csc(C2(N3CCCCC3)CCCCC2)c1", "output": "## Molecular Property Analysis: TENOCYCLIDINE\n\n### Structure\n```\nc1csc(C2(N3CCCCC3)CCCCC2)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 249.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.39 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.750\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CCC(O)(c2ccc(F)cc2)C(C(=O)c2ccc(F)cc2)C1\nDrug Name: FLAZALONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN1CCC(O)(c2ccc(F)cc2)C(C(=O)c2ccc(F)cc2)C1\nDrug Name: FLAZALONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 331.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1\nXL-418\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 609.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1\nXL-418", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 609.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.78 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 93.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(=O)O[C@]1(C(C)=O)CCC2[C@@H]3C[C@H](C)C4=CCCC[C@]4(C)[C@H]3CC[C@@]21C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.48 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(=O)O[C@]1(C(C)=O)CCC2[C@@H]3C[C@H](C)C4=CCCC[C@]4(C)[C@H]3CC[C@@]21C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 372.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.48 | ‚ö† High (>5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1\nCandidate Name: PROPANIDID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1\nCandidate Name: PROPANIDID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 337.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\nDrug Name: IOXAGLATE MEGLUMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1464.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO\nDrug Name: IOXAGLATE MEGLUMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1464.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12\nCandidate Name: PRUVANSERIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12\nCandidate Name: PRUVANSERIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nc1cncnc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PYRIMIDINE\n\n### Structure\n```\nc1cncnc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 80.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 0.48 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 25.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nc1cncnc1", "output": "## Molecular Property Analysis: PYRIMIDINE\n\n### Structure\n```\nc1cncnc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 80.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 0.48 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 25.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC(=O)OCC(C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)N2C)c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC(=O)OCC(C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)N2C)c1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.89 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC1CC(OC(=O)C(OC(=O)c2cccnc2)c2ccccc2)CC(C)(C)C1\nName: MICINICATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC1CC(OC(=O)C(OC(=O)c2cccnc2)c2ccccc2)CC(C)(C)C1\nName: MICINICATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 381.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])c1ccc(Oc2ccc(N=C=S)cc2)cc1\nNITROSCANATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nO=[N+]([O-])c1ccc(Oc2ccc(N=C=S)cc2)cc1\nNITROSCANATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCNC(C)Cc1ccccc1OC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 179.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCNC(C)Cc1ccccc1OC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 179.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1\nName: LY-3009120\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1\nName: LY-3009120", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 424.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 91.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1ccc2c(c1)CN1C(=O)c3ccccc3C1=N2\nDANIQUIDONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1ccc2c(c1)CN1C(=O)c3ccccc3C1=N2\nDANIQUIDONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c(c1)c(CC(=O)SCc1cccnc1)c(C)n2C(=O)c1ccc(Cl)cc1\nDrug Name: PIMETACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 465.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc2c(c1)c(CC(=O)SCc1cccnc1)c(C)n2C(=O)c1ccc(Cl)cc1\nDrug Name: PIMETACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 465.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 279.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F\nCandidate Name: FLUCONAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F\nCandidate Name: FLUCONAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.74 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 81.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCCOc1ccccc1OC(c1ccccc1)C1CNCCO1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: REBOXETINE\n\n### Structure\n```\nCCOc1ccccc1OC(c1ccccc1)C1CNCCO1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 313.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.19 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 39.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.890\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCCOc1ccccc1OC(c1ccccc1)C1CNCCO1", "output": "## Molecular Property Analysis: REBOXETINE\n\n### Structure\n```\nCCOc1ccccc1OC(c1ccccc1)C1CNCCO1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 313.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.19 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 39.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.890\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nO=c1cc[nH]c(=O)[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: URACIL\n\n### Structure\n```\nO=c1cc[nH]c(=O)[nH]1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 112.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.94 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 65.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nO=c1cc[nH]c(=O)[nH]1", "output": "## Molecular Property Analysis: URACIL\n\n### Structure\n```\nO=c1cc[nH]c(=O)[nH]1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 112.1 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | -0.94 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 65.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.450\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC#C[C@H](CC(=O)OCC)NC(=O)CCC(=O)Nc1ccc(C(=N)N)cc1\nXEMILOFIBAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC#C[C@H](CC(=O)OCC)NC(=O)CCC(=O)Nc1ccc(C(=N)N)cc1\nXEMILOFIBAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.76 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 134.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ENGLITAZONE\n\n### Structure\n```\nO=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 353.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.52 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 55.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.910\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nO=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1", "output": "## Molecular Property Analysis: ENGLITAZONE\n\n### Structure\n```\nO=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 353.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.52 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 55.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.910\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1.O=S(=O)(O)O\nDrug Name: CEFTOLOZANE SULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 764.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -3.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 302.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1.O=S(=O)(O)O\nDrug Name: CEFTOLOZANE SULFATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 764.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -3.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |\n| H-Bond Donors | 7.0 | ‚ö† High (>5) |\n| Polar Surface Area | 302.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCOC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: GRISEOFULVIN\n\n### Structure\n```\nCOC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 352.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.81 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 71.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCOC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O", "output": "## Molecular Property Analysis: GRISEOFULVIN\n\n### Structure\n```\nCOC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 352.8 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.81 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 71.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.830\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(CC(C#N)(c1ccccc1)C(C)C)N(C)C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(CC(C#N)(c1ccccc1)C(C)C)N(C)C", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 244.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O\nName: PF-00562271\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 507.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 129.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O\nName: PF-00562271", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 507.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 129.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O\nCandidate Name: DAUNORUBICIN CITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 719.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 185.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O\nCandidate Name: DAUNORUBICIN CITRATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 719.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.03 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 185.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC(=O)C1=C(O)C(C)(C)C(O)=C(Cc2c(OC)cc(O)c(C(=O)CCC)c2O)C1=O\nDrug Name: DESASPIDIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCC(=O)C1=C(O)C(C)(C)C(O)=C(Cc2c(OC)cc(O)c(C(=O)CCC)c2O)C1=O\nDrug Name: DESASPIDIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\\C(=O)O\nName: VICRIVIROC MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 649.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\\C(=O)O\nName: VICRIVIROC MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 649.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1\nIRSOGLADINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1\nIRSOGLADINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 256.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl\nReactive_Met_001\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)Cl\nReactive_Met_001", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21\nSERTRALINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21\nSERTRALINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 306.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(/C=N/NC(=O)c2ccncc2)c(C(=O)O)c1OC\nDrug Name: OPINIAZIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(/C=N/NC(=O)c2ccncc2)c(C(=O)O)c1OC\nDrug Name: OPINIAZIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C/C(=N\\Nc1ccc(S(C)(=O)=O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C\nDrug Name: LINAROTENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.28 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C/C(=N\\Nc1ccc(S(C)(=O)=O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C\nDrug Name: LINAROTENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.28 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNc1ccc(Cc2ccc(F)cc2)c(N)n1\nSAMPIRTINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 217.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNc1ccc(Cc2ccc(F)cc2)c(N)n1\nSAMPIRTINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 217.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]12CCC(c3ccccc3)(CC1)C(=O)C2\nCandidate Name: QUINUCLIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 216.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: C[N+]12CCC(c3ccccc3)(CC1)C(=O)C2\nCandidate Name: QUINUCLIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 216.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 17.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNc1nc(=O)[nH]cc1F\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 129.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNc1nc(=O)[nH]cc1F", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 129.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1\nDIFLOXACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1\nDIFLOXACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21\nSertraline\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21\nSertraline", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)/C=C\\C(=O)O.O=C1Cc2cc3c(CCC4CCN(Cc5ccccc5)CC4)noc3cc2N1\nCandidate Name: ICOPEZIL MALEATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 491.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)/C=C\\C(=O)O.O=C1Cc2cc3c(CCC4CCN(Cc5ccccc5)CC4)noc3cc2N1\nCandidate Name: ICOPEZIL MALEATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 491.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC1(C)CC(=O)NC(=O)C1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 155.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC1(C)CC(=O)NC(=O)C1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 155.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O\nALPROSTADIL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O\nALPROSTADIL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\\C)CCC=C(C)C\nGEFARNATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.42 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\\C)CCC=C(C)C\nGEFARNATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 400.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 8.42 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1\nDrug Name: APRICOXIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1\nDrug Name: APRICOXIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 356.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.50 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 587.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.77 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 587.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.77 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO.O.O.O.O.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.[Ca+2]\nName: BENZOYLPAS CALCIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 642.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO.O.O.O.O.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.O=C(Nc1ccc(C(=O)[O-])c(O)c1)c1ccccc1.[Ca+2]\nName: BENZOYLPAS CALCIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 642.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 86.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1\nName: TELMISARTAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.26 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1\nName: TELMISARTAN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 514.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.26 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[Si](C)(C)c1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc([Si](C)(C)C)c1\nDrug Name: AMSILAROTENE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 385.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[Si](C)(C)c1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc([Si](C)(C)C)c1\nDrug Name: AMSILAROTENE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 385.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@H]1C[C@H]2C[C@H]3c4[nH]c5ccc(OC)cc5c4CCN(C2)[C@@H]13\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@H]1C[C@H]2C[C@H]3c4[nH]c5ccc(OC)cc5c4CCN(C2)[C@@H]13", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 310.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.94 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: RILMAKALIM\n\n### Structure\n```\nCC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 401.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 83.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O", "output": "## Molecular Property Analysis: RILMAKALIM\n\n### Structure\n```\nCC1(C)Oc2ccc(S(=O)(=O)c3ccccc3)cc2[C@@H](N2CCCC2=O)[C@@H]1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 401.5 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.71 | 0-5 | ‚úì |\n| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 83.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1\nDrug Name: PIPOTIAZINE PALMITATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 714.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 10.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1\nDrug Name: PIPOTIAZINE PALMITATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 714.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 10.06 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C#C[C@]1(O)CC[C@H]2[C@@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C\nDrug Name: TIBOLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C#C[C@]1(O)CC[C@H]2[C@@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C\nDrug Name: TIBOLONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O\nDABIGATRAN ETEXILATE MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 723.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.81 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 151.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O\nDABIGATRAN ETEXILATE MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 723.9 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.81 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 151.5 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOP(=O)(/N=C(\\SCCS/C(=N/P(=O)(OCC)OCC)SCc1ccccc1)SCc1ccccc1)OCC\nCandidate Name: ZILANTEL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 664.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.39 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOP(=O)(/N=C(\\SCCS/C(=N/P(=O)(OCC)OCC)SCc1ccccc1)SCc1ccccc1)OCC\nCandidate Name: ZILANTEL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 664.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.39 | ‚ö† High (>5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 95.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)CCCn1nnnc1-c1ccc2c(c1)[C@@H](Oc1ccc(=O)[nH]n1)[C@](C)(O)C(C)(C)O2\nCandidate Name: MAZOKALIM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 484.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 154.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCOC(=O)CCCn1nnnc1-c1ccc2c(c1)[C@@H](Oc1ccc(=O)[nH]n1)[C@](C)(O)C(C)(C)O2\nCandidate Name: MAZOKALIM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 484.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |\n| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 154.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1\nETOMOXIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1\nETOMOXIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 326.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.00 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 48.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1\nMARITUPIRDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 304.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 8.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1\nMARITUPIRDINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 304.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 8.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\n[AsH3]\nName: ARSENIC\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 78.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\n[AsH3]\nName: ARSENIC", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 78.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC.Cl\nTIAPRIDE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC.Cl\nTIAPRIDE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12\nName: ZAFIRLUKAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 575.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12\nName: ZAFIRLUKAST", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 575.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 115.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1\nEDOXABAN TOSYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 720.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 136.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1\nEDOXABAN TOSYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 720.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 136.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O\nDrug Name: TELBIVUDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O\nDrug Name: TELBIVUDINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 242.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nOc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2\n(-)-EPICATECHIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nOc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2\n(-)-EPICATECHIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 290.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)c1cccc2c(S(=O)(=O)Nc3ccc(NC(=O)C(C)(C)COC(=O)CN)cc3)cccc12\nDrug Name: LITOMEGLOVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CN(C)c1cccc2c(S(=O)(=O)Nc3ccc(NC(=O)C(C)(C)COC(=O)CN)cc3)cccc12\nDrug Name: LITOMEGLOVIR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 498.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 130.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCC/C=C\\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]\nDrug Name: LATANOPROSTENE BUNOD\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 507.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(CCC/C=C\\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]\nDrug Name: LATANOPROSTENE BUNOD", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 507.6 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 139.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1.O.O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 162.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1.O.O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 162.9 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC1(C)[C@@H](O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)OCC6CCC[N+]6(C)C)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12.COS(=O)(=O)[O-]\nDrug Name: ROXOLONIUM METILSULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 694.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC1(C)[C@@H](O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)OCC6CCC[N+]6(C)C)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12.COS(=O)(=O)[O-]\nDrug Name: ROXOLONIUM METILSULFATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 694.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(N=[N+]=[N-])cc1\nName: ZIDOMETACIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(N=[N+]=[N-])cc1\nName: ZIDOMETACIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.22 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 117.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-]\nName: METHSCOPOLAMINE BROMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-]\nName: METHSCOPOLAMINE BROMIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 398.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nOC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1\nDIPHENIDOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nOC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1\nDIPHENIDOL", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 309.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nC=C(C#N)C(=O)OCCCCCCCC\nOCRYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 209.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nC=C(C#N)C(=O)OCCCCCCCC\nOCRYLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 209.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC1=C(/C=C/C(C)=C\\C=C\\C(C)=C\\C(=O)O)C(C)(C)CCC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ALITRETINOIN\n\n### Structure\n```\nCC1=C(/C=C/C(C)=C\\C=C\\C(C)=C\\C(=O)O)C(C)(C)CCC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 300.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.60 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.530\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC1=C(/C=C/C(C)=C\\C=C\\C(C)=C\\C(=O)O)C(C)(C)CCC1", "output": "## Molecular Property Analysis: ALITRETINOIN\n\n### Structure\n```\nCC1=C(/C=C/C(C)=C\\C=C\\C(C)=C\\C(=O)O)C(C)(C)CCC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 300.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 5.60 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.530\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCO/N=C1\\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCO/N=C1\\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 401.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.98 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)c3nccc4ccccc34)C(=O)N12\nDrug Name: PRALNACASAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 523.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)c3nccc4ccccc34)C(=O)N12\nDrug Name: PRALNACASAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 523.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 0.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 147.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1N=C([O-])NC1(c1ccccc1)c1ccccc1.[Na+]\nDrug Name: PHENYTOIN SODIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 274.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C1N=C([O-])NC1(c1ccccc1)c1ccccc1.[Na+]\nDrug Name: PHENYTOIN SODIUM", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 274.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1.[Cl-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 273.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=[N+]([O-])c1ccc(-c2csc3[n+]2CCN3)o1.[Cl-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 273.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.63 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)NC(=O)c1nn(-c2ccc(F)cc2F)c2c1[C@H]1CC[C@@H]2C1\nName: TEDALINAB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)(C)NC(=O)c1nn(-c2ccc(F)cc2F)c2c1[C@H]1CC[C@@H]2C1\nName: TEDALINAB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 345.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCOC(C)c1c(C)c2cc3nc(c4c5[nH]c(cc6nc(cc1[nH]2)C(C)=C6CC)c(C)c5C(=O)C4)[C@@H](CCC(=O)O)[C@@H]3C\nDrug Name: HPPH\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 636.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.42 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCCCCCOC(C)c1c(C)c2cc3nc(c4c5[nH]c(cc6nc(cc1[nH]2)C(C)=C6CC)c(C)c5C(=O)C4)[C@@H](CCC(=O)O)[C@@H]3C\nDrug Name: HPPH", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 636.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.42 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 121.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nOC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: FLUCONAZOLE\n\n### Structure\n```\nOC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 306.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.74 | 0-5 | ‚úì |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.750\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nOC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F", "output": "## Molecular Property Analysis: FLUCONAZOLE\n\n### Structure\n```\nOC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 306.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 0.74 | 0-5 | ‚úì |\n| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 81.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.750\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1\nDrug Name: GSK-1004723\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 641.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.77 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1\nDrug Name: GSK-1004723", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 641.3 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 7.77 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 50.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1\nDrug Name: TEMOPORFIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 680.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.76 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 138.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1\nDrug Name: TEMOPORFIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 680.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 9.76 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 138.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2[nH]c(SCc3ncc(C)c(OC)c3C)nc2c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc2[nH]c(SCc3ncc(C)c(OC)c3C)nc2c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 329.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 60.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1\nLUMACAFTOR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1\nLUMACAFTOR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 452.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CS(=O)(=O)[O-].C[N+]1(C)[C@@H]2C[C@@H](OC3c4ccccc4CSc4ccccc43)C[C@H]1[C@@H]1O[C@@H]12\nCandidate Name: SEVITROPIUM MESILATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 475.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CS(=O)(=O)[O-].C[N+]1(C)[C@@H]2C[C@@H](OC3c4ccccc4CSc4ccccc43)C[C@H]1[C@@H]1O[C@@H]12\nCandidate Name: SEVITROPIUM MESILATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 475.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 21.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1nc(Nc2ccc(F)cc2)nc(N2CCc3ccccc3C2C)c1C\nName: REVAPRAZAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1nc(Nc2ccc(F)cc2)nc(N2CCc3ccccc3C2C)c1C\nName: REVAPRAZAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 362.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.10 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O.O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 767.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O.O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 767.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 180.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-]\nDrug Name: DOXACURIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1106.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-]\nDrug Name: DOXACURIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1106.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12\nRALOXIFENE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 510.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12\nRALOXIFENE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 510.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 6.08 | ‚ö† High (>5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 70.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@H]3OP(=O)(O)O[C@H]32)c(=O)n1\nDrug Name: CIFOSTODINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@H]3OP(=O)(O)O[C@H]32)c(=O)n1\nDrug Name: CIFOSTODINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 305.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.40 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 146.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCNC1(c2ccccc2Cl)CCCCC1=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: KETAMINE\n\n### Structure\n```\nCNC1(c2ccccc2Cl)CCCCC1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 237.7 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.90 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 29.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.860\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCNC1(c2ccccc2Cl)CCCCC1=O", "output": "## Molecular Property Analysis: KETAMINE\n\n### Structure\n```\nCNC1(c2ccccc2Cl)CCCCC1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 237.7 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.90 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 29.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.860\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCc1cc2ccccc2c(OCCN(C)C)n1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCc1cc2ccccc2c(OCCN(C)C)n1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 272.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Nc1ccc(Cl)cc1)NS(=O)(=O)c1ccc2c(c1)CCC2\nDrug Name: SULOFENUR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=C(Nc1ccc(Cl)cc1)NS(=O)(=O)c1ccc2c(c1)CCC2\nDrug Name: SULOFENUR", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCc1ncc(C[n+]2ccccc2C)c(N)n1.Cl.[Cl-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCc1ncc(C[n+]2ccccc2C)c(N)n1.Cl.[Cl-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 315.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 55.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O\nName: PENTETIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 196.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O\nName: PENTETIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 393.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 196.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O\nLOPINAVIR\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 628.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 120.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O\nLOPINAVIR", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 628.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 120.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12.CS(=O)(=O)O\nIBUTAMOREN MESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 624.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12.CS(=O)(=O)O\nIBUTAMOREN MESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 624.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 388.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nNCCCC(O)(P(=O)(O)O)P(=O)(O)O\nALENDRONIC ACID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 161.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nNCCCC(O)(P(=O)(O)O)P(=O)(O)O\nALENDRONIC ACID", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.1 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 161.3 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=S(=O)(Nc1cccc(OCc2ccc3ccccc3n2)c1)C(F)(F)F\nCandidate Name: RITOLUKAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=S(=O)(Nc1cccc(OCc2ccc3ccccc3n2)c1)C(F)(F)F\nCandidate Name: RITOLUKAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 382.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.08 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl\nName: MILNACIPRAN HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl\nName: MILNACIPRAN HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC1CCC(CN2CCCCC2)CC1\nName: LEPTACLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC1CCC(CN2CCCCC2)CC1\nName: LEPTACLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 181.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.O=C(O)c1cc(S(=O)(=O)O)ccc1O\nDrug Name: MECLOCYCLINE SULFOSALICYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 695.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.O=C(O)c1cc(S(=O)(=O)O)ccc1O\nDrug Name: MECLOCYCLINE SULFOSALICYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 695.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(C=CC(O)CC(O)CC(=O)O)cc1-c1ccc(F)c(C(C)C)n1\nDrug Name: Cerivastatin\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: COc1ccc(C=CC(O)CC(O)CC(=O)O)cc1-c1ccc(F)c(C(C)C)n1\nDrug Name: Cerivastatin", "output": "## Drug Analysis Report\n\n### Prediction: ‚ùå FAILED/WITHDRAWN\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Failure Analysis\n\n**Reason for Failure:** nan\n\nThis compound was withdrawn/failed likely due to:\n1. **Safety signals** detected in clinical trials or post-market surveillance\n2. **Mechanism-related toxicity** affecting non-target tissues\n3. **Drug-drug interaction** potential from metabolic vulnerabilities\n\n### Lessons Learned\nTo avoid similar failures, future candidates should:\n- Undergo comprehensive safety profiling early in development\n- Include diversity in clinical trial populations\n- Monitor for class-related adverse effects", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1nc[nH]c1CN1CCN(C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](Cc2ccccc2)C1=O\nGGTI-2418\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1nc[nH]c1CN1CCN(C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](Cc2ccccc2)C1=O\nGGTI-2418", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 441.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 118.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC\nSUXETHONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC\nSUXETHONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 318.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.05 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C\nCandidate Name: TASQUINIMOD\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C\nCandidate Name: TASQUINIMOD", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 406.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.55 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1cccc(OC(C)CNC(=N)Cc2cccc(C)c2)c1.Cc1ccc(S(=O)(=O)O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 484.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1cccc(OC(C)CNC(=N)Cc2cccc(C)c2)c1.Cc1ccc(S(=O)(=O)O)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 484.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 54.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1nnc(SCC2=C(C(=O)OCc3oc(=O)oc3C)N3C(=O)[C@@H](NC(=O)[C@H](OC(=O)[C@@H](C)N)c4ccccc4)[C@H]3SC2)s1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 661.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 197.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1nnc(SCC2=C(C(=O)OCc3oc(=O)oc3C)N3C(=O)[C@@H](NC(=O)[C@H](OC(=O)[C@@H](C)N)c4ccccc4)[C@H]3SC2)s1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 661.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |\n| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 197.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCOC(=O)C(=O)Nc1cccc(-c2nnn[nH]2)c1\nName: TAZANOLAST\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCOC(=O)C(=O)Nc1cccc(-c2nnn[nH]2)c1\nName: TAZANOLAST", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 289.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 109.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: ATIBEPRONE\n\n### Structure\n```\nCc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 330.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.96 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O", "output": "## Molecular Property Analysis: ATIBEPRONE\n\n### Structure\n```\nCc1c(C)c2ccc(OCc3nnc(C(C)C)s3)cc2oc1=O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 330.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.96 | 0-5 | ‚úì |\n| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 65.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.680\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nC#CCN(C)CC1=Cc2ccccc2Oc2ccccc21\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 275.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nC#CCN(C)CC1=Cc2ccccc2Oc2ccccc21", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 275.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C\nCandidate Name: RIBOFLAVIN 5'-PHOSPHATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 208.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C\nCandidate Name: RIBOFLAVIN 5'-PHOSPHATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 456.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -1.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 6.0 | ‚ö† High (>5) |\n| Polar Surface Area | 208.1 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\n[Cl-].[Cl-].[Zn+2]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 136.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\n[Cl-].[Cl-].[Zn+2]", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 136.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nNc1cc2[nH]cnc2c(=O)[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: DEZAGUANINE\n\n### Structure\n```\nNc1cc2[nH]cnc2c(=O)[nH]1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 150.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.17 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 87.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.490\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nNc1cc2[nH]cnc2c(=O)[nH]1", "output": "## Molecular Property Analysis: DEZAGUANINE\n\n### Structure\n```\nNc1cc2[nH]cnc2c(=O)[nH]1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 150.1 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | -0.17 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |\n| PSA | 87.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.490\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Limited CNS penetration expected\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Low (hydrophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- May undergo renal clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCOC(=O)c1cccc(-c2ccccc2)c1O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCN(CC)CCOC(=O)c1cccc(-c2ccccc2)c1O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 313.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1243.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 126.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 1243.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 8.07 | ‚ö† High (>5) |\n| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 126.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nc1cncc([C@@H]2CCCN2)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: NORNICOTINE\n\n### Structure\n```\nc1cncc([C@@H]2CCCN2)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 148.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.51 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 24.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nc1cncc([C@@H]2CCCN2)c1", "output": "## Molecular Property Analysis: NORNICOTINE\n\n### Structure\n```\nc1cncc([C@@H]2CCCN2)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 148.2 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 1.51 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 24.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.650\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCc1cccnc1NS(=O)(=O)c1ccc(C#Cc2ccc(O)c(C(=O)O)c2)cc1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCc1cccnc1NS(=O)(=O)c1ccc(C#Cc2ccc(O)c(C(=O)O)c2)cc1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 408.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 116.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C[N+](C)(C)C)OC(N)=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 161.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C[N+](C)(C)C)OC(N)=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 161.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 0.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCOCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\\O)c3csc(N)n3)[C@H]2SC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 413.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 167.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCOCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\\O)c3csc(N)n3)[C@H]2SC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 413.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.71 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 167.4 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C\nAMINOPENTAMIDE SULFATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C\nAMINOPENTAMIDE SULFATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 296.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.80 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\n[11CH3]Oc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1\nName: JHU-75528 C-11\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 469.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\n[11CH3]Oc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1\nName: JHU-75528 C-11", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 469.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.86 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)CCO/C(=C1\\C2CC3C(C2)C13)c1ccccc1\nCandidate Name: TREPTILAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCN(CC)CCO/C(=C1\\C2CC3C(C2)C13)c1ccccc1\nCandidate Name: TREPTILAMINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]cnc2c(CN3C[C@H](CO)[C@@H](O)C3)c[nH]c12\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=c1[nH]cnc2c(CN3C[C@H](CO)[C@@H](O)C3)c[nH]c12", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 264.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.96 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 105.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2Cl\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2Cl", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nO=C([O-])C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1.[Na+]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.65 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nO=C([O-])C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1.[Na+]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 477.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.65 | ‚ö† High (>5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 75.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1\nDrug Name: CYCLAZOCINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1\nDrug Name: CYCLAZOCINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 271.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl\nName: LEVOBUPIVACAINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl\nName: LEVOBUPIVACAINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 324.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.90 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nBr.CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCOCC3)c(OC)c(C(C)(C)C)c1)C2\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 608.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nBr.CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCOCC3)c(OC)c(C(C)(C)C)c1)C2", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 608.5 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.79 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 84.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCC[N+](CCO)(CCO)Cc1ccccc1\nName: BENZOXONIUM\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCCCCCCCCCC[N+](CCO)(CCO)Cc1ccccc1\nName: BENZOXONIUM", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 364.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.91 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 402.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.77 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)/C=N/NC(=O)c2ccncc2)O[C@@H](CO)[C@H](O)[C@H]1O\nCandidate Name: STREPTONIAZID\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 700.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -7.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 17.0 | ‚ö† High (>10) |\n| H-Bond Donors | 15.0 | ‚ö† High (>5) |\n| Polar Surface Area | 368.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)/C=N/NC(=O)c2ccncc2)O[C@@H](CO)[C@H](O)[C@H]1O\nCandidate Name: STREPTONIAZID", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 700.7 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | -7.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 17.0 | ‚ö† High (>10) |\n| H-Bond Donors | 15.0 | ‚ö† High (>5) |\n| Polar Surface Area | 368.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nDescribe the molecular properties and drug-likeness of:\nCC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: KETOPROFEN\n\n### Structure\n```\nCC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 254.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.11 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 54.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Describe the molecular properties and drug-likeness of:\nCC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1", "output": "## Molecular Property Analysis: KETOPROFEN\n\n### Structure\n```\nCC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 254.3 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 3.11 | 0-5 | ‚úì |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |\n| PSA | 54.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.850\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O\nCandidate Name: DASATINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1.O\nCandidate Name: DASATINIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n\n### Success Factors\n\nThis drug was successfully approved, demonstrating:\n1. **Favorable safety profile** through clinical development\n2. **Clear efficacy** in target patient population\n3. **Acceptable risk-benefit ratio** for intended indication\n\n### Key Success Indicators\n- Completed Phase III trials with positive outcomes\n- Manageable side effect profile\n- Clear differentiation from existing treatments", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCOC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1\nName: AZD-1656\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 128.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCOC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1\nName: AZD-1656", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 478.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |\n| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 128.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: IOLOPRIDE\n\n### Structure\n```\nCCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 404.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.22 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.740\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O", "output": "## Molecular Property Analysis: IOLOPRIDE\n\n### Structure\n```\nCCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 404.2 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 2.22 | 0-5 | ‚úì |\n| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 61.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.740\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- Moderate plasma protein binding expected\n- Estimated Vd: Moderate\n\n**Metabolism:**\n- CYP450 substrate likely\n- Low CYP inhibition expected\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1.O=C(O)CC(O)(CC(=O)O)C(=O)O\nMOSAPRIDE CITRATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 614.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1.O=C(O)CC(O)(CC(=O)O)C(=O)O\nMOSAPRIDE CITRATE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 614.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCc1cccc([C@H](C)c2ncc[nH]2)c1C\nDEMIDITRAZ\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCc1cccc([C@H](C)c2ncc[nH]2)c1C\nDEMIDITRAZ", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 200.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 28.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(C)CCOC(C)(c1ccccc1)c1ccccn1\nName: DOXYLAMINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(C)CCOC(C)(c1ccccc1)c1ccccn1\nName: DOXYLAMINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 270.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nC[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1\nName: DUVELISIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nC[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1\nName: DUVELISIB", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 416.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1\nCandidate Name: NONOXYNOL 9\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 616.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1\nCandidate Name: NONOXYNOL 9", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 616.8 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 103.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nCCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: CETABEN\n\n### Structure\n```\nCCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 361.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 7.28 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 17.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.290\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nCCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1", "output": "## Molecular Property Analysis: CETABEN\n\n### Structure\n```\nCCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 361.6 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 7.28 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 49.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 17.0 | ‚â§10 | ‚ö† |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.290\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚ö† FAIL\n\n### Natural Product Flag\nThis compound is derived from or inspired by natural products, which often have:\n- Complex stereochemistry\n- Unique mechanisms of action\n- Potentially better target selectivity", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCN(CCC)C1Cc2cccc3cc(O)cc(c23)C1\nALENTEMOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 283.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCN(CCC)C1Cc2cccc3cc(O)cc(c23)C1\nALENTEMOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 283.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1\nCandidate Name: OTAMIXABAN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1\nCandidate Name: OTAMIXABAN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 446.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 132.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1\nCandidate Name: CETIRIZINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1\nCandidate Name: CETIRIZINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 461.8 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 354.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 71.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nNc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 316.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 163.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nNc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 316.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 163.7 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCn1nnc([C@H]2O[C@@H](n3cnc4c(N)nc(N[C@H](CO)Cc5ccccc5)nc43)[C@H](O)[C@@H]2O)n1\nName: GW-328267\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCn1nnc([C@H]2O[C@@H](n3cnc4c(N)nc(N[C@H](CO)Cc5ccccc5)nc43)[C@H](O)[C@@H]2O)n1\nName: GW-328267", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 482.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |\n| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O\nCandidate Name: RATHYRONINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 651.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O\nCandidate Name: RATHYRONINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 651.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1.[Cl-]\nName: PYRVINIUM CHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1.[Cl-]\nName: PYRVINIUM CHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 418.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCCc1cc2c(s1)CN[C@@H]1CCc3cc(OC(C)=O)c(OC(C)=O)cc3[C@@H]21\nName: ADROGOLIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCCc1cc2c(s1)CN[C@@H]1CCc3cc(OC(C)=O)c(OC(C)=O)cc3[C@@H]21\nName: ADROGOLIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 399.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: [C-]#[O+]\nDrug Name: CARBON MONOXIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 28.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: [C-]#[O+]\nDrug Name: CARBON MONOXIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 28.0 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 19.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1cc(CN2CCOCC2)c2cc(O)c(O)cc2o1\nDrug Name: FOLESCUTOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 277.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: O=c1cc(CN2CCOCC2)c2cc(O)c(O)cc2o1\nDrug Name: FOLESCUTOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 277.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |\n| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCCCc1ccc(C(N)=O)nc1\nBUPICOMIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 178.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCCCc1ccc(C(N)=O)nc1\nBUPICOMIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 178.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.52 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 56.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\nDrug Name: FLUPREDNISOLONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\nDrug Name: FLUPREDNISOLONE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 378.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CCCCNCC1COc2cccc(OCC)c2O1\nCandidate Name: ETHOMOXANE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CCCCNCC1COc2cccc(OCC)c2O1\nCandidate Name: ETHOMOXANE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 265.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.61 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)c1cccc(C(C)C)c1NC(=O)CN(CC(=O)O)CC(=O)O\nCandidate Name: DISOFENIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: CC(C)c1cccc(C(C)C)c1NC(=O)CN(CC(=O)O)CC(=O)O\nCandidate Name: DISOFENIN", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 350.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.34 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 106.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCN1CCC(N(Cc2cccs2)c2ccccc2)CC1\nTHENALIDINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCN1CCC(N(Cc2cccs2)c2ccccc2)CC1\nTHENALIDINE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 286.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.85 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21\nDrug Name: RALIMETINIB\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21\nDrug Name: RALIMETINIB", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 420.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.55 | ‚ö† High (>5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 85.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1\nCandidate Name: BEPOTASTINE BESYLATE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 547.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1\nCandidate Name: BEPOTASTINE BESYLATE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 547.1 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 62.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nO=c1c(I)c[nH]cc1I\nName: IOPYDONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 346.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nO=c1c(I)c[nH]cc1I\nName: IOPYDONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 346.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.58 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 32.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCCC(CC)COC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1\nDENAVERINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCCC(CC)COC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1\nDENAVERINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 383.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nOC(C#CCN1CCCC1)(c1ccccc1)c1ccccc1\nName: BUTINOLINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nOC(C#CCN1CCCC1)(c1ccccc1)c1ccccc1\nName: BUTINOLINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 291.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCCNc1ccc(C(=O)OCCN(C)C)c(O)c1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCCNc1ccc(C(=O)OCCN(C)C)c(O)c1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 280.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 61.8 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O\nDrug Name: TAZOFELONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CC(C)(C)c1cc(CC2SCNC2=O)cc(C(C)(C)C)c1O\nDrug Name: TAZOFELONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 321.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCCN(CC)S(=O)(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1\nName: ETISULERGINE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCCN(CC)S(=O)(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1\nName: ETISULERGINE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 376.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 68.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: PRODIPINE\n\n### Structure\n```\nCC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 279.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.48 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:\nCC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1", "output": "## Molecular Property Analysis: PRODIPINE\n\n### Structure\n```\nCC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 279.4 Da | 150-500 Da | ‚úì |\n| LogP (cLogP) | 4.48 | 0-5 | ‚úì |\n| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 0 | ‚â§5 | ‚úì |\n| PSA | 3.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.800\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- Good oral absorption expected\n- Likely CNS penetrant\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- May undergo phase II metabolism primarily\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Moderate half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚úì PASS\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCC1(c2ccccc2)NC(=O)N(C)C1=O\nDrug Name: MEPHENYTOIN\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCC1(c2ccccc2)NC(=O)N(C)C1=O\nDrug Name: MEPHENYTOIN", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 218.3 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 1.47 | ‚úì Good (<5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 49.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAs a pharmaceutical researcher, analyze this compound:\nCC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl\nTERODILINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "As a pharmaceutical researcher, analyze this compound:\nCC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl\nTERODILINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 317.9 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)c1ccc(NC(=O)c2ccccc2N)c(C)c1\nDrug Name: ATOLIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Analyze this drug candidate and predict its approval likelihood:\nSMILES: CCN(CC)c1ccc(NC(=O)c2ccccc2N)c(C)c1\nDrug Name: ATOLIDE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 297.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCC(C)NCC(O)COc1ccccc1C1C[C@@H]2CC[C@H]1C2\nName: BORNAPROLOL\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCC(C)NCC(O)COc1ccccc1C1C[C@@H]2CC[C@H]1C2\nName: BORNAPROLOL", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 303.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)CN1C(=O)COc2ccccc21\nCandidate Name: PARAXAZONE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 206.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: NC(=O)CN1C(=O)COc2ccccc21\nCandidate Name: PARAXAZONE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 206.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.10 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 72.6 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCl.Nc1ccc(/N=N/c2ccccc2)c(N)n1\nName: PHENAZOPYRIDINE HYDROCHLORIDE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCl.Nc1ccc(/N=N/c2ccccc2)c(N)n1\nName: PHENAZOPYRIDINE HYDROCHLORIDE", "output": "## Drug Analysis Report\n\n### Prediction: ‚úÖ APPROVED\n**Confidence Level:** High\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 249.7 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |\n| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCc1cccc(CC)c1C(OCCN(C)C)c1ccccn1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCc1cccc(CC)c1C(OCCN(C)C)c1ccccn1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 312.5 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC[N+](CC)(CC)CCOc1ccc(/C=C/c2ccccc2)cc1.[I-]\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 451.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC[N+](CC)(CC)CCOc1ccc(/C=C/c2ccccc2)cc1.[I-]", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 451.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |\n| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nProvide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccnc2c1CCCCC2[S+]([O-])c1nc2ccccc2[nH]1\nCandidate Name: NEPAPRAZOLE\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Provide a comprehensive drug development assessment for:\nMolecular Structure: COc1ccnc2c1CCCCC2[S+]([O-])c1nc2ccccc2[nH]1\nCandidate Name: NEPAPRAZOLE", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 341.4 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |\n| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nAnalyze the ADMET properties of this compound:\nO=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O\n<|im_end|>\n<|im_start|>assistant\n## Molecular Property Analysis: RAFOXANIDE\n\n### Structure\n```\nO=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 626.0 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.95 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 58.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.310\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS\n<|im_end|>", "instruction": "Analyze the ADMET properties of this compound:\nO=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O", "output": "## Molecular Property Analysis: RAFOXANIDE\n\n### Structure\n```\nO=C(Nc1ccc(Oc2ccc(Cl)cc2)c(Cl)c1)c1cc(I)cc(I)c1O\n```\n\n### Physicochemical Properties\n\n| Property | Value | Optimal Range | Status |\n|----------|-------|---------------|--------|\n| Molecular Weight | 626.0 Da | 150-500 Da | ‚ö† |\n| LogP (cLogP) | 6.95 | 0-5 | ‚ö† |\n| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |\n| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |\n| PSA | 58.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |\n| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |\n\n### Drug-Likeness Score\n**QED (Quantitative Estimate of Drug-likeness):** 0.310\n- Score ranges from 0 (least drug-like) to 1 (most drug-like)\n- QED >0.5 is generally considered favorable\n\n### ADMET Predictions\n\n**Absorption:**\n- May have oral absorption challenges\n- Limited CNS penetration expected\n\n**Distribution:**\n- High plasma protein binding likely\n- Estimated Vd: High (lipophilic)\n\n**Metabolism:**\n- CYP450 substrate likely\n- Potential CYP inhibition risk\n\n**Excretion:**\n- Likely hepatic clearance\n- Long half-life expected\n\n### Rule-Based Assessments\n\n**Lipinski's Rule of 5:** ‚ö† FAIL\n**Veber Rules (Oral Bioavailability):** ‚úì PASS", "task_type": "property_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 708.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 170.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 708.0 Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |\n| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 170.8 √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nNCCC[C@](N)(C(=O)O)C(F)F\nName: EFLORNITHINE, (S)-\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 182.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nNCCC[C@](N)(C(=O)O)C(F)F\nName: EFLORNITHINE, (S)-", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 182.2 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | -0.23 | ‚úì Good (<5) |\n| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 0 | ‚úì Compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **excellent drug-like properties**:\n- Fully compliant with Lipinski's Rule of 5\n- Good balance of hydrophilicity/lipophilicity for membrane permeation\n- Suitable molecular weight for oral bioavailability", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nPredict whether this drug candidate will succeed in clinical trials:\nCC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.90 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery\n<|im_end|>", "instruction": "Predict whether this drug candidate will succeed in clinical trials:\nCC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O", "output": "## Drug Analysis Report\n\n### Prediction: üî¨ IN DEVELOPMENT\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | 358.6 Da | ‚úì Good (<500) |\n| LogP (Lipophilicity) | 6.90 | ‚ö† High (>5) |\n| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |\n| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |\n| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |\n| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **acceptable drug-like properties** with minor concerns:\n- Minor deviation from Lipinski's Rule of 5\n- May require formulation optimization for oral delivery", "task_type": "drug_analysis"}
{"text": "<|im_start|>user\nEvaluate the safety and efficacy potential of the following molecule:\nCN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3\nName: Rosiglitazone (Avandia)\n<|im_end|>\n<|im_start|>assistant\n## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics\n<|im_end|>", "instruction": "Evaluate the safety and efficacy potential of the following molecule:\nCN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3\nName: Rosiglitazone (Avandia)", "output": "## Drug Analysis Report\n\n### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED\n**Confidence Level:** Medium\n\n### Molecular Properties Analysis\n\n| Property | Value | Assessment |\n|----------|-------|------------|\n| Molecular Weight | nan Da | ‚ö† High (>500) |\n| LogP (Lipophilicity) | nan | ‚ö† High (>5) |\n| H-Bond Acceptors | nan | ‚ö† High (>10) |\n| H-Bond Donors | nan | ‚ö† High (>5) |\n| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |\n| Rule of 5 Violations | nan | ‚ö† Non-compliant |\n\n### Drug-Likeness Assessment\n\nThe compound shows **poor drug-like properties**:\n- Multiple violations of Lipinski's Rule of 5\n- May have bioavailability challenges\n- Consider structural modifications to improve pharmacokinetics", "task_type": "drug_analysis"}
